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1 Summary 
Tumour necrosis factor (TNF) is an important cytokine with great physiological relevance 
and effects ranging from pro-inflammatory to immuno-regulatory functions. On a cellular 
level, it induces signalling processes by crosslinking its receptors and by initiating the 
formation of an intracellular, multi-protein receptor-signalling complex (RSC). Investigation 
of the TNF-RSC by modified tandem affinity purification (moTAP) and mass spectrometry 
revealed the presence of three novel components in this complex: heme-oxidised IRP2 
ubiquitin ligase-1 (HOIL-1), HOIL-1-interacting protein (HOIP) and SHANK-associated 
RH-domain-interacting protein (SHARPIN). Previous studies showed that HOIL-1 and HOIP 
form an E3-complex that mediates the generation of linearly linked ubiquitin chains and is 
hence referred to as linear ubiquitin chain assembly complex (LUBAC). Identification of 
peptides specific for SHARPIN in the mass spectrometric analysis of the native TNF-RSC 
together with its sequence similarity to HOIL-1 raised the questions whether SHARPIN 
contributes functionally to TNF-signalling and/or the E3-activity of LUBAC. 
In this thesis, it could be shown that all three proteins are specifically recruited to the 
TNF-RSC in a cIAP1/2-dependent manner. As SHARPIN, HOIL-1 and HOIP can bind ubiquitin 
chains this suggests that the three proteins are recruited via cIAP1/2-generated ubiquitin 
chains. In addition, HOIP is required for presence of SHARPIN and HOIL-1 in the TNF-RSC. 
This, together with the finding that these three factors form a stimulation-independent 
protein complex in the cytosol, indicates that LUBAC is recruited to the TNF-RSC as a 
tripartite complex via its central component HOIP. 
In-vitro ubiquitination assays showed that SHARPIN is not only a physical but also a 
functional component of LUBAC. HOIP can generate ubiquitin chains when combined with 
either SHARPIN, HOIL-1 or both and was shown to exclusively generate linear linkages via a 
HECT-like mechanism. NEMO was identified as a common target of all possible LUBAC-
combinations in vitro and, in line with this, the activity of LUBAC is required for full 
activation of NF-B following TNF stimulation.  
The results obtained in this thesis identify SHARPIN as a third component of LUBAC, an E3-
complex that is specifically recruited to the TNF-RSC and regulates TNF signalling by 
modifying specific target proteins with linearly linked ubiquitin chains. 
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2 Introduction 
2.1 The ubiquitin system 
Ubiquitin is a small, relatively heat-stable polypeptide of 76 aminoacids that was first 
isolated from bovine thymus (Goldstein, 1974; Schlesinger et al., 1975)  and was found to be 
identical to an essential component of an energy-dependent protein degradation system 
that had been referred to as ATP-dependent proteolysis factor 1 (APF-1) (Ciechanover et al., 
1978; Wilkinson et al., 1980). Ubiquitin is covalently linked via its C-terminus to the amino-
groups of lysine residues or the N-terminus of other proteins by the concerted action of 
three classes of proteins, a ubiquitin activating enzyme (E1), a ubiquitin conjugating protein 
(E2) and a ubiquitin ligase (E3) (Figure 1 and (Ciechanover et al., 1982; Hershko et al., 1983). 
  
 
Figure 1: Schematic representation of the ubiquitination process. In a first ATP-dependent step ubiquitin is 
activated by the E1. In a second reaction it is transferred onto a catalytic cysteine within the E2 and with the 
help of an E3 it is conjugated to an aminogroup, usually the -aminogroup of a lysine residue, within the target 
protein. Depending on the class of E3 participating in the process the last step can involve the formation of an 
E3-ubiquitin thioester intermediate or can occur independently thereof. PPi: inorganic phosphate, RING: really 
interesting new gene, HECT: Homologous to the E6-AP Carboxyl Terminus. 
Ubiquitin itself contains 7 internal lysine-residues, which in addition to the -aminogroup of 
methionine 1 (M1) can be used as conjugation points. Therefore the formation of 
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differentially linked chains is possible and these chains differ both structurally and 
functionally (Komander, 2009; Peng et al., 2003; Virdee et al., 2010). In the context of 
protein degradation the target is often modified with ubiquitin chains linked via lysine (K) 48 
and this leads to its recognition by the proteasome and its degradation (Chau et al., 1989; 
Ciechanover et al., 1980; Hershko et al., 1980). Tagging of target proteins can be reversed by 
the action of ubiquitin specific proteases known as deubiquitinases (DUBs) (Clague et al., 
2012; Komander et al., 2009a; Reyes-Turcu et al., 2009). Ubiquitin is encoded on 4 highly 
conserved genes. Two of these encode linear polyubiquitin in which ubiquitin molecules are 
linked to each other from ‘‘head-to-tail,’’ and the other two genes encode ubiquitin fused to 
ribosomal subunits. Hence, one important function exerted by specific members of the DUB 
family is to co- or posttranslationally cleave the resulting ubiquitin fusion proteins into single 
ubiquitin moieties (Baker and Board, 1987; Finley et al., 1987; Ozkaynak et al., 1984; Reyes-
Turcu et al., 2009; Wiborg et al., 1985). 
Ubiquitin is the prototype of a family of proteins that, in spite of variable sequences, display 
a remarkably similar structure, referred to as the -GRASP fold. This structure contains a 
domain with two -sheets followed by an -helix and another two -sheets (Schulman and 
Harper, 2009; van der Veen and Ploegh, 2012; Vijay-Kumar et al., 1987). Due to the 
similarities to ubiquitin, the structure and the group of proteins containing it are also 
referred to as the ubiquitin-like (UBL)-fold and -family, respectively. Members of the UBL-
family include, amongst others, NEDD8, ATG8, SUMO1-3, FAT10 and ISG15 that, like 
ubiquitin, can be covalently conjugated to target proteins via an isopeptide bond. The 
mechanisms of tagging proteins with the different UBLs are similar but rely on specific 
enzymes and only the process of ubiquitination will be discussed here (van der Veen and 
Ploegh, 2012).  
2.1.1 The ubiquitination process 
The ubiquitination process involves three steps. In the initial step ubiquitin is activated in an 
ATP-dependent manner by the E1. The second step involves the formation of an energy-rich 
thioester bond between ubiquitin and the E2 and in the final step, which is facilitated by an 
E3, an isopeptide bond between the C-terminus of ubiquitin and an aminogroup in the 
target protein is established and ubiquitin thus becomes covalently linked to the substrate.    
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2.1.1.1 Ubiquitin-activating enzymes (E1s) 
In humans there are two ubiquitin-specific E1s, UBA1 and UBA6 (Chiu et al., 2007; Jin et al., 
2007; Pelzer et al., 2007). The two proteins are distantly related and share about 40 % 
sequence identity. Whereas UBA1 is involved in charging a variety of E2s with ubiquitin, 
UBA6 is more restricted in its activity and charges the UBA6-specific E2 USE1. In addition the 
two enzymes seem to differ in their catalytic efficiencies in vivo. Almost all UBA1 molecules 
as well as its substrates are in their activated or charged forms at steady state whereas only 
50 % of the UBA6 and USE1 molecules are activated or charged under the same conditions 
(Jin et al., 2007).  
Structurally, E1s are characterised by three domains, the adenylation-domain, the catalytic 
cysteine containing domain and the C-terminal ubiquitin fold domain (UFD) (Schulman and 
Harper, 2009). The adenylation-domain is responsible for the initial binding of the 
substrates ubiquitin and ATP•Mg2+ and for the acyl-adenylation of ubiquitin. It is a 
pseudo-symmetric domain that resembles the prokaryotic proteins molybdopterin 
biosynthetic enzyme B (MoeB) and thiamine biosynthesis protein F (ThiF) (Lake et al., 2001; 
Lee and Schindelin, 2008). These bacterial proteins are involved in the C-terminal acyl-
adenylation of molybdopterin converting factor subunit 1 (MoaD) and thiamine biosynthesis 
protein S (ThiS), thus enabling them to form a C-terminal thiocarboxylate which facilitates 
the insertion of sulphur into the organic cofactors thiamine and molybdopterin respectively 
(Hochstrasser, 2000; Rajagopalan, 1997; Taylor et al., 1998). Human E1s resemble MoeB and 
ThiF not only structurally but also in the mechanism catalysing the adenylation of their 
substrates (Pickart and Eddins, 2004). Generally the reaction mediated by the E1 can be 
divided into two steps, the initial formation of a ubiquitin-adenylate intermediate and the 
following generation of an E1-Ub thioester.  The activation of ubiquitin is initiated by the E1 
binding to its substrates. Structural studies on MoeB and ThiF suggest that one of their two 
symmetrical catalytic centres binds a surface on the substrate that corresponds to the 
hydrophobic L8-I44-H68-V70 patch in ubiquitin whereas the other contributes to the 
stabilisation of this interaction. The monomer that is not involved in nucleotide binding 
contains a conserved arginine that is involved in binding ATP and an aspartate residue 
coordinating Mg2+ (Lee and Schindelin, 2008; Pickart and Eddins, 2004; Schulman and 
Harper, 2009) (Figure 2, upper panel).  
 
2. Introduction 
  
9 
 
 
Figure 2: Activation of ubiquitin by the E1. In the first step the E1 binds ATP•Mg
2+ 
and catalyses the C-terminal 
acyl-adenylation of ubiquitin (upper panel). In the second part of the reaction (lower panel), the catalytic 
cysteine of the E1 attacks the ubiquitin-adenylate and a thioester linkage is formed between the C-terminus of 
ubiquitin and the catalytic cysteine. The individual steps are reversible in principle and the reaction is driven by 
the release of inorganic phosphate (PPi) and AMP.  
The key catalytic residues including the Mg2+-coordinating aspartate and basic residues that 
provide electrostatic stabilization to the departing pyrophosphate product are conserved in 
E1 enzymes from E. coli to humans. The conserved arginine that contributes to ATP-binding 
is located in a distant region of the linear sequence of UBA1 (Pickart and Eddins, 2004). By 
making positive contacts with residue 72 of ubiquitin UBA1 can distinguish its substrate 
from the UBL-protein NEDD8 which at this position contains an alanine instead of the 
arginine present in ubiquitin (Lee and Schindelin, 2008; Walden et al., 2003a; Walden et al., 
2003b). This ensures that only the correct substrate can enter the ubiquitination cascade. 
Once all substrates are bound the E1 facilitates the attack of the C-terminal carboxylate 
oxygen of ubiquitin at the -phosphate of ATP. This results in the C-terminal adenylation of 
ubiquitin which stays non-covalently associated with the E1 (E1~Ub(A)) and the release of 
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inorganic phosphate (PPi) (Haas and Rose, 1982; Haas et al., 1982; Haas et al., 1983). The 
ubiquitin-adenylate is attacked by the catalytic cysteine of UBA1 which, under the 
elimination of AMP, results in an E1-Ub(T) complex that is covalently linked by a thioester 
bond between the C-terminus of ubiquitin and the catalytic centre of the E1 (Figure 2, lower 
panel) (Ciechanover et al., 1982; Ciechanover et al., 1981; Haas et al., 1982). Although a 
general base poised to deprotonate the catalytic cysteine has not been identified, a network 
of polar and charged side chains surrounding the thioester bound was found to be critically 
involved in the catalysis (Huang et al., 2007; Schulman and Harper, 2009).  Both steps of this 
process, i.e. the adenylation of ubiquitin and the formation of the thioester bond, are in 
principle reversible but the release of PPi and AMP drives the progression through the 
reaction (Haas and Rose, 1982; Haas et al., 1982).  
Once the thioester intermediate has been established UBA1 catalyses the adenylation of a 
second ubiquitin which remains non-covalently associated with the adenylation domain. 
UBA1 thereby becomes asymmetrically associated with two ubiquitin molecules 
(E-Ub(T)~Ub(A)) (Figure 3; (Haas and Rose, 1982; Schulman and Harper, 2009).  
 
 
Figure 3: Schematic representation of the 
different steps of the reaction catalysed 
by the E1. Step 1 shows the activation of 
ubiquitin by the formation of ubiquitin-
adenylate, step 2 represents the thioester 
formation, step 3 depicts the additional 
association with a second adenylated 
ubiquitin and step 4 shows the transfer of 
ubiquitin to the E2. Modified from (Haas 
and Rose, 1982).  
In order for the ubiquitination reaction to proceed UBA1 needs to associate with an E2 and 
transfer the activated ubiquitin to its catalytic centre. Although UBA1 can work with a 
variety of different E2s it needs to be ensured that E2s are not charged with the wrong kind 
of UBL. UBA1 therefore needs to select only ubiquitin-specific E2s. This is achieved mainly 
by interactions between the UFD of the E1 and the N-terminal sequence of the E2’s catalytic 
domain (Huang et al., 2007; Lee and Schindelin, 2008; Wenzel et al., 2011b). Subtle 
differences between the UFDs of UBA1 and UBA6 allow them to interact with different E2s 
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(Jin et al., 2007). The interaction between E2s and the E1 in its uncharged state is usually 
weak as shown by the observation that UBA1 can be separated from the E2 by gelfiltration 
(Hershko et al., 1983). On the other hand doubly charged UBA1 (E1-Ub(T)~Ub(A)) binds 
uncharged E2s with nanomolar affinities (Haas et al., 1988). This increased affinity could be 
due to the availability of additional binding sites. Indeed, the ubiquitin thioester itself may 
act as an interaction point. Furthermore, a rotation in the E1’s UFD could unmask an 
additional E2 binding surface in the adenylation domain of the E1 and make a negatively 
charged groove in the UFD accessible. This feature can be recognised by two conserved 
lysine residues that are present in the 1-helix of all ubiquitin-specific E2s but absent from 
E2s involved in the conjugation of other UBLs (Huang et al., 2007; Lee and Schindelin, 2008; 
Ye and Rape, 2009). The conformational changes induced in the E1 by its charging with 
ubiquitin therefore contribute to both affinity and specificity for the E2. In addition, the 
rotation of the UFD and possibly the catalytic domain could also bring the ubiquitin 
thioester into close proximity to the catalytic centre of the E2 and may thus be a 
prerequisite for the ubiquitin transfer to occur (Huang et al., 2007; Schulman and Harper, 
2009). In this thioester transfer reaction the C-terminus of the covalently bound ubiquitin is 
transferred from the E1 to the catalytic cysteine of the E2. By elimination of the 
E1-ubiquitin-bond one of the binding sites for the E2 is lost and the thioester-linked E2-
ubiquitin complex is released from the E1. This enables the charged E2 to interact with an 
E3 which, due to a structural overlap in the E1- and E3-binding sites on the E2, is not 
possible in the presence of an E1 (Eletr et al., 2005). In addition, the dissociation of the E1-
E2 complex enables the E1 to participate in additional rounds of ubiquitin-activation and 
transfer.  
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2.1.1.2 Ubiquitin-conjugating enzymes (E2s) 
Ubiquitin conjugating enzymes are characterised by a conserved catalytic domain of 
approximately 150 aminoacids that assumes a compact structure in the shape of an 
elongated ellipsoid and that is referred to as Ubc domain. This domain contains 4 -helices, 
a short 310 helix, i.e. a right handed helix in which the stabilising hydrogen-bonds are formed 
between the CO-group of one aminoacid and the NH-group of the aminoacid three residues 
later, and a 4-stranded antiparallel -sheet (Lin et al., 2002; Wenzel et al., 2011b; Ye and 
Rape, 2009). Apart from the catalytic cysteine, the enzymatic reaction also involves other 
essential residues as for example an HPN-motif approximately 10 aminoacids N-terminal of 
the catalytic cysteine in which histidine serves a structural role and asparagine is involved in 
mediating the formation of an isopeptide bond between ubiquitin and the substrate. These 
conserved aminoacids are located in a groove on the bottom of the domain which is formed 
by the loop connecting helix 2 and helix 3 and the loop proximal to the catalytic cysteine 
(Wenzel et al., 2011b; Wu et al., 2003; Ye and Rape, 2009). In addition to the signature Ubc 
domain, E2s can also contain additional domains that vary in size and structure and that can 
contribute to E3- or substrate binding or regulate the intrinsic activity of the E2. According 
to the presence or absence of these additional features E2s can be allocated to 4 subclasses: 
class I contains only the Ubc-domain, class II has a C-terminal extension, class III E2s are 
characterised by additional domains in their N-terminus and class IV comprises of E2s that 
have additional domains in both their N- and their C-terminus (van Wijk and Timmers, 
2010). However, this classification does not permit predictions concerning the functionality 
of the E2. Alternatively, E2s can be classed into those initiating chain formation, those that 
interact with ubiquitin moieties already attached to a substrate and that exclusively 
promote chain elongation and those that can fulfil both functions. In the group of chain-
initiating E2s it can further be distinguished between those E2s that target lysine residues in 
an unspecific manner and therefore serve as general activators of the ubiquitination process 
and those that recognise a sequence or motif in the proximity of the aminogroup to be 
targeted and that therefore act in a more substrate-specific manner (Ye and Rape, 2009). 
Finally, E2s could be divided into groups based on their ability to catalyse the formation of 
isopeptide bonds. Most E2s can transfer the activated ubiquitin to either cysteine residues 
on an E3 thereby forming another thioester intermediate or to lysine residues of target 
proteins or ubiquitin through formation of an isopeptide-bond. On the other hand it was 
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recently found that UBE2L3 lacks lysine reactivity and the formation of an E3-ubiquitin 
thioester is therefore obligatory in reactions catalysed by this E2. It is possible that other E2s 
have similar requirements but, due to the concept being quite recent, this has not been fully 
established (Wenzel et al., 2011a). Because the E2-thioester bond is relatively stable and in 
order to ensure substrate specificity, E2s need to cooperate with E3s in transferring 
ubiquitin (Song et al., 2009). Although N- or C-terminal domains can contribute to some 
extent, the E3-binding is mainly mediated by the Ubc-domain of an E2. Specifically, polar 
and charged residues in helix 1, hydrophobic residues in loop 7 and, depending on the E3, a 
conserved hydrophobic residue in loop 4 mediate this interaction. Variations in these 
interacting parts generate specificity of the E2-E3 combinations (Ye and Rape, 2009) 
meaning that not every E2 can interact with every E3 and vice versa. However, as expected 
from the respective numbers (there are about 38 E2s and 600-1000 E3s encoded in the 
human genome) E2-E3 pairs are usually not exclusive. Most E2s can bind different E3s while 
many E3s can also accommodate different E2s. As described previously, the E2-E3 
interaction generally needs to be dissolved for the E2 to be recharged by the E1. E2-E3 
complexes are therefore of a transient nature, with the binding partners displaying only low 
affinities in the micromolar range for each other (Wenzel et al., 2011b; Yin et al., 2009b). 
Nevertheless, these associations are sufficient for the catalysis to occur. The structural and 
catalytic requirements for a transfer of ubiquitin between thiols or from a thiol to an amine 
should include an oxyanion hole that can stabilise the charged intermediate formed during 
the attack of the thiol- or aminogroup. In addition a general base might be required to 
deprotonate the attacking group which may be especially relevant for the -aminogroup of 
lysine which has a high pKa. However, most of these features have not been identified in E2s 
(Pickart and Eddins, 2004). It is therefore possible that E1 or E3 contribute certain catalytic 
elements in the respective reactions. Although binding of an E3 substantially increases the 
rate of ubiquitin discharge from the E2’s catalytic centre, the fact that the binding of the E3 
occurs at a surface of the E2 that is distant from its active site makes this direct cooperation 
seem less likely (Das et al., 2009b; Deshaies and Joazeiro, 2009; Ozkan et al., 2005; Zheng et 
al., 2000). On the other hand binding of the E3 or a substrate might induce conformational 
changes in the E2 that might cause potential cryptic groups in the active centre to adopt a 
catalytic conformation. A strictly conserved asparagine (Asn) residue for example could then 
form part of the oxyanion hole (Ozkan et al., 2005; Wu et al., 2003). A schematic 
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representation of ubiquitin being transferred from the E2 to a target or the catalytic 
cysteine of an E3 is shown in Figure 4.  
 
 
 
 
 
 
Figure 4: Schematic representation of the 
ubiquitin-transfer from an E2 to a target 
or an E3. An E2 that was charged by the 
corresponding E1 carries activated 
ubiquitin in a thioester bond. This can be 
attacked by the catalytic cysteine of an E3 
(right part) or by an aminogroup of a 
target protein or a ubiquitin-molecule 
already associated with a substrate. 
Usually the aminogroup involved in the 
formation stems from a lysine residue 
(shown here) but the -aminogroup can 
also be involved (resulting bond not 
shown). The catalytic residues present in 
the E2 have not been entirely clarified but 
a conserved Asn residue is thought to be 
involved in stabilising the intermediate.  
 
In this reaction E2s are not only carriers that transfer ubiquitin from the E1 to the E3 or the 
substrate but they also have an important regulatory role. Due to the internal lysine 
residues present in ubiquitin the formation of inter-ubiquitin linkages and thus ubiquitin-
chains is possible. The function of these chains depends both on length and linkage type 
(Hochstrasser, 2006) and E2s are involved in determining both these features. The length of 
a ubiquitin chain depends on the availability of chain-elongating E2s and on the processivity 
of the ubiquitination reaction. The term processivity is defined as the number of ubiquitin 
molecules transferred to a substrate during a single round of its association with the E3 
(Hochstrasser, 2006). E2s can influence this factor because it depends on efficient chain 
initiation, which is usually the rate limiting step in a ubiquitination reaction (Deshaies and 
Joazeiro, 2009). This first step can be supported by substrate binding sites within the E2. The 
reaction can be further optimised by atypical E2-E3 interactions that enable recharging of 
the E2 without the need to fully dissociate from the E3. Other factors that can enhance the 
processivity and thereby favour the generation of longer chains include the oligomerisation 
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of E2s or even the pre-assembly of ubiquitin chains on the active site of the E2 which can 
then be transferred en bloc to the substrate (Brzovic et al., 2006; Li et al., 2007; Li et al., 
2009b; Ravid and Hochstrasser, 2007). In addition, non-covalent interactions between an E2 
and ubiquitin may force the acceptor ubiquitin to adopt a certain orientation making only a 
particular aminogroup accessible to the active centre thereby determining linkage 
specificity. This influence on chain topology exerted by the E2 is especially relevant in 
reactions that proceed without the formation of a covalent E3-ubiquitin intermediate 
(Eddins et al., 2006; Nagy and Dikic, 2010; VanDemark et al., 2001).  
2.1.1.3 Ubiquitin ligases (E3s) 
Although E2s can have substrate-binding features, modification of targets with ubiquitin 
usually depends on a third class of proteins, the ubiquitin ligases (E3). All E3s share E2-
binding properties and the ability to recognise specific substrates. However, in the case of 
E3-complexes, these two functions may be performed by different subunits of the protein 
assembly (Pickart and Eddins, 2004). Due to the necessity to ensure specific recognition of a 
plethora of different substrates, a large number of E3s exists which can be subdivided into 
two major classes, the RING/U-box- and the HECT-ligases. The former group comprises 
approximately 95 % of all predicted E3s (Li et al., 2008).  Although both subgroups facilitate 
the transfer of ubiquitin from the charged E2 to the target protein, members of the two 
families differ both structurally and in the mechanism they employ. While RING-E3s act as a 
scaffold bridging the E2 and the substrate, HECT-ligases contain a catalytic cysteine and 
form a thioester intermediate with ubiquitin before transferring it onto the target (Figure 1). 
Thus the active centre mediating the formation of the final (iso)peptide-bond differs 
depending on the E3 involved with aminolysis being catalysed by HECT-ligases themselves 
whereas the active centre of the E2 is responsible in RING-dependent reactions (Deshaies 
and Joazeiro, 2009; Rotin and Kumar, 2009).  
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2.1.1.3.1 HECT-ligases 
The founding member of this family of proteins is the human papilloma virus (HPV) 
E6 associated protein (E6AP) (Huibregtse et al., 1995). Proteins are classified as members of 
this family based on the presence of a bilobal HECT-domain, which is formed by 
~350 aminoacids and which is homologous to E6AP’s C-terminus. The N-terminal lobe of this 
domain (N-lobe) mediates E2 binding whereas the C-terminal lobe (C-lobe) contains the 
catalytic cysteine (Huibregtse et al., 1995; Pickart, 2001). Apart from this signature domain, 
which is generally located in the C-terminal part of the E3, most members of the HECT-
family contain additional structures in their N-terminus that can for example be involved in 
substrate binding (Rotin and Kumar, 2009). According to the specific N-terminal domains 
HECT-ligases can be subcategorised into three groups. Nedd4 ligases are characterised by a 
C2 domain, which binds to phospholipids and targets the protein to membranes, and by two 
to four WW-domains that typically bind PY-motifs in substrates thereby mediating protein-
protein interactions (Kanelis et al., 2001; Staub et al., 1996). HECT-E3s containing regulator 
of chromosome condensation 1 (RBCC1)-like domains (RLDs) are referred to as HERC-ligases. 
The RLD assumes a 7-bladed -propeller fold and apart from mediating interaction with 
chromatin might also serve as a guanine exchange factor (GEF) for the small GTPase Ran 
(Garcia-Gonzalo and Rosa, 2005; Renault et al., 2001; Renault et al., 1998). E3s of this class 
can further be subdivided into large HERCs which contain multiple RLDs and small HERCs 
which contain only a single copy of this domain. Finally, HECT-ligases containing other 
N-terminal features such as ankyrin repeats, zinc fingers, UBA-, PHD- or RING-domains are 
assigned to the group of “other HECTs” (Rotin and Kumar, 2009).  
Like E2s, HECT-E3s accept ubiquitin on a catalytic cysteine by forming a thioester 
intermediate which is then attacked by the aminogroup of a target residue resulting. This 
results in the formation of an isopeptide-bond and thus in the ubiquitination of the target 
(Pickart and Eddins, 2004; Scheffner et al., 1995). As in the case of E2s (see section 2.1.1.2), 
the active site of HECT-ligases lacks well-positioned candidates for the anticipated general 
base and the oxyanion hole (Pickart and Eddins, 2004). It is therefore likely that 
conformational changes induced by substrate- or ubiquitin-binding lead to a rearrangement 
in the catalytic centre. The need for a change in conformation is further emphasised by the 
observation that, if the native conformation was maintained, the catalytic centre of the E2 
would be separated from the E3’s catalytic cysteine by a distance too great to enable 
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ubiquitin transfer (Verdecia et al., 2003).  Due to their active role in transferring ubiquitin 
specificity for a certain chain topology can be an intrinsic, E2-independent property of HECT-
E3s (Kim and Huibregtse, 2009).  
2.1.1.3.2 RING- and U-box-E3 ligases 
Members of the RING-family are characterised by a RING domain which, unlike the HECT-
domain can be located anywhere within the protein. This characteristic domain is a 
cysteine- and histidine-rich domain that was first identified in really interesting new gene 1 
(RING1) (Freemont et al., 1991). It consists of a central -helix and several small -strands 
that are separated by variable loops (Pickart and Eddins, 2004). On one surface a shallow 
hydrophobic groove is formed by the central helix and the loops. The overall primary 
sequence of this domain is not well conserved. However, characteristic cysteine and 
histidine residues, which are buried in the domain’s core where they coordinate two zinc 
ions, and their spacing are largely invariant. Although swapping of cysteine and histidine 
residues or replacement by other zinc-coordinating residues is possible in certain cases, the 
canonical RING-sequence can be summarised as C-X2-C-X9-39-C-X1-3-H-X2-3-C-X2-C-X4-48-C-X2-C 
(Deshaies and Joazeiro, 2009). The zinc-coordinating residues are interleaved, yielding a 
rigid globular structure (see Figure 5A) (Barlow et al., 1994; Borden et al., 1995). A similar 
overall structure is assumed by the UFD2-homology (U-box) domain. UFD2 is a yeast protein 
that is involved in the elongation of ubiquitin chains and is hence categorised as an E4 
(Koegl et al., 1999). Other proteins containing this domain can however also act as E3s in a 
manner very similar to that of RING-containing E3s (Jiang et al., 2001). The U-box domain 
does not coordinate zinc ions but like the RING-domain it has a hydrophobic core and two 
interaction centres. Charged or polar residues, that correspond to the zinc-coordinating 
residues of the RING in their function and position, form salt bridges and hydrogen-bonds 
whereby the domain adopts an overall RING-like fold (Ohi et al., 2003). Functionally, the 
RING-domain was first thought to be involved in DNA-binding but many RING-containing 
proteins were soon found to act as ubiquitin ligases (Freemont et al., 1991; Joazeiro et al., 
1999; Lorick et al., 1999; Xie and Varshavsky, 1999). Indeed most RING-proteins seem to 
posses the ability to act as an E3. However, there are a few exceptions. In these cases 
heterodimerisation with an active RING-E3, mediated by the RING-domain itself or other 
domains present in the respective proteins can greatly increase the activity of the latter 
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protein (Hashizume et al., 2001; Linares et al., 2003; Wang et al., 2004). Furthermore, 
dimerisation of the E3 can increase the processivity of ubiquitination by favouring the 
recruitment of multiple E2s or by inducing conformational changes required for activity 
(Feltham et al., 2011; Feltham et al., 2010; Tang et al., 2007). Unlike HECT-ligases, RING-E3s 
do not form a covalent intermediate with ubiquitin (Joazeiro and Weissman, 2000). Instead 
they mediate ubiquitination of a substrate by inducing sufficient proximity between the E2 
which binds to the hydrophobic groove on the surface of the RING-domain (Zheng et al., 
2000) and the target protein. It is thought that the rigidity of the RING-domain is well suited 
for fixing the E2 and the substrate in a favourable position. In addition, binding of the E3 
induces conformational changes in the E2 (see section 2.1.1.2) and thus RING-E3s indirectly 
favour ubiquitination (Pickart and Eddins, 2004; Zheng et al., 2000). The lysine targeted by 
this reaction is likely to be chosen based on its ability to access the thioester-bond in the 
catalytic centre of the E2 rather than by the surrounding primary sequence. However a 
certain influence could be exerted by the proximal residues as nearby basic residues could 
lower the pKa of the aminogroup and thus enhance its reactivity (Deshaies and Joazeiro, 
2009). An influence of the E3 on the selection of the target residue seems likely and could 
be mediated by binding the substrate in a way that makes only a certain residue accessible 
for ubiquitination. However, conserved residues on the E3 that would be suitable to guide 
substrates in this way have not been identified (Pickart and Eddins, 2004). On the other 
hand, domains outside the RING-domain might also contribute to binding and orienting the 
target. Indeed about three quarters of all RING-ligases are predicted to have additional 
domains such as SH2-, SH3-, PDZ- or UBL-domains (Li et al., 2008). Based on these domains 
and on sequence homology subclasses of RING-proteins can be established, the largest 
classes being the TRIM/RBCC family which is characterised by a B-box and a coiled-coil 
domain (Meroni and Diez-Roux, 2005; Sardiello et al., 2008) and the RBR/TRIAD group of E3s 
which comprises those E3s that contain two RING-domains separated by an 
in-between-RING (IBR) domain (Eisenhaber et al., 2007; Marin and Ferrus, 2002).  
The founding member of the latter subfamily was Parkin, a protein that, when mutated and 
inactivated, predisposed to several forms of Parkinson’s disease (Foroud et al., 2003; Kitada 
et al., 1998; Oliveira et al., 2003a; Oliveira et al., 2003b; Pankratz et al., 2003). Structurally it 
contains an N-terminal UBL-domain followed by two typical RING-domains (C3HC4) and an 
intermediate IBR which is characterised by a C6HC pattern (Kitada et al., 1998; Morett and 
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Bork, 1999; van der Reijden et al., 1999). The sequence of RING1-IBR-RING2 comprises 
around 200 aminoacids, and is referred to as RBR-domain (Eisenhaber et al., 2007; Marin 
and Ferrus, 2002). This structural element, like isolated RING-domains, can be located 
anywhere in a protein and is the defining feature of the RBR-family (Wenzel and Klevit, 
2012). In humans this group comprises only approximately 15 members so far. However, the 
RBR-proteins constitute an ancient and highly diversified family, members of which can be 
found in fungi, plants and animals (Marin, 2009; Marin and Ferrus, 2002; Marin et al., 2004). 
Many of the RBR-proteins were shown to act as E3s. The three parts of the RBR-domain are 
all cysteine- and histidine-containing zinc-coordinating features but they nevertheless show 
certain differences. Comparison of the general formulas for RING1 (C-X2-C-X10–24-C-X1–6-H-X2-
C-X2-C-X14–25-C-X2–9-C) and RING2 (C-X2-C-X9–11-C-X-H-X2-C-X1–4-C-X4-C-X2-C) shows that the 
RING1 domain is longer, usually around 60 aminoacids, and shows greater tolerance 
towards changes in sequence or size of its loops than the RING2 which comprises only 
approximately 40 residues. The IBR-RING is intermediate in size (~50 aminoacids) and like 
the RING1 more variable in the loops connecting the zinc coordinating residues (Eisenhaber 
et al., 2007; Marin and Ferrus, 2002). On the other hand the identity of these cysteine and 
histidine residues is more strictly conserved in the N-terminal domains. Indeed, structural 
studies revealed that the RING2-domain of ARIH1 (also known as human homolog of 
Drosophila ariadne-1 (HHARI)), assumes an atypical conformation coordinating only a single 
zinc ion (Figure 5B; (Capili et al., 2004).  
A recent study found that the RING2 domain of ARIH1 is required for E3 activity and 
involved in formation of a ubiquitin thioester (Wenzel et al., 2011a). Accordingly, a HECT-
like mechanism was suggested for all RBR-E3s (Figure 5C and (Wenzel and Klevit, 2012)). 
Whereas the functions of RING1- and RING2-domains consist of E2-binding and carrying out 
the enzymatic reaction, respectively, the relevance of the IBR-domain is less well 
understood. It is possible that it has a structural role in bringing RING1 and RING2 into close 
proximity thus allowing the catalytic cysteine to attack the thioester bond of the RING1-
bound E2-ubiquitin complex (Wenzel and Klevit, 2012). However additional studies will have 
to clarify whether this is the only function of this domain.  
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Figure 5: Schematic representation of classical and atypical RING-domains and of the HECT-like mechanism 
adopted by RBR-E3s. A: Representation of a classical RING-domain. A sequence of 7 cysteine (C) and one 
histidine (H) residues forms an interleaved structure coordinating two zinc residues. X indicates interspacing 
aminoacids. The backbone is shown as a black line; non-covalent interactions are depicted as dashed lines. B: 
Schematic structure of a classical RING coordinating two zinc ions as compared to the RING2 domain of ARIH1 
which does not show a canonical RING fold and only binds one zinc ion. Modified from (Capili et al., 2004).  C: 
RBR E3s act via a HECT-like mechanism. Ubiquitin is transferred from the E2-ubiqutin complex that is bound by 
the RING1-domain to a catalytic cysteine present in the RING2 of the E3 before being conjugated to the target 
protein.  
Overall, RBRs can be categorised as RING-HECT-hybrids, and due to their direct involvement 
in ubiquitin transfer they are likely to determine the topology of the generated ubiquitin 
chain independently of the E2 involved and are thus critically involved in determining the 
fate of their target proteins.  
2.1.2 Different forms of ubiquitination 
Like phosphorylation, ubiquitination leads to a covalent posttranslational modification of a 
target protein. The attachment of a ubiquitin moiety can occur at one (monoubiquitination) 
or several sites (multi-monoubiquitination). In contrast to phosphorylation, ubiquitination 
has a further layer of complexity as chains of ubiquitin can be generated. This results from 
the possibility to attach the C-terminus of a ubiquitin molecule to the N-terminus or one of 
the 7 internal lysine residue of the preceding moiety and allows the formation of eight 
different types of polyubiquitin (Behrends and Harper, 2011). Chains in which identical 
lysine residues mediate linkage of sequential ubiquitin molecules, e.g. the C-terminus of the 
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distal ubiquitin forms an isopeptide-bond with lysine 48 of the proximal ubiquitin 
throughout the chain, are referred to as homotypic chains (Figure 6).  
 
 
 
Figure 6: Types of 
ubiquitination. A 
target protein can be 
modified on one or 
several sites by single 
ubiquitin molecules 
or by ubiquitin 
chains. Polyubiquitin 
can be linked via one 
of the seven lysine 
residues of ubiquitin 
or its N-terminus 
resulting in 
differentially linked 
chains. Different 
linkages can also be 
combined in one 
chain.  
K48-linked chains, that were the first to be functionally characterised (Chau et al., 1989) are 
referred to as canonical whereas all other linkage types are usually referred to as non-
canonical or atypical chains. This nomenclature can vary slightly as K63-linked ubiquitin, the 
second linkage to be associated with a functional outcome (Deng et al., 2000; Spence et al., 
1995), is sometimes counted among the canonical forms of ubiquitination. In addition to the 
homotypic chains the formation of heterotypic ubiquitin conjugates is possible. In the latter 
not only one but different lysine residues are used to conjugate ubiquitin molecules thus 
creating a chain that contains alternating linkage types. The group of heterotypic 
polyubiquitin chains also comprises branched or forked linkages in which a single ubiquitin is 
extended at two or more lysine residues (Ben-Saadon et al., 2006; Kim et al., 2007; Peng et 
al., 2003).  
Modification of a target by covalent conjugation of ubiquitin molecules can change its fate 
by exerting an allosteric effect on its activity as for example in the activation or inactivation 
of an enzyme by ubiquitination-induced conformational changes. Alternatively, 
ubiquitination can enable interactions with proteins that specifically bind ubiquitin via 
ubiquitin-binding domains (UBDs) (Dikic et al., 2009; Komander, 2009; Scaglione et al., 2007; 
Todi et al., 2009). There are at least 20 different types of UBDs, including for example 
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ubiquitin binding zinc fingers (ZnF) (UBZ), nuclear protein localisation 4 ZnFs (NZFs), 
ubiquitin conjugating (Ubc) domains, typically found in E2s, ubiquitin interacting motifs 
(UIMs) and ubiquitin-associated (UBA) domains. The individual domains employ different 
structural elements and can recognise different surfaces on the ubiquitin molecule. Their 
interaction with conformations generated by a specific linkage between two ubiquitin 
molecules allows them to specifically bind one but not another type of ubiquitin chains 
(Dikic et al., 2009; Hurley et al., 2006). Despite the structural similarities in a UBD-family, 
specific recognition of a particular linkage type can usually not be attributed to UBDs of only 
a single family and in addition different members of the same family can show different 
linkage specificities (Dikic et al., 2009; Raasi et al., 2005).  Although UBDs usually show very 
low affinities for isolated ubiquitin molecules they can efficiently mediate the interaction 
between ubiquitin and the UBD-containing protein, also referred to as a ubiquitin receptor 
(Hurley et al., 2006). Efficient binding in spite of low affinity is usually due to increased 
avidity which can be accomplished by the presence of multiple UBDs in a protein, by 
oligomerisation of ubiquitin receptors or by accumulation of ubiquitin-receptors and -chains 
in cellular compartments or in multi-protein complexes. Binding of ubiquitin receptors to a 
ubiquitinated protein can alter the activity, localisation or stability of the modified target 
protein. Due to the ability of ubiquitin-interacting proteins to differentiate between the 
different forms of ubiquitination (Dikic et al., 2009; Raasi et al., 2005) the fate of a target 
depends on the type of modification it is subject to. This applies not only to the difference 
between mono- and polyubiquitination but also to differentially linked ubiquitin chains. An 
additional aspect that contributes to the specific outcomes of ubiquitination with the 
individual forms of ubiquitination relates to different linkages being more or less refractory 
towards the disassembly by particular DUBs. These proteases usually also contain UBDs 
allowing them to interact with ubiquitin chains of specific linkage types thus enabling them 
to efficiently and specifically cleave the (iso)peptide bonds linking the individual ubiquitin 
molecules (Bremm et al., 2010; Faesen et al., 2011; Komander et al., 2009a; Virdee et al., 
2010).  
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2.1.2.1 Monoubiquitination 
When compared to other posttranslational modifications such as phosphorylations, 
ubiquitination involves the attachment of a relatively large molecule to the target. Although 
the bigger surface area of ubiquitin provides a variety of potential interaction sites (Searle et 
al., 2012; Winget and Mayor, 2010) most UBDs bind to a hydrophobic area surrounding 
Ile44 (Ile44 patch) of ubiquitin, rendering the recognition of monoubiquitin by different 
UBDs mutually exclusive. This exclusivity can prevent a single ubiquitin molecule from 
triggering different and possibly opposing signals at the same time. However, it is possible 
that wherever cooperation of two ubiquitin-binding proteins is needed, their UBDs may 
recognise different features in the ubiquitin molecule allowing the receptors to be recruited 
at the same time (Dikic et al., 2009). Therefore, attachment of a single ubiquitin molecule to 
one or several sites in a target protein can not only be the initiating step of a 
polyubiquitination (Windheim et al., 2008) but may in itself already alter the fate of the 
substrate. In the DNA-damage response for example, monoubiquitination of histones or of 
the DNA sliding clamp proliferating-cell nuclear antigen (PCNA) is of functional relevance. In 
yeast the ubiquitination status of PCNA is decisive for the method by which replication 
passes damaged DNA. Monoubiquitination of PCNA triggers translesion synthesis, which is 
more error prone than the template switching pathway initiated by K63-ubiquitinated PCNA 
(Hoege et al., 2002; Ulrich and Jentsch, 2000). Multiple-monoubiquitination is also 
implicated in internalisation and subsequent lysosomal degradation of cell surface receptors 
(Haglund et al., 2003). Here some of the subunits of the multimeric endosomal-sorting 
complex required for transport (ESCRT) machinery contain UBDs which are responsible for 
ubiquitinated cargoes to be recruited and to be transported to multivesicular bodies (MVBs) 
where they are degraded in a lysosomal manner (Hirano et al., 2006; Raiborg and Stenmark, 
2009; Williams and Urbe, 2007). A role for multi-monoubiquitination in the context of 
protein degradation is indicated by the finding that processing of the nuclear factor kappa B 
(NF-B) precursor p105 to the NF-B subunit p50 can be initiated by the conjugation of 
single ubiquitin moieties rather than of a polyubiquitin chain (Kravtsova-Ivantsiv et al., 
2009). In addition, following genotoxic stress monoubiquitination of phosphorylated and 
SUMOylated NF-B essential modulator (NEMO, also known as IKK), the regulatory subunit 
of the inhibitor of kappa B kinase (IKK) complex, in the nucleus leads to its export to the 
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cytoplasm where it can mediate the induction of the NF-B pathway (Hadian and 
Krappmann, 2011; Huang et al., 2003).  
2.1.2.2 Polyubiquitination 
As mentioned previously the generation of ubiquitin chains can occur by the formation of an 
(iso)peptide-bond between the carboxyl-group of the incoming ubiquitin moiety and an 
aminogroup of the preceding molecule. The latter group can be provided by the N-terminal 
methionine (M1) or by one of the internal lysine residues (K6, K11, K27, K29, K33, K48 or 
K63). Studies in both yeast and cell lines found that all possible linkage types exist in vivo. 
Different studies found K48 to be the most abundant linkage type with 29 % and 52 % of all 
ubiquitin chains being linked in this manner in yeast and HEK293 cells respectively (Dammer 
et al., 2011; Xu et al., 2009b). The percentages of the other chain types were estimated as 
11 % (K6), 28 % (K11), 9 % (K27), 3 % (K29), 4 % (K33) and 16 % (K63) in yeast (Xu et al., 
2009b) and 2 % (K11), 8 % (K29), 38 % (K63) of all ubiquitin chains were found to be linked in 
an atypical manner in HEK293 cells where the amounts of K6-, K27-, K33- and M1-linked 
chains accounted for less than 0.5 % (Dammer et al., 2011). Due to technical limitations of 
the analysis and because certain linkages are formed in a stimulation- or cell cycle 
dependent manner, the observed percentages may not represent the physiological 
relevance of the individual chain types. Branched chains including for example K29 and K33 
linkages were also identified and it was found that in contrast to all other homomeric chains 
these forked chains cannot be degraded by the proteasome (Kim et al., 2007). Indeed, 
inhibition of the proteasome increases the amount of all linkages in HeLa cells (Meierhofer 
et al., 2008) and of all chain types apart from K63-linked chains in yeast. In addition, all 
linkages could signal for degradation by purified proteasomes in vitro (Xu et al., 2009b). 
Although this could indicate that all linkages apart from K63 target for proteasomal 
degradation and are thus functionally redundant, it is likely that recognition of different 
chains by proteins that regulate the transport to the proteasome and by proteasomal 
subunits themselves differs both qualitatively and quantitatively. In addition, differential 
DUB-sensitivity may allow transient non-proteolytic functions to be mediated by some, i.e. 
the more stable, but not by other, i.e. the more DUB-sensitive, linkage types. Along these 
lines specific binding of proteasome-independent UBDs may protect selected chain types 
from transport to the proteasome as well as from DUB-mediated disassembly. Indeed 
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specific receptors, proteases and functions have been described for the different linkage 
types (Dikic et al., 2009; Komander et al., 2009a). Specific recognition is enabled by the fact 
that differentially linked ubiquitin chains differ not only in the linkage between individual 
ubiquitin molecules but also in their overall conformation (Virdee et al., 2010) thus creating 
specific binding surfaces that are absent from monoubiquitin or other chain types. These 
different topologies result from the fact that all potential linkage points in the ubiquitin 
molecule are located on different surfaces and point into different directions. The 
exceptions are M1 and K63 which are in close proximity (Figure 7 and (Vijay-Kumar et al., 
1987). Accordingly, K63- and linear chains assume a similar extended conformation in which 
the individual ubiquitin moieties do not make contact. However, the two chain types can be 
differentiated by the chemical characteristics of the linkage. M1 chains are linked by a 
peptide- instead of an isopeptide bond and are thus conformationally more restrained 
(Komander et al., 2009b). On the other hand K6-, K11- and K48-linked chains have a 
different structure. K6-linked chains assume an asymmetric compact conformation in which 
the Ile44 patch of the proximal ubiquitin which contains the lysine residue involved in the 
linkage binds to another hydrophobic surface containing L71, I36 and I8, the so called Ile36 
patch, on the distal ubiquitin. The resulting structure is further fixed by additional 
interactions and the Ile44 patch of the distal ubiquitin remains accessible thus allowing 
interaction with UBDs (Virdee et al., 2010). Two different conformations exist for K11 
chains. One of the structures involves an asymmetric interaction between the areas 
surrounding Glu24 on the distal and K29 and K33 in the proximal ubiquitin moiety. In the 
other the ubiquitin molecules interact via their respective Ile36 patches. Both 
conformations exist in an equilibrium and contribute to a higher order assembly in crystals 
(Bremm et al., 2010; Matsumoto et al., 2010). Finally, K48 chains assume a conformation in 
which the two Ile44 patches of subsequent ubiquitin moieties interact with the linking 
residues being closely packed against the ubiquitin units. In tetramers further contacts 
between molecules exist leading to an overall pseudo-tetragonal structure. Nevertheless, 
interactions with K48-linked chains are possible as an equilibrium with more open 
conformations exists and because UBA-domains can insert between the Ile44-patches of 
interacting molecules (Cook et al., 1992; Trempe et al., 2005; Varadan et al., 2004; Varadan 
et al., 2005). The structures of the other linkage types have not been determined to date 
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but due to the location of the linking residues as well as to distinct cellular functions (see 
below) it can be assumed that they all adopt specific conformations. 
Figure 7: Structural features of ubiquitin and of different ubiquitin chains. Upper panels: Two different 
angles of the ubiquitin structure (PDB: 1UBQ; (Vijay-Kumar et al., 1987) reveal that the different potential 
linkage points for the formation of ubiquitin chains, i.e. the N-terminal methionine 1 (M1, depicted in red) and 
the seven internal lysine residues (K6-K63, shown in yellow with dark blue side chains), are located on different 
surfaces of the molecule and face into different directions. Lower panel: Table summarising structural and 
functional differences between the different linkage types. Modified from (Komander, 2009) under 
incorporation of information obtained from (Virdee et al., 2010) and (Bremm et al., 2010).  
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and alpha-synuclein (-syn) by TNF-receptor associated factor (TRAF) 6 thereby causing 
accumulation of these Parkinson’s disease associated proteins in cytoplasmic aggregates 
(Zucchelli et al., 2010). 
2.1.2.2.2 K11-linkages 
As mentioned previously K11-linkages were found to account for 28 % of all ubiquitin chains 
in yeast but only for 2 % in human cells. The low amount of K11-linkages identified in 
HEK293 cells may be due to the abundance of this linkage type being strongly cell cycle 
dependent, reaching maximum levels during mitosis (Jin et al., 2008; Matsumoto et al., 
2010). This is in accordance with a functional role of this chain type as a signal for 
proteasomal degradation of cell cycle related proteins such as cyclin B1, cyclin A and 
Securin. Modification of these substrates is mediated by the anaphase-promoting 
complex/cyclosome (APC/C) in cooperation with the K11-specific E2 UBE2S and with UBE2C 
(Jin et al., 2008; Kirkpatrick et al., 2006; Williamson et al., 2009). K11-linked ubiquitination of 
cyclin B1 was shown to be sufficient for its proteasomal degradation in vitro (Jin et al., 2008) 
and although specific UBDs that may be involved in shuttling K11-ubiquitinated proteins to 
the proteasome have not been identified, a physiological role for this modification is 
suggested by the finding that depletion of both UBE2C and UBE2S causes mitotic arrest 
(Williamson et al., 2009). In addition, K11-linked chains have been suggested to be 
functionally important in the endoplasmatic reticulum associated degradation (ERAD) 
pathway (Xu et al., 2009b). Furthermore, a potentially non-proteolytic function was 
suggested in the context of TNF-signalling. It was described that cellular inhibitor of 
apoptosis (cIAP) 1 in conjunction with the promiscuous E2 UBE2D can attach K11-linked 
chains to RIP1 (Dynek et al., 2010) and K11-linkages were found to be associated with RIP1 
in the native TNF-receptor signalling complex (RSC) (Gerlach et al., 2011). It has not been 
clarified whether this leads to RIP1 degradation and thus termination of signal transduction 
emanating from the receptor complex or whether K11-chains have a proteasome-
independent function in this context. The latter notion is supported by the finding that the 
UBD of NEMO can bind to K11-dimers with similar affinity as to K63-linked dimers (Dynek et 
al., 2010) indicating that K11-chains could be a potential recruitment platform for the IKK-
complex. In addition, Cezanne, a DUB that was described to negatively regulate TNF-induced 
NF-B activation was found to preferentially cleave K11-linked chains (Bremm et al., 2010; 
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Enesa et al., 2008) further implying that K11-chains have a signal-promoting rather than a 
degradative function in the context of TNF-induced signal transduction.  
2.1.2.2.3 K27-linked chains 
Due to the close proximity of lysines K27, K29 and K33 their analysis by mass spectrometry is 
challenging and this has somewhat dampened the investigation of these linkages types 
(Komander, 2009). Accordingly, little is known concerning the structure and function of K27-
linked chains. Like K6-linked chains they were reported to be attached to misfolded DJ-1 and 
-synuclein favouring their aggregation (Zucchelli et al., 2010). In addition, it was reported 
that upon viral infection, the E3 ligase tripartite motif containing 23 (TRIM23) conjugates 
K27-linked to NEMO thereby promoting NF-B activation and the production of antiviral 
IFN (Arimoto et al., 2010). In another context, attachment of the same linkage type to the 
same substrate was reported to have an entirely different outcome. In this case, the 
bacterium Shigella was found to hijack the ubiquitin conjugation system of the host cell 
leading to K27-ubiquitination of NEMO followed by its degradation. This led to a dampening 
of the host’s proinflammatory response (Ashida et al., 2010). Further investigation is needed 
to clarify the structure and function of K27-linked chains and especially to established 
whether this chain type preferentially targets proteins for proteasomal degradation or 
whether it fulfils other, signalling related tasks.  
2.1.2.2.4 Ubiquitin chains conjugated via K29 
Together with K6- and K27-chains K29-linked ubiquitin was reported to be conjugated to 
DJ-1 and -synuclein by TRAF6 in the context of Parkinson’s disease (Zucchelli et al., 2010). 
Furthermore, another member of the TRAF family, TRAF7 was found to generate this linkage 
type on NEMO and the NF-B subunit p65 leading to their lysosomal degradation and to a 
down-regulation of NF-B signalling (Zotti et al., 2011). K29-linked chains were also reported 
to target Deltex (DTX) for lysosomal degradation when attached to this protein by the action 
of the E3 ligase E3 ubiquitin-protein ligase Itchy homolog (ITCH) (Chastagner et al., 2006). 
Furthermore, K29-linked chains were also implicated in the ubiquitin fusion degradation 
pathway where the E3 Ufd5 is responsible for their generation (Johnson et al., 1995). In 
addition, it was shown that the DUB TRABID preferentially cleaves K29-linked chains (Virdee 
et al., 2010) providing an indirect hint that ubiquitin of this linkage type might play a role in 
the Wnt-pathway where TRABID was found to play a role (Tran et al., 2008). Finally, several 
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members of the AMP-activated protein kinase (AMPK) family are inactivated by K29-linked 
ubiquitination as this modification seems to prevent the phosphorylation required for 
kinase activity (Al-Hakim et al., 2008). 
2.1.2.2.5 K33-linkages 
Although they are not well characterised, K33-linked chains were found to collaborate with 
K29-linked chains in the regulation of AMP kinases (Al-Hakim et al., 2008). Furthermore, a 
role in TCR-signalling for this linkage type was suggested. Here, TCR was reported to be 
targeted by Casitas B-lineage lymphoma proto-oncogene b (Cbl-b) and ITCH with the 
resulting ubiquitination inhibiting phosphorylation of TCRand preventing its association 
with the downstream tyrosine kinase (zeta-chain associated protein of 70kDa) ZAP-70 
thereby restricting TCR signalling (Huang et al., 2010).  
2.1.2.2.6 K48-linked ubiquitin chains 
Ubiquitin chains conjugated via K48 represent the best characterised linkage type. It was 
recognised early on in ubiquitin research that ubiquitin’s function as a tag targeting proteins 
for proteasomal degradation is usually not mediated by the conjugation of single ubiquitin 
molecules but by attachment of K48-linked chains consisting of at least 4 ubiquitin 
molecules (Chau et al., 1989; Thrower et al., 2000). This can be mediated by a variety of E2-
E3 combinations amongst them those involving the K48-specific E2s UBE2R1 or UBE2K 
(Haldeman et al., 1997; Petroski and Deshaies, 2005). Once modified the ubiquitinated 
protein is recognised by a set of specific ubiquitin-binding proteins, Rad23, Dsk2, and Ddi1, 
which bind ubiquitin via UBA-domains whereas their N-terminal UBL-domain binds the 
proteasome (Chen and Madura, 2002; Elsasser et al., 2002; Funakoshi et al., 2002; Rao and 
Sastry, 2002). These ubiquitin receptors may therefore capture substrates remotely and 
then mediate their shuttling to the proteasome (Finley, 2009). In the proteasome itself S5a 
(hRpn10) and Rpn13, two additional ubiquitin receptors that bind ubiquitin via ubiquitin 
interaction motifs (UIMs) or a pleckstrin-like receptor for ubiquitin (Pru) domain might take 
over the binding of the ubiquitin chains (Deveraux et al., 1994; Husnjak et al., 2008; Kang et 
al., 2007; Schreiner et al., 2008; Wang et al., 2005). Alternatively, ubiquitin chains of 
sufficient length may bind shuttling and proteasome intrinsic receptors at the same time or 
stay associated with the shuttling receptors which are in turn bound by the proteasomal 
receptors via their UBL-domains (Finley, 2009). Once a ubiquitinated substrate has been 
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recognised by the regulatory subunit (19S) of the proteasome, ubiquitin chains are removed 
by proteasome intrinsic proteases, the substrate is unfolded and threaded through a narrow 
channel into the core particle (20S) where it is hydrolysed resulting in a variety of peptides 
(Ardley et al., 2001; Goldberg et al., 2002; Groll et al., 2000; Kisselev et al., 1999; Lee et al., 
2002; Lee et al., 2001; Navon and Goldberg, 2001). Thus, due to its role in protein 
degradation, K48-linked ubiquitin impacts diverse processes such as removal of aged or 
misfolded proteins thereby regulating protein homeostasis, the cell cycle which depends on 
specific degradation of different proteins in the different phases of the progression through 
the cycle and different signalling pathways which are regulated both positively and 
negatively by the proteasomal degradation of antagonists or agonists, respectively.  
2.1.2.2.7 Ubiquitin chains conjugated via lysine 63  
K63-linked chains were the first type of polyubiquitin to be shown to have non-proteolytic 
functions when they were found to play role in the DNA damage response (Spence et al., 
1995). An E2 complex consisting of UBE2N and UBE2V2 was shown to specifically generate 
K63-linked chains even in the absence of an E3. This specificity is generated by a non-
covalent interaction between UBE2V2, which structurally resembles an E2 but lacks a 
catalytic cysteine, and the acceptor ubiquitin. The interactions between ubiquitin and the E2 
complex position ubiquitin in a way that results in selective presentation of K63 to the active 
site (Deng et al., 2000; Eddins et al., 2006; VanDemark et al., 2001).  
In addition to its implication in different DNA-damage related pathways (Hoege et al., 2002; 
Spence et al., 1995), K63-linked chains may assist or even replace monoubiquitination in the 
context of endocytosis as they may be recognised more efficiently by the relevant ubiquitin 
receptors (see section 2.1.2.1 and (Duncan et al., 2006; Geetha et al., 2005). A role for K63-
linked chains is further supported by the implication of the K63-specifc DUB AMSH in this 
process (McCullough et al., 2004; Sato et al., 2008). An important field regulated by K63-
linked ubiquitin is that of intracellular signal transduction. This linkage type was suggested 
to play a role in the Wnt- and interferon-response factor signalling pathways (Komander, 
2009) and has a firmly established role in signalling initiated by different cytokines (Harhaj 
and Dixit, 2012; Jiang and Chen, 2011). It was shown that K63-linkages serve as recruitment 
platforms in the context of different receptor associated or -induced complexes (Conze et 
al., 2008; Ea et al., 2006; Kanayama et al., 2004; Oeckinghaus et al., 2007; Wu et al., 2006). 
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Genetic depletion of UBE2N as well as replacement of wild-type ubiquitin with a mutant 
incapable of generating K63-linked chains showed that this linkage type is indispensable for 
IL-1- but not TNF-induced signal transduction, although it may still collaborate with other 
chain types in the context of the latter stimulus (Xu et al., 2009a; Yamamoto et al., 2006). 
Mechanistically it was shown that K63-linked chains are often generated by TRAFs or IAPs 
and that they are responsible for the recruitment of the preformed IKK- and TGF-activated 
kinase (TAK)1-binding protein (TAB)–TAK1-kinase complexes (Ea et al., 2006; Kanayama et 
al., 2004; Lee et al., 2004; Silke and Brink, 2010; Wu et al., 2006). Especially the TAB–TAK1 
complex depends on K63-linked ubiquitin for its recruitment, as its regulatory subunit, TAB2, 
has been shown to preferentially bind this linkage type (Kulathu et al., 2009). Thus, in the 
context of intracellular signal transduction, K63-linked chains are indirectly and possibly also 
directly (Fan et al., 2010) involved in the activation of kinases initiating the NF-B and 
mitogen activated protein kinase (MAPK) pathways.  
2.1.2.2.8 M1-linked or linear chains 
As mentioned in section 1.1 ubiquitin is translated as a polyubiquitin precursor, i.e. in form 
of a polypeptide in which ubiquitin molecules are linked via their C- and N-termini, 
respectively. Co- and posttranslational cleavage of these chains by specific DUBs generates 
the cellular pool of monoubiquitin (Baker and Board, 1987; Finley et al., 1987; Komander et 
al., 2009a; Ozkaynak et al., 1984; Reyes-Turcu et al., 2009; Wiborg et al., 1985). However, it 
was recently shown that a specialised E3 ligase complex referred to as linear ubiquitin chain 
assembly complex (LUBAC) is able to re-establish M1-linked chains from this pool of 
monoubiquitin (Kirisako et al., 2006) thus creating an eighth and uniquely lysine 
independent form of ubiquitin linkage. As M1-linked chains structurally resemble K63-linked 
chains (see section 2.1.2.2) functional similarities could have been anticipated. However, the 
first function of linear chains to be uncovered was their implication in proteasomal 
degradation of a model substrate (Kirisako et al., 2006). This observation was supported by 
studies that found that fusion of a non-cleavable linear tetra-ubiquitin chain to a target 
protein can lead to the degradation of this protein (Prakash et al., 2009; Zhao and Ulrich, 
2010) and that linear chains can bind the same proteasomal receptors as K48-linked chains 
(Thrower et al., 2000). In a signalling context the activity of LUBAC was linked to the 
degradation of TRIM25 and hence to suppression of type I interferon induction following 
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stimulation of RIG-I (Inn et al., 2011). On the other hand it was shown that LUBAC can 
ubiquitinate NEMO (Tokunaga et al., 2009) and that the UBAN (ubiquitin-binding in NEMO 
and ABIN (A20-binding inhibitor of NF-B)-domain of this protein binds M1-linked ubiquitin 
dimers with much higher affinity than K63-linked dimers (Lo et al., 2009; Rahighi et al., 
2009). This selectivity can be explained by contacts between the UBAN domain and surfaces 
of the dimer specific to this linkage type (Rahighi et al., 2009). Presence on and recognition 
by NEMO, the regulatory subunit of the IKK-complex implies that linear chains have a role in 
the NF-B pathway. Indeed, down-regulation or absence of LUBAC-components was found 
to affect signal transduction induced by TNF, IL-1, CD40, lipopolysaccharide (LPS), 
lymphotoxin- receptor (LTR), or by genotoxic stress (Gerlach et al., 2011; Ikeda et al., 
2011; Niu et al., 2011; Tokunaga et al., 2011). Both modification of NEMO with linear chains 
and the ability of this protein to bind M1-linked chains seem to be important in this context. 
Mutants preventing NEMO’s modification (K285,309R) were unable to restore IL-1- or 
LUBAC-induced NF-B induction in NEMO-deficient cells (Tokunaga et al., 2009) whereas 
mutations that abolished NEMO’s ability to bind linear chains without preventing its 
association with K63-linked chains reduce NF-B activation in response to TNF (Hadian et 
al., 2011; Rahighi et al., 2009). Furthermore, mutations affecting ubiquitin binding by NEMO 
are associated with X-linked ectodermal dysplasia and immunodeficiency (Rahighi et al., 
2009). Finally, linear chains may also serve as a recruitment platform for negative regulators 
of signalling processes such as the UBAN-containing proteins ABIN1 and Optineurin which 
were reported to interfere with TNF-induced NF-B activation by competing with NEMO for 
binding to ubiquitinated RIP1 (Zhu et al., 2007) and by assisting the DUBs A20 and CYLD 
(cylindromatosis) in down-regulating TNF-signalling (Harhaj and Dixit, 2011).  
2.1.3 Physiological and pathophysiological roles of the ubiquitin system 
Due to its important regulatory role in a variety of intracellular processes and its 
involvement in many signalling pathways, ubiquitination has an impact on many biological 
processes. This is exemplified by its involvement in defending the organism from invading 
pathogens, where recognition and clearance of the pathogen by the innate immune system 
as well as activation of the adaptive immune response are subject to regulation by the 
ubiquitin system. Recognition of pathogens is often mediated by the binding of pathogen 
associated molecular patterns (PAMPs) by pathogen-recognition receptors of the Toll-like-
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receptor (TLR), the retinoic acid inducible gene I (RIG-I)-like receptor (RLR) or the Nucleotide 
Oligomerisation Domain (NOD)-like receptor (NLR) families. Activation of these receptors 
triggers intracellular pathways leading to NF-B- or interferon regulatory factor (IRF)-
dependent expression of effector molecules such as proinflammatory cytokines or type I 
interferons (IFNs) that counteract the infection directly and indirectly by eliciting an 
adaptive immune response (Jiang and Chen, 2011; Kawai and Akira, 2011). The pathways 
leading to the activation of these transcription factors involve the assembly of multi-protein 
complexes which initiate signalling and which require non-proteolytic ubiquitin chains for 
their assembly and stability (Schmukle and Walczak, 2012). Furthermore, downstream 
signalling may depend on the removal of inhibitory proteins as for example the 
inhibitor of kappa B (IB) which in the unstimulated state binds NF-B dimers and prevents 
their translocation to the nucleus. Following its phosphorylation by the IKK-complex 
(Regnier et al., 1997) IB is recognised by the substrate binding subunit, -transducin 
repeat-containing protein (TRCP), of the Skp, Cullin, Fbox (SCF) E3-complex and is 
subsequently ubiquitinated and degraded by the proteasome (Alkalay et al., 1995; Chen et 
al., 1995; Palombella et al., 1994; Spencer et al., 1999; Tan et al., 1999; Winston et al., 1999; 
Yaron et al., 1997; Yaron et al., 1998). In context of the adaptive immune system, 
intracellular signalling initiated by the T- or B-cell receptors, by CD40- or by BAFF which also 
involves the activation of the NF-B and MAPK pathways is subject to the same type of 
regulation (Jiang and Chen, 2011).  
Furthermore, selective autophagy, which represents a cell-autonomous effector mechanism 
of the innate immune system and fights intracellular bacteria by isolating them in double-
membrane surrounded autophagosomes thus depriving them of nutrients and targeting 
them to microbicidal autolysosomes, depends on ubiquitination (Randow, 2011). 
S.typhimurium, streptococcus pyogenes as well as other bacteria acquire a dense ubiquitin 
coat when entering the cytosol. The ubiquitin molecules may be conjugated to bacterial 
proteins directly or to host-proteins associating with the bacterium by a so far unidentified 
E3. This ubiquitination is sensed by specific autophagy receptors, that, in a manner 
comparable to the proteasome shuttling receptors (see section 2.1.2.2.6), target their cargo 
to the autophagosomes. This process is based on the ability of the autophagy receptors, as 
for example p62, NDP52 and Optineurin (Thurston et al., 2009; Wild et al., 2011; Zheng et 
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al., 2009), to simultaneously bind ubiquitin and LC3/Atg8, a ubiquitin-like protein covalently 
coupled to the membranes of phagophores, the double-membrane precursors of 
autophagosomes (Fengsrud et al., 2000), thus mediating the interaction between cargo and 
engulfing membrane (Randow, 2011).  
Finally, the surface expression and peptide-loading of MHC molecules is regulated by 
ubiquitination. Ubiquitination of MHC class II molecules which present antigenic peptides to 
T-helper cells leads to their endocytosis and lysosomal degradation (Shin et al., 2006; van 
Niel et al., 2008). In addition, incorrectly folded MHC class I molecules are degraded via the 
ER-associated degradation (ERAD) pathway in a ubiquitin-dependent manner (Burr et al., 
2011) and even more importantly the antigenic peptides presented to cytotoxic T-cells by 
MHC class I molecules are generated by proteasomal processing of intracellular proteins 
(Michalek et al., 1993; Rock and Goldberg, 1999).  
On the other hand, pathogens often employ the ubiquitin system to manipulate or evade an 
immune response. Mechanisms involved can include the degradation of host proteins 
critically involved in raising an appropriate immune response as for example components of 
the NF-B or interferon pathways or MHC molecules. Alternatively, pathogens can aim to 
prevent or counteract specific ubiquitination events for example by the expression of DUBs 
(Jiang and Chen, 2011; Randow, 2011; Randow and Lehner, 2009). To mediate these effects, 
pathogens can either express specific proteins suitable for the respective task or adaptor 
proteins allowing them to hijack specific components of the host’s ubiquitination system. 
Specific example for the mentioned schemes, include the ubiquitin dependent degradation 
of the NF-B subunit p65 by the gammaherpesvirus MUHV.4 protein ORF3 (Rodrigues et al., 
2009), the ubiquitination of NEMO that is mediated by the IpaH9.8 protein expressed by 
Shigella felxneri (Ashida et al., 2010) and the degradation of IRF3 and IRF7 which are 
targeted by the rotavirus protein NS1 and the KSHV protein replication and transcription 
activator (RTA) (Barro and Patton, 2005; Bauhofer et al., 2007; Yu and Lai, 2005). 
Furthermore, in a case of E3-hijacking, the highly conserved V-proteins of several 
paramyxoviruses, including mumps virus, human parainfluenza virus type 2 (HPIV2) and 
simian virus 5 (SV5), target signal transducer and activator of transcription (STAT)s, 
important mediators of IFN-signal transduction, for ubiquitination and degradation by 
recruiting them to DNA Damage Binding Protein 1 (DDB1), the substrate binding subunit of 
the Cul4A E3 ligase-complex (Li et al., 2006b; Parisien et al., 2002). 
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To evade the action of cytotoxic T-cells, human CMV (cytomegalovirus) encodes proteins, 
US2 and US11, which, probably indirectly, initiate the ubiquitination and degradation of 
MHC class I molecules via the ERAD pathway (Lilley and Ploegh, 2004; Wiertz et al., 1996; Ye 
et al., 2004). Similarly, K3, a protein expressed by Kaposi’s sarcoma virus (KSHV) and the 
canonical member of the viral RING-CH ligase family, associates with and ubiquitinates MHC 
class I in a post-ER compartment, leading to its internalization, ESCRT-dependent sorting 
and lysosomal degradation (Cadwell and Coscoy, 2005; Lehner et al., 2005; Wang et al., 
2007). Finally, strategies to prevent ubiquitination events generally or specifically are 
employed by bacteria and viruses. The proteins CHBP from Burkholderia pseudomallei and 
its homologue Cif from Escherichia coli deamidate specific glutamine residue within 
ubiquitin and thus prevent the formation of ubiquitin chains (Cui et al., 2010) in general. 
Individual ubiquitination events can be more specifically counteracted by expression of 
DUBs or by adaptor proteins that recruit the host’s proteases to a designated target. An 
example of a virally encoded DUB is UL36USP which by a so far unknown mechanism affects 
pathogenicity but not replication of viruses (Bottcher et al., 2008; Jarosinski et al., 2007). 
Overall this shows that the immune system, as an example of many complex processes is 
highly regulated by ubiquitination and that this can also be exploited by pathogens. 
Due to its implication in intracellular signalling and in the regulation of physiological 
processes, deregulations affecting the ubiquitin system have been associated with a set of 
different diseases. Although the association of a faulty proteasomal degradation process 
with the pathogenesis of different disorders is the best studied aspect of this connection, 
alterations at any stage of the ubiquitination system can have detrimental results.  
Replacement of the C-terminal glycine in ubiquitin itself by a 20-residue extension can result 
from a dinucleotide deletion on the mRNA-level. Expression of this ubiquitin mutant (Ub+1) 
was associated with Alzheimer’s disease (van Leeuwen et al., 1998). Mechanistically, for a 
protein to be degraded by the proteasome, it needs to interact with the proteasomal 
machinery via a ubiquitin moiety and to have a tail that is long enough to be able to reach 
the inner proteolytic chamber. Ub+1 can be incorporated into ubiquitin chains but its C-
terminal extension is too short for the molecule to be degraded. Therefore Ub+1 binds the 
proteasome but cannot be processes, thus exerting an inhibitory effect on the degradation 
machinery which may cause or at least aggravate the accumulation of insoluble protein 
deposits observed in Alzheimer’s disease (Shabek et al., 2009). Alterations in a substrate 
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that changes its ubiquitination pattern can also be the cause for disease as exemplified by a 
mutation in the epithelial Na+ channel ENaC that prevents its interaction with the E3 ligase 
Nedd4-2. This leads to an accumulation of the ion channel and to a deregulation of Na+-
reabsorption. This is associated with a condition referred to as Liddle's syndrome which is 
characterized by early onset of severe hypertension (Rotin and Schild, 2008; Staub et al., 
1997; Zhou et al., 2007). On the other hand, not only disturbances in the covalent 
attachment of ubiquitin chains to specific substrates but also the non-covalent binding to 
nonproteolytic ubiquitin chains can have deleterious effects. Several studies have identified 
mutations in the UBAN motif of NEMO, that inhibit its ability to bind ubiquitin chains and 
alter its specificity of binding linear ubiquitin chains, in patients with anhidrotic ectodermal 
dysplasia and immunodeficiency (Doffinger et al., 2001; Filipe-Santos et al., 2006; Rahighi et 
al., 2009). Although missense mutations in UBA1 are associated with spinal muscular 
atrophy, a motor neuron disorder in which the ubiquitin-dependent degradation of proteins 
in this cell type is affected (Ramser et al., 2008), and mutations in the E2 UBE2A are linked 
with an X-linked mental retardation syndrome (Budny et al., 2010; de Leeuw et al., 2010; 
Nascimento et al., 2006), the most common part of the ubiquitination process to be 
affected are the ubiquitin ligases. This can be attributed to the large number of proteins 
included in this group and to their role of providing the ubiquitination process with 
substrate selectivity. Mutations in different E3s can affect different targets and processes 
and accordingly alterations in particular E3s have been associated with a multitude of 
diseases. Loss of function in the HECT-E3 E6AP is implicated in the development of 
Angelman syndrome, a neurodevelopmental disorder characterised by mental retardation, 
seizures and movement disorders (Kishino et al., 1997; Rougeulle et al., 1997; Vu and 
Hoffman, 1997). On the other hand, a gain of function of this E3 in complex with the viral 
protein E6 leads to the destabilisation of tumour suppressors, most importantly p53, thus 
promoting proliferation, transformation and eventually the development of HPV-induced 
cervical cancer (Scheffner et al., 1993; Scheffner and Staub, 2007).  BRCA1 mutations lead to 
a high incidence of breast and ovarian cancers (Futreal et al., 1994) and alterations in many 
other E3s have also been implicated in causing cancer (Kirkin and Dikic, 2011). This can be 
explained by a multilayered mechanism which includes the ubiquitin-dependent regulation 
of oncogenic proteins and the role of ubiquitin in maintaining a balance between pro-
survival and cell death pathways (Lipkowitz and Weissman, 2011; Vucic et al., 2011). In 
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addition, a loss of function in E3s or an overall down-regulation of proteasomal protein 
degradation has been associated with neurodegenerative disorders such as Parkinson’s 
disease, where mutation of the E3 ligase Parkin causes the accumulation of misfolded, 
insoluble aggregates (Foroud et al., 2003; Kitada et al., 1998; Lucking et al., 2000; Oliveira et 
al., 2003a; Oliveira et al., 2003b; Pankratz et al., 2003). 
2.2 The TNF/TNFR-system  
2.2.1 The TNF/TNFR-superfamilies 
As indicated by its name TNF was originally identified as a product of macrophages that 
causes lysis of tumour cells (Carswell et al., 1975). Its cDNA was cloned in 1984 (Marmenout 
et al., 1985; Pennica et al., 1984) and many related proteins were identified in the following 
years. TNF thus became the founding member of a cytokine family referred to as the TNF-
superfamily (TNF-SF). With the exception of lymphotoxin alpha (LT) and vascular 
endothelial growth inhibitor (VEGI), which are secreted, members of this family generally 
are transmembrane proteins with a single transmembrane domain and a C-terminal 
extracellular domain. They are hence classified as type II transmembrane proteins 
(Aggarwal, 2003). Soluble forms of the different members of the TNF-SF can be generated 
by proteolytic cleavage of the transmembrane proteins by a specific set of proteases (Black 
et al., 1997; Lum et al., 1999; Nocentini et al., 1997; Powell et al., 1999). The extracellular 
part of the transmembrane forms which is retained in the soluble variants and which is also 
referred to as TNF-homology domain is responsible for the ability of the different ligands to 
bind to their respective receptors. It also mediates the assembly of non-covalent ligand-
trimers. The individual chains interact via hydrophobic surfaces and the aromatic residues 
involved account for most of the 20-30 % sequence similarity observed between the 
different members of the TNF-SF (Fesik, 2000; Locksley et al., 2001). Although mono- or 
dimeric forms of the different ligands may exist, their biological activity is mediated by the 
trimeric forms (Black et al., 1997; Cabal-Hierro and Lazo, 2012). This is due to the 
requirement for a 3:3-stoichiometry in ligand-receptor complexes to activate the receptors. 
Both forms of the ligands can engage the respective receptors but depending on the specific 
cytokine and receptor the soluble variant can have agonistic or antagonistic effects 
(Aggarwal, 2003). The receptors mediating the effects of TNF-SF cytokines belong to the 
TNF receptor superfamily (TNFR-SF). They are type I transmembrane proteins that typically 
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contain one to six cysteine rich domains (CRDs) (Wajant et al., 2003). These pseudorepeats 
are usually approximately 40 aminoacids long and contain six highly conserved cysteine 
residues that form three intrachain disulfide bonds (Locksley et al., 2001; Smith et al., 1994). 
The resulting scaffold of disulfide bridges causes the receptor to adopt an elongated 
conformation. This shape allows the receptor to fit in the lateral grooves between 
protomers of the ligand trimer which in turn permits the crosslinking of three receptor 
monomers by a trimeric ligand into an active 3:3-complex (Banner et al., 1993). Although 
ligand-independent assembly of receptors via a pre-ligand assembly domain (PLAD) in their 
distal CRD was observed (Chan et al., 2000; Siegel et al., 2000) the resulting complexes 
assume a conformation that differs from that of the ligand-induced multimers and pre-
assembled receptors therefore still require ligand binding, which might induce 
conformational changes or allow formation of higher order multimers, for their activation 
(Locksley et al., 2001; Naismith et al., 1996; Naismith and Sprang, 1995). As receptors of the 
TNFR-SF generally lack enzymatic activity in their intracellular domains they rely on the 
activation-induced recruitment of adaptor proteins to initiate signalling. Based on the 
differences in their intracellular domains three subgroups of the TNFR-SF, the death domain 
(DD)- and the TRAF-interaction motif (TIM)-containing groups as well as the receptors 
lacking a functional intracellular domain, can be defined which differ in the intracellular 
adaptors recruited (Hehlgans and Pfeffer, 2005; Locksley et al., 2001). The DD-comprising 
receptors, like TNFR1, CD95, TRAILR1 and TRAILR2, recruit TNF receptor associated protein 
with a DD (TRADD) or Fas associated protein with a DD (FADD) and can therefore induce 
both gene-induction and programmed cell death in the form of apoptosis or potentially 
necroptosis (Laster et al., 1988; Vanlangenakker et al., 2012), whereas the second group of 
receptors as for example TNFR2, CD40, fibroblast growth factor inducible 14 (Fn14) or B cell 
activation factor receptor (BAFFR), recruits TRAFs and initiates signalling which is largely 
restricted to prosurvival outcomes. Finally, the third group comprises receptors like 
TRAILR3, TRAILR4 and Osteoprotegerin (OPG) that lack functional intracellular domains. 
Individually and together members of the TNF/TNFR-superfamilies have prominent roles in 
a variety of biological processes including organogenesis and regulation of the immune 
system (Aggarwal, 2003; Hehlgans and Pfeffer, 2005).  
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2.2.2 TNF 
The human TNF gene is located on chromosome 6p21.3 and contains at least four NF- 
binding motifs and cJun N-terminal kinase (JNK)-responsive elements in its promoter region 
(Collart et al., 1990; Tsai et al., 2000). These elements are required for full TNF expression as 
shown by the observation that its transcription is down-regulated both in JNK1/2-deficient 
mouse embryonic fibroblasts (MEFs), macrophages and T-cells (Das et al., 2009a; Ventura et 
al., 2003) and in RelB-deficient macrophages (Weih et al., 1997). Furthermore, TNF 
expression is regulated on the mRNA level by an AU-rich element (ARE) in the 
3’untranlsated region (UTR) which recruits tristetrapolin, a zinc finger protein that 
accelerates the turnover of the mRNA. This destabilising effect can be counteracted by 
binding of different proteins that mediate mRNA stability and translation (Carballo et al., 
1998; Kontoyiannis et al., 1999). Especially the p38 MAPK pathway has been implicated in 
this stabilisation and thus in promoting TNF expression (Dumitru et al., 2000; Hitti et al., 
2006). Translation of the mRNA leads to a generation of a 26 kDa protein consisting of 
233 aminoacids which is directed to the plasmamembrane by a signal peptide comprising its 
first 76 residues (Kriegler et al., 1988; Pennica et al., 1984). The membrane integrated form 
can then be cleaved by a metalloprotease referred to as TNF alpha converting enzyme 
(TACE). This cleavage leads to release from the membrane and thus to the formation of 
soluble TNF (Black et al., 1997; Kriegler et al., 1988). Production of TNF occurs mainly in 
macrophages but also in a variety of other cell types including lymphoid cells, mast cells, 
endothelial cells, fibroblasts and in neuronal tissues (Carswell et al., 1975; Wajant et al., 
2003; Williamson et al., 1983). Due to the stimulation-dependent regulatory mechanisms 
that control the expression of TNF and its role in regulating the innate immune system, TNF 
is produced in response to a variety of proinflammatory stimuli as for example triggering of 
TLRs. The release of large amounts of TNF in response to LPS or other bacterial products is in 
line with a role of this protein in defending the host against invading pathogens. Using 
genetic deletion or neutralisation of TNF with antibodies (e.g. Infliximab) or soluble receptor 
molecules (e.g. Enbrel), it could be shown that infections with different pathogens such as 
Listeria monocytogenes, Mycobacteria tuberculosis, M. avium, Salmonella typhimurium or 
Toxoplasma gondii are exacerbated in the absence of TNF (Bean et al., 1999; Ehlers, 2003; 
Pfeffer et al., 1993). Mechanistically, TNF promotes an efficient immune response by 
inducing the production of proinflammatory cytokines and by increasing the expression of 
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adhesion molecules that are essential for the interaction between endothelial cells and 
lymphocytes and that hence regulate trafficking of circulating immune cells into tissues 
(Roach et al., 2002). Finally, TNF increases the phagocytic ability of macrophages (Bekker et 
al., 2001). In spite of its important role in promoting immune responses, TNF can also be 
harmful to the host. Deregulated, prolonged exposure to TNF can result in chronic 
inflammation, a wasting syndrome referred to as cachexia or, when the TNF-levels are high, 
lead to shock (Beutler et al., 1985a; Beutler et al., 1985b; Kettelhut et al., 1987; Tracey et al., 
1986). Even in the context of an infection TNF is not always beneficial as shown by the 
finding that TNF- or TNFR1-deficient mice show a delayed pathological response when 
challenged with certain pathogens such as Citrobacter rodentium or Mycobacterium bovis 
(Goncalves et al., 2001; Zganiacz et al., 2004). While these opposing effects of TNF in 
different infection models can be attributed to the different pathogens investigated it was 
also show that spatio-temporal differences in TNF production can have decisive effects on 
the outcome. In a mouse model in which caecal ligation and puncture lead to abdominal 
infection and immunoparalysis, it was shown that the effect of TNF-injection during the 
immunoparalysis, which prevents efficient production of endogenous TNF, can be beneficial 
or detrimental depending on location and timing (Echtenacher et al., 2003). Taken together 
this shows that the overall effect of TNF depends on the tissue, on the precise cellular 
context and on the timing and duration of the stimulus (Wajant et al., 2003). In addition to 
its role in promoting and regulating immune responses, TNF also affects organogenesis and 
architecture of lymphoid tissues. Although the development of TNF-deficient mice is largely 
normal, they lack primary B cell follicles, organised follicular dendritic cell (DC) networks and 
germinal centres (Pasparakis et al., 1996; Pasparakis et al., 1997) indicating that TNF is 
essential in establishing these features.  
2.2.3 TNFR1 versus TNFR2 
The multiple biological and pathological effects exerted by TNF are mediated by its binding 
to TNFR1 (also known as p55 TNFR or TNFRSF1a) and TNFR2 (also p75 TNFR or TNFRSF1b) 
which were both cloned in 1990 (Gray et al., 1990; Heller et al., 1990; Loetscher et al., 
1990a; Loetscher et al., 1990b; Schall et al., 1990). These receptors are single membrane 
proteins belonging to the TNFR-SF. They share approximately 28 % homology which can be 
attributed almost exclusively to their extracellular domains (Dembic et al., 1990; MacEwan, 
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2002). Here both receptors contain four CRDs of which CRD1 comprises a PLAD whereas 
CRD2 and CRD3 are responsible for ligand binding (Banner et al., 1993; Chan et al., 2000; Eck 
and Sprang, 1989; Mukai et al., 2010). However, structural differences between the two 
receptors result in an altered mode of ligand recognition (Mukai et al., 2010) which could be 
a possible explanation as to why soluble TNF can efficiently activate TNFR1 but not TNFR2 
(Grell et al., 1998; Grell et al., 1995; Krippner-Heidenreich et al., 2002) although both 
receptors can bind soluble and membrane-bound TNF. The different half-lives of the 
resulting receptor-ligand complexes could contribute to the specific activation of TNFR2 by 
the membrane-bound form of the ligand and might also be responsible for the kinetic 
differences observed regarding the activation of the two receptors (MacEwan, 2002). 
Furthermore, the two receptors also differ in their expression patterns with TNFR1 being 
constitutively and widely expressed whereas the expression of TNFR2 is highly regulated 
and restricted to certain cell types which mostly belong to the immune system (Dembic et 
al., 1990; Erikstein et al., 1991; Hohmann et al., 1990; Naume et al., 1991; Tannenbaum et 
al., 1993). Most importantly the intracellular domains of TNFR1 and TNFR2 differ 
significantly. While TNFR1 contains a globular bundle of -helices in its C-terminus that form 
a DD, a sequence of a few aminoacids in TNFR2 can be bound by adaptor proteins through 
charged residues and thus serves as a TIM (Locksley et al., 2001; Rothe et al., 1994b; 
Tartaglia et al., 1993a). Therefore the two receptors belong to different subgroups of the 
TNFR-SF and signal transduction and biological outcomes initiated can differ significantly. 
Nevertheless there are overlapping functions and crosstalk between the receptors and it 
thus depends on the context if TNFR1 and TNFR2 have similar, distinct or even opposing 
outcomes (Cabal-Hierro and Lazo, 2012; Faustman and Davis, 2010; MacEwan, 2002). 
Overall activation of the two receptors has been implicated in both physiological and 
pathophysiological situations. TNFR1-deficient mice show enhanced sensitivity to certain 
pathogens as for example Mycobacteria tuberculosis, Lysteria monocytogenes or Leishmania 
major (Flynn et al., 1995; Rothe et al., 1994a; Vieira et al., 1996). It was also found that 
TNFR1-/- mice die from necrotising encephalitis when orally infected with a strain of 
toxoplamsa gondii that displays low virulence and does not kill wild-type or TNFR2-deficient 
mice (Deckert-Schluter et al., 1998). This indicates that TNF’s role in defending the host 
against these pathogens is mediated by TNFR1. In addition, this receptor seems to be 
involved in liver regeneration following partial hepatectomy (Yamada et al., 1997). On the 
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other hand TNFR2 also has specific protective roles as for example by regulating antigen 
induced differentiation of T cells (Grell et al., 1999; Kim et al., 2006; Kim and Teh, 2001), by 
contributing to the elimination of autoreactive T cells in diabetic immunity thereby 
facilitating pancreatic regeneration (Kodama et al., 2005; Ryu et al., 2001) and by playing a 
role in angiogenesis (Goto et al., 2006). Furthermore, TNFR2 seems to have a role in 
cardioprotection as demonstrated by the findings that TNFR2-/- mice are more prone to 
heart failure and show reduced survival after infarction (Monden et al., 2007) and that 
TNFR2 signalling protects heart cells from ischemia in isolated heart preparations from 
female mice (Wang et al., 2008). Another beneficial role of TNFR2 may be relevant in 
demyelating disorders as for example multiple sclerosis. Systemic blocking of TNF in patients 
suffering from this kind of disorder increased lesions in the central nervous system and 
disease activity (Kassiotis and Kollias, 2001) indicating that TNF has a protective role in this 
context. This beneficial effect could be mediated by TNFR2 as it was shown that 
regeneration of oligodendrocyte precursors, that form myelin, can be induced in a TNFR2-
dependent manner (Arnett et al., 2001). In addition, it was found that TNFR2 is involved in 
the repair of the striatum following viral encephalitis in a mouse model (Rodriguez et al., 
2009) and that it promotes neuroprotection in the context of retinal ischemia in mice 
(Fontaine et al., 2002). In the former model TNFR1 serves a similar but locally distinct 
function by mediating the repair of the hippocampus (Rodriguez et al., 2009). On the other 
hand it seems to counteract TNFR2 in retinal ischemia as it was associated with 
neurodegeneration in this context (Fontaine et al., 2002). However, activation of TNFR2 
does not have an exclusively beneficial role and polymorphism and deregulation in the 
expression of this receptor have been implicated in a variety of pathological conditions. This 
included familiar rheumatoid arthritis, Cohn’s disease, ulcerative colitis and systemic lupus 
erythematosus (SLE) (Barton et al., 2001; Dieude et al., 2002; Komata et al., 1999; Pierik et 
al., 2004; Sashio et al., 2002). TNFR2 was also found to play a role in experimental hepatitis, 
in graft-versus-host-disease and in the neurovascular damage arising in a model of cerebral 
malaria (Ishikawa et al., 2002; Kusters et al., 1997; Stoelcker et al., 2002). Furthermore, an 
up-regulation of TNFR2 correlates with a bad prognosis in renal cell carcinoma (Al-Lamki et 
al., 2010).  
All the distinct but overlapping functions of TNFR1 and TNFR2 are initiated by intracellular 
signal transduction cascades that emanate from the receptors upon TNF-stimulation. As in 
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their functional outcomes the two TNF receptors share the activation of certain common 
signalling events such as the NF-B and MAPK-pathways, but also differ in certain aspects as 
for example the direct induction of programmed cell death.  
2.2.3.1 TNFR1 signalling 
Binding of a TNF-trimer to TNFR1 induced trimerisation of the receptor. It was shown that 
the receptor multimers formed upon activation exclusively contain TNFR1 and that no 
heterotrimerisation with TNFR2 could be observed (Idriss and Naismith, 2000; Locksley et 
al., 2001; Moosmayer et al., 1994). In addition to promoting trimerisation ligand binding 
potentially also triggers conformational changes in preformed receptor multimers. The 
activated receptors then initiate intracellular signalling cascades which eventually result in a 
biological outcome. Depending on the cellular context, TNFR1 activation can lead to 
induction of proinflammatory cytokines, cell proliferation, differentiation or cell death (Chen 
and Goeddel, 2002; Wajant et al., 2003). Because TNFR1, like other members of the 
TNFR-SF, does not exhibit enzymatic activity it relies on the recruitment of cytoplasmic 
proteins which form a receptor-associated complex from which all signalling pathways 
emanate and which is thus referred to as receptor signalling complex (RSC).  
2.2.3.1.1 The TNFR1-SC 
Upon stimulation TRADD is recruited to the intracellular domain of TNFR1 via homotypic 
interactions of their DDs (Hsu et al., 1995). The serine threonine kinase receptor interacting 
protein 1 (RIP1) can associate with TNFR1 in an equivalent manner (Ermolaeva et al., 2008; 
Haas et al., 2009; Pobezinskaya et al., 2008) but could also indirectly bind to the receptor via 
TRADD (Hsu et al., 1996a). The latter protein serves as an adaptor for TRAF2 and this 
interaction is mediated via the C-terminal TRAF-domain present in TRAF2 which is also 
responsible for homotrimerisation (Hsu et al., 1996b; Shu et al., 1996). Indeed, TRAF2 forms 
mushroom-shaped trimers in which each off the protomers is capable of interacting with 
one TRADD molecule (Park et al., 2000). An alternative mode of TRAF2 recruitment seems to 
exist as suggested by the observation that TRAF2 is absent from the TNF-RSC in TRADD-
deficient MEFs (Ermolaeva et al., 2008; Haas et al., 2009; Pobezinskaya et al., 2008) but not 
in TRADD-deficient macrophages (Pobezinskaya et al., 2008). It was suggested that in this 
case RIP1 may be the relevant adaptor. However, in presence of TRADD, RIP1 is dispensable 
for TRAF2 recruitment in MEFs (Haas et al., 2009). The TRAF2 related protein TRAF5 is often 
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referred to as a component of the TNF-RSC although its recruitment has not been shown to 
date (Wajant and Scheurich, 2011). TRAF2 associates with the cIAP1 and cIAP2 with high 
efficacy and thus serves as an adaptor for their association with the TNF-RSC (Mace et al., 
2010; Shu et al., 1996; Zheng et al., 2010). Structural studies revealed that a TRAF2 trimer 
interacts with one cIAP2 molecule in an asymmetric manner and it was also shown that a 
cIAP-interaction motif (CIM) comprising aminoacids 283-293 of TRAF2 and the BIR1-domain 
of cIAP mediate this interaction and are thus required for the recruitment of cIAP to the 
TNFR (Samuel et al., 2006; Varfolomeev et al., 2008; Vince et al., 2009). Once this core 
complex is assembled several components are modified by ubiquitin chains of a non-
proteolytic nature. TRAF2, cIAP1 and cIAP2 have all been suggested to be the relevant E3 
involved in generating these ubiquitin chains (Bertrand et al., 2008; Ea et al., 2006; 
Varfolomeev et al., 2008; Wertz et al., 2004). However, the ability of TRAF2 to contribute to 
these modifications is controversial (Alvarez et al., 2010; Yin et al., 2009a). Functionally, 
these ubiquitination events are a prerequisite for the recruitment of downstream 
components such as the TAB/TAK- and IKK-complexes (Ea et al., 2006; Kanayama et al., 
2004; Li et al., 2006a; Wu et al., 2006). Especially, K63-linked chains on RIP1 have been 
implicated in this task but several lines of evidence suggest that ubiquitinated RIP1 may not 
be responsible for recruiting downstream effectors on its own. It was found that the activity 
of UBE2N as well as K63-linkages are dispensable for TNF-induced IKK-activation (Xu et al., 
2009a), components of the TNF-RSC other than RIP1 were shown to be ubiquitinated 
(Bertrand et al., 2008; Fan et al., 2010; Li et al., 2009a; Shi and Kehrl, 2003) and additional 
ubiquitin linkages, including K11-linked chains (Dynek et al., 2010; Gerlach et al., 2011) were 
found in the complex. It is however established that ubiquitin is responsible for or at least 
considerably contributes to the recruitment of kinase complexes and thus to the initiation of 
signal transduction (Chen, 2012; Gautheron and Courtois, 2010; Kanarek and Ben-Neriah, 
2012; Wajant and Scheurich, 2011). The assembly of the TNF-RSC and ubiquitination events 
mediated by cIAP and possibly TRAF2 are depicted schematically in Figure 8. 
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Figure 8: Schematic representation of the TNFR1 associated signalling complex. Upon crosslinking by TNF, 
TNFR1 recruits TRADD and RIP1 via homotypic interaction of the respective DDs. TRADD then serves as an 
adaptor for recruitment of TRAF2 which in turn recruits cIAP1 and cIAP2. These E3s then mediate 
ubiquitination of different complex components with several types of ubiquitin chains including K63- and K11-
linkages. These non-proteolytic poly-ubiquitins then act as a recruitment platform for the preassembled 
TAB/TAK- and IKK-complexes which upon their activation initiate downstream signalling. 
 
2.2.3.1.2 TNFR1-induced signal transduction 
TNFR1 activation induces a variety of downstream signalling pathways. The best studied are 
the activation of NF-B and MAPKs, especially p38 and JNK (Karin and Gallagher, 2009) and 
the induction of programmed cell death. However, other events such as the activation of 
AKT (protein kinase B, PKB) or protein kinase C (PKC) have been reported as well (Osawa et 
al., 2001; Ozes et al., 1999; Schutze et al., 1990; Wiegmann et al., 1992).  
The term NF-B refers not to a single protein but to a family of homo- and heterodimeric 
transcription factors formed by the combination of members of the Rel family which 
comprises RelA (p65), RelB, cRel, p52 and p50 (Hoffmann and Baltimore, 2006; Oeckinghaus 
and Ghosh, 2009). All five Rel proteins are characterised by a Rel homology domain (RHD) 
which confers the ability to dimerise and to bind DNA (Chen et al., 1998; Ghosh et al., 1995; 
Muller and Harrison, 1995; Muller et al., 1995). In addition, RelA, RelB and cRel contain a 
transactivation domain (TAD) which is absent from p52 and p50 (Hayden and Ghosh, 2008). 
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Therefore, some of the potential NF-B dimers lack transcriptional activity and thus serve an 
inhibitory function unless they gain the ability to act as a transcription factor by association 
with additional components (Ballard et al., 1992; Bours et al., 1993; Franzoso et al., 1992; 
Kunsch et al., 1992; Mercurio et al., 1992; Ryseck et al., 1992; Schmid et al., 1991; Schmitz 
and Baeuerle, 1991). In a resting state, preformed NF-B dimers exist but they are 
prevented from translocating to the nucleus and exerting their transcriptional activity by 
members of the IB family (Baeuerle and Baltimore, 1988; Baeuerle et al., 1988; Kanarek et 
al., 2010). Proteins of this family are characterised by five to seven ankyrin repeats and 
include the typical members IB, IB, IB, the atypical proteins IB and BCL3 as well as 
p100 and p105 which are the precursors of the NF-B subunits p52 and p50 respectively 
(Ghosh et al., 1990; Meyer et al., 1991; Naumann et al., 1993a; Naumann et al., 1993b; 
Oeckinghaus and Ghosh, 2009; Schmid et al., 1991). Hence, the essential step in NF-B 
activation is freeing the dimeric transcription factor from its inhibitor. This process involves 
phosphorylation, ubiquitination and proteasomal degradation of IB. Once the kinase 
complex consisting of IKK, IKK and the regulatory subunit NEMO has been recruited to 
the TNF-RSC via the interaction of NEMO with ubiquitin chains and potentially with RIP1 (Ea 
et al., 2006; Wu et al., 2006; Zhang et al., 2000) the kinase subunits are activated. 
Mechanistically this may involve conformational changes induced in NEMO when it binds to 
ubiquitin that translate onto the kinase subunits, trans-autophosphorylation of IKKs 
favoured by clustering of kinases in the TNF-RSC or phosphorylation of IKK by an upstream 
kinase (Oeckinghaus and Ghosh, 2009; Rahighi et al., 2009; Tang et al., 2003a). Although 
RIP1 itself is a kinase, its activity was shown to be dispensable for NF-B activation (Lee et 
al., 2004) and therefore the kinases responsible for IKK phosphorylation and activation have 
been suggested to be MAPK/ERK kinase kinase 1 (MEKK1), MEKK2, MEKK3 or TAK1 (Lee et 
al., 1998; Schmidt et al., 2003; Shim et al., 2005; Yang et al., 2001). While absence or down-
regulation of each of these kinases individually or in combination affects TNF-induced NF-B 
activation, there is currently no clear understanding of their interplay or potential 
redundancy. Once IKK, the main IKK in the canonical pathway of NF-B activation (Chu et 
al., 1999; Hacker and Karin, 2006; Hu et al., 1999; Li et al., 1999) has become 
phosphorylated in its activation loop and is thus active, it phosphorylated IB at serines 32 
and 36 (Brown et al., 1995; DiDonato et al., 1996; Ghosh and Baltimore, 1990; Traenckner et 
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al., 1995). Other canonical IBs are targeted in a similar manner and in all cases 
phosphorylation generates a degron motif that is recognised by the SCFTRCP-E3 complex 
which then mediates the conjugation of K48-linked ubiquitin to lysines 21 and 22 of IB 
(Hatakeyama et al., 1999; Kanarek et al., 2010; Scherer et al., 1995; Shirane et al., 1999; Wu 
and Ghosh, 1999; Yaron et al., 1997; Yaron et al., 1998). Ubiquitinated IBs are recognised 
and degraded by the 26S proteasome thereby uncovering the nuclear localisation sequence 
of previously bound NF-B dimers and allowing them to translocate to the nucleus where 
they can bind specific B-sites and initiate the transcription of target genes (Kanarek et al., 
2010). Among these targets are several inhibitors of NF-B activation which in a negative 
feedback loop ensure the timely termination of the signal as failure to down-regulate NF-B 
activity can result in chronic inflammation and tumour formation (Ben-Neriah and Karin, 
2011). These negative regulators include IBwhich can bind NF-B dimers and lead to 
their export from the nucleus via its nuclear export sequence (NES) (Huxford et al., 1998; 
Jacobs and Harrison, 1998; Le Bail et al., 1993; Malek et al., 1998), as well as A20 and CYLD, 
two DUBs that remove non-proteolytic ubiquitin chains from the apical complex. This results 
in interactions with downstream components being lost and eventually in termination of the 
signal (Brummelkamp et al., 2003; Heyninck and Beyaert, 2005; Jono et al., 2004; Kovalenko 
et al., 2003; Krikos et al., 1992; Trompouki et al., 2003; Wertz et al., 2004).  
In parallel to activating NF-B, TNF also induces different MAPK pathways. MAPKs are serine 
threonine kinases that can be activated by a variety of cellular stresses and stimuli in a 
hierarchical cascade of phosphorylation events (Cargnello and Roux, 2011; Schaeffer and 
Weber, 1999; Wajant et al., 2003). Specific scaffolding proteins mediate the interaction 
between different components of the pathway thus allowing the downstream MAPK to be 
phosphorylated within a conserved Threonine-X-Tyrosine motif by a specific MAPK kinase 
(MAPKK, MAP2K, MAPK/ERK kinase (MEK), MKK) which in turn was activated by its MAPKK 
kinase (MAPKKK, MAP3K, MEKK). Once activated MAPKs can regulate downstream kinases 
and initiate activation of transcription factors thus translating extracellular stimuli into a 
wide range of cellular responses. In mammalian cells several MAPK modules, including the 
extracellular signal regulated kinases 1/2 (ERK1/2)-, the JNK- and the p38-cascades, have 
been identified (Cargnello and Roux, 2011). In the context of TNFR1 signalling the most 
potently activated MAPKs are JNK and p38 (Karin and Gallagher, 2009). Following TNF 
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stimulation different JNK isoforms, especially the widely expressed JNK1 and JNK2 which are 
also known as stress-activated protein kinase (SAPK) and SAPK, respectively, are 
phosphorylated and activated (Derijard et al., 1994; Kyriakis et al., 1994; Westwick et al., 
1994).  This depends on the MAP2Ks MKK4 and especially MKK7 as shown by the finding 
that although MKK4 is required for maximal JNK activation it cannot carry out this activation 
on its own in MKK7-deficient MEFs (Derijard et al., 1995; Tournier et al., 2001; Tournier et 
al., 1997). The upstream MAP3K for this pathway has not been unambiguously identified 
but a role for TAK1, MEKK1 or MEKK3 has been suggested (Blank et al., 1996; Minden et al., 
1994; Ninomiya-Tsuji et al., 1999; Xia et al., 2000). Furthermore, an additional class of 
kinases, the MAP4Ks may contribute to JNK activation by phosphorylating the MAP3Ks. For 
example it was shown over-expression of group I germinal centre kinases (GCKs), which can 
be differentiated from group II GCKs by the their regulatory domains, can lead to MAP3K 
phosphorylation and that GCK and GCK-related (GCKR) can activate MEKK1 (Kyriakis, 1999; 
Shi and Kehrl, 1997; Yao et al., 1999; Yuasa et al., 1998). The system is further complicated 
by a second phase of prolonged JNK activation that depends on a different set of proteins, 
including apoptosis signal-regulating kinase 1 (ASK1) (Tobiume et al., 2001). Whereas the 
first transient wave of JNK signalling leads to the activation of AP-1, a family of 
heterodimeric transcription factors composed of Jun, Fos, JDP and ATF proteins, prolonged 
activation of this MAPK has been associated with production of reactive oxygen species 
(ROS) and the induction of cell death (Roulston et al., 1998; Tobiume et al., 2001; Ventura et 
al., 2004; Ventura et al., 2003).  
Activation of the MAPK p38 follows the same scheme of events but involves different 
kinases. Although there are four p38 isoforms (,,,), p38is the most widely and highly 
expressed variant and therefore the best characterised member of this subgroup of MAPKs 
(Cuadrado and Nebreda, 2010; Han et al., 1994; Jiang et al., 1996; Jiang et al., 1997; Lee et 
al., 1994; Mertens et al., 1996; Rouse et al., 1994). As in the case of the JNK-module, 
MEKK1-3, TAK1, ASK1 and other potential MAP3Ks have been implicated in the initiation of 
the p38 pathway (Blank et al., 1996; Ninomiya-Tsuji et al., 1999); (Cargnello and Roux, 2011; 
Minden et al., 1994; Xia et al., 2000). The MAP2Ks activating p38 by phosphorylating it in its 
activation loop are MKK3, MKK6 and to a certain extent MKK4 (Derijard et al., 1995; Enslen 
et al., 1998; Han et al., 1996; Johnson and Lapadat, 2002; Stein et al., 1996). Once activated 
p38 phosphorylates a multitude of cytoplasmic and nuclear proteins, amongst them, as in 
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the case of JNK, components of AP-1 transcription factors which then mediate the manifold 
outcomes of this pathway as for example the production of proinflammatory cytokines 
(Cuadrado and Nebreda, 2010). Importantly, the NF-B and MAPK pathways following TNF 
stimulation are not independent events but regulate the biological outcome of the stimulus 
by a complex crosstalk and interplay (De Smaele et al., 2001; Papa et al., 2004; Schwabe and 
Brenner, 2006; Tang et al., 2001). This overall effect is also determined by a different arm of 
TNF-signalling which, in contrast to the gene-inducing pathways that mainly result in a pro-
survival outcome, induces cell death in the form of apoptosis or necroptosis (Figure 9). 
 
Figure 9: Schematic representation of TNF-signalling. Upon cross-linking by TNF, TNFR1 recruits TRADD, RIP1, 
TRAF2, cIAP1/2 and the TAB/TAK- and IKK-complexes. This receptor associated complex (TNF-RSC or complex I) 
initiates pathways inducing the activation of NF-B and MAPKs which eventually leads to the expression of 
pro-survival genes. Extended TNF stimulation can result in the formation of secondary, death-inducing 
complexes (complex II and complex IIB) and kill the cell in two different ways which are referred to as 
apoptosis or necroptosis, respectively. See text for details. 
 
Both forms of programmed cell death are initiated not at the TNF-RSC itself but at 
secondary cytoplasmic complexes (Cho et al., 2009; He et al., 2009; Micheau and Tschopp, 
2003; Zhang et al., 2009). Upon dissociation from TNFR1, TRADD can either recruit or be 
replaced by FADD thus allowing procaspases 8 and 10 to associate with the complex, which 
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is referred to as complex II, where they are activated (Micheau and Tschopp, 2003). The 
active initiator caspase dimers can then directly cleave and activate effector caspases as for 
example caspase 3 or by cleaving Bid can engage a mitochondrial amplification loop. The 
latter induces the permeabilisation of the outer mitochondrial membrane and via the 
release of cytochrome C from the mitochondria leads to formation of the apoptosome, an 
activation platform for the initiator caspase 9 which can again activate effector caspases 
(Kantari and Walczak, 2011). These effectors can then cleave a great number of substrates 
thereby executing a form of cell death, called apoptosis, which is characterised by no 
intracellular content being released and which is thus considered non-immunogenic. 
Alternatively, a different secondary death-inducing complex, referred to as complex IIB or 
necrosome, can be formed especially in situations when the activity of caspases is blocked. 
In this case the main mediators of death induction are the kinases RIP1 and RIP3. The cell 
death pathway emanating from complex IIB is less well characterised than apoptosis 
induction by complex II but is thought to involve phosphorylation of downstream 
components and the production of ROS. Overall this pathway induces a type of cell death 
that is referred to as necroptosis and that results in bursting of the cell and therefore 
creates a pro-inflammatory milieu (Cho et al., 2009; Festjens et al., 2006; He et al., 2009; 
Vanlangenakker et al., 2012; Zhang et al., 2009). The transition from the TNF-RSC 
(complex I) to either of the death-inducing complexes has not been characterised well to 
date. The formation of the secondary complexes occurs upon prolonged stimulation with 
TNF and the deubiquitination of RIP1 seems to be an essential step in this process 
(O'Donnell et al., 2007). In addition, the formation of the necrosome and the induction of 
necroptosis requires the kinase activities of RIP1 and RIP3 (Cho et al., 2009; He et al., 2009; 
Holler et al., 2000; Vandenabeele et al., 2010). Other factors controlling the formation of 
death inducing complexes and the execution of cell death programmes include the crosstalk 
between the different TNF-induced signalling pathways. Pro-survival proteins that are up-
regulated via the gene expression inducing pathways activated upon TNF stimulation can 
prevent aberrant death of a cell. This group includes the cellular FLICE like inhibitory protein 
(cFLIP) which on the one hand is recruited to complex II where it prevents the activation of 
caspase 8 homodimers thereby blocking the apoptosis pathway and which on the other 
hand, in a heterodimer with caspase 8, mediates RIP1 cleavage thus preventing necroptosis 
(Hu et al., 1997; Kreuz et al., 2001; Oberst et al., 2011). Overall TNF induces a complex 
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network of signalling pathways (Figure 9) that allows this cytokine to initiate its various 
biological effects. For the correct balance between the different arms to be maintained a 
tight regulation is required and many of the regulatory mechanisms are dependent on 
ubiquitination or deubiquitination events mediated by E3s such as cIAP1/2 or TRAF2 or 
DUBs like A20 or CYLD (Harhaj and Dixit, 2012; Wajant and Scheurich, 2011).  
2.2.3.2 TNFR2 signalling 
Although some of the components contributing to both TNFR1- and TNFR2-mediated signal 
transduction were first found to be associated with TNFR2, the complex associated with this 
receptor and the signalling pathways emanating from this protein assembly are much less 
understood than in the case of TNFR1. It was shown that TRAF2 interacts directly with the 
intracellular domain of TNFR2 and can thus serve as an adaptor for TRAF1, TRAF3, cIAP1 and 
cIAP2 (Rothe et al., 1995b; Rothe et al., 1994b). It can be assumed that the TAB/TAK- and 
IKK-complexes could be recruited in a similar ubiquitin-dependent manner as described for 
TNFR1-signalling although little data exists to support this hypothesis. Downstream of the 
signal initiating complex there are many similarities between TNFR1- and TNFR2-induced 
signalling. Like TNFR1, TNFR2 was reported to trigger the activation of NF-B and JNK 
although with different kinetics and possibly less efficiently (Haridas et al., 1998; Jupp et al., 
2001; Laegreid et al., 1994; Rothe et al., 1995b; Vandenabeele et al., 1995). In contrast to 
TNFR1, TNFR2 can also activate the non-canonical pathway of NF-B activation (Rauert et 
al., 2010). Here, TRAF2 and cIAP1 are degraded in a cIAP1- and K48-ubiquitination 
dependent manner. Because they are components of a destruction complex targeting the 
NF-B inducing kinase (NIK), this kinase is stabilised and can mediate phosphorylation of 
IKK and p100 thereby initiating p100 processing to p52 and thus the generation of an 
active transcription factor (Li et al., 2002; Wu et al., 2005). In addition, TNFR2 can modulate 
TNFR1-induced cell death (Fotin-Mleczek et al., 2002; Grell et al., 1999; Vercammen et al., 
1995; Weiss et al., 1997). Multiple mechanisms could contribute to this crosstalk. One of 
them is referred to as “ligand-passing” and suggests that by binding TNF, TNFR2 increases 
the local concentration of this cytokine in the vicinity of TNFR1 and eventually transfers the 
ligand to this receptor thereby favouring its prolonged stimulation and hence the induction 
of cell death (Tartaglia et al., 1993b). Another model includes the induction of TNF 
expression by activation of gene-expression inducing pathways upon TNFR2 stimulation. The 
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TNFR2 mediated degradation of TRAF2 and cIAP may in addition cause a shift in the balance 
between pro-survival and death-inducing signalling induced by TNFR1 and thus sensitise 
cells to TNFR1 induced cytotoxicity (Grell et al., 1999; Vercammen et al., 1995). In spite of its 
more restricted expression pattern TNFR2 can therefore significantly alter the outcome of 
TNF stimulation and changes in the TNFR1:TNFR2 ratio caused by an increase or decrease in 
the highly regulated expression of TNFR2 may therefore be a mechanism in controlling the 
overall signalling output (Wajant et al., 2003).  
2.3 Three novel components of the TNF-RSC 
In spite of the regulatory role exerted by TNFR2 most aspects of TNF-signalling are mediated 
by TNFR1 and all the different pathways contributing to the signal transduction network 
initiated by this receptor emanate from the receptor associated complex. A detailed 
knowledge of all the components of this multi-protein assembly is therefore crucial to gain 
an understanding of how signalling is initiated and regulated upon TNF stimulation. In an 
attempt to fully elucidate the composition of this complex, the native TNF-RSC was purified 
using a modified tandem affinity purification (moTAP) procedure. A form of TNF that 
contained a triple FLAG-tag followed by a PreScission cleavage site and a biotinylated Avi-
tag was used to stimulate U937 cells and to isolate the TNFR-associated complex in a two-
step precipitation process (Haas et al., 2009). Mass-spectrometric analysis of the purified 
complex identified not only most of the previously known TNF-RSC constituents but also 
revealed the presence of three novel components, SHANK-associated RH domain protein 
SHARPIN), heme-oxidized IRP2 ubiquitin ligase 1 (HOIL-1) and HOIL-1 interacting protein 
(HOIP) (Gerlach et al., 2011; Haas et al., 2009).  
2.3.1 SHARPIN 
SHARPIN is a protein of 387 aminoacids that was first identified as an interactor of SHANK1 
in a yeast-two-hybrid screen of a rat brain cDNA library (Lim et al., 2001). It was found that 
SHARPIN interacts with the ankyrin repeats of SHANK1 via its C-terminal part that contains 
an NZF- and an UBL-domain (Figure 10) while its N-terminal part mediates 
homodimerisation. It was therefore suggested that SHARPIN plays a role in regulating the 
complexity of the SHANK-based protein network in the postsynaptic density of excitatory 
synapses in the brain (Lim et al., 2001). However, expression of SHAPRIN is not restricted to 
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the brain and the first study investigating this protein in mice found it to be up-regulated in 
the gastric fundus of W/WV mice that have a mutation in the tyrosine kinase KIT and a role 
for SHARPIN in the function of the interstitial cells of Cajal (ICC), which are gastrointestinal 
(GI) pacemaker cells that generate and propagate electrical slow waves, was suggested 
(Daigo et al., 2003). Later a spontaneous mutation in the Sharpin gene was found to be 
causative for the chronic proliferative dermatitis mutation (cpdm) phenotype (Wang et al., 
2012). Cpdm mice are characterised by severe inflammation of several organs, especially 
the skin, by eosinophil accumulation, defects in lymphoid organ development and an 
altered Th1-Th2 balance with an increase of type 2 cytokines and impaired Th1 cytokine 
production (HogenEsch et al., 1993; HogenEsch et al., 1999; HogenEsch et al., 2001). In line 
with this SHARPIN was reported to be important for the production of proinflammatory 
cytokines and for the induction of Th1 differentiation by dendritic cells (Wang et al., 2012). 
On the intracellular level SHARPIN was reported to be a regulator of several different 
signalling pathways. It was found to associate with the phosphatase eyes-absent (EYA-1) 
which can also act as a transcriptional cofactor and to enhance its activity. This interaction 
was reported to be important for craniofacial development in zebrafish (Landgraf et al., 
2010). In addition SHARPIN was reported to regulate the mitochondrial apoptosis pathway 
(Liang and Sundberg, 2011) and to be required for TLR2 induced signalling as shown by 
alterations in the phosphorylation of ERK and the translocation of p65 to the nucleus in the 
absence of SHARPIN (Zak et al., 2011). On the other hand, SHARPIN was also described to 
inhibit NF-B activation (Liang et al., 2011) and to act as a negative regulator of integrin 
signalling by associating directly with the intracellular region of -integrins thus impairing 
their binding to talin and kindlin thereby preventing 1-integrins from switching into their 
active conformation (Rantala et al., 2011). Furthermore, it was shown to negatively affect 
the phosphatase activity of PTEN in human tumour cell lines and to promote tumorigenesis 
(He et al., 2010). 
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2.3.2 HOIL-1 
HOIL-1 was identified as an E3 ligase for oxidised iron regulatory protein 2 (IRP2) of 
498 aminoacids (Yamanaka et al., 2003) and as a hepatitis B virus X-associated protein 
(XAP3) (Cong et al., 1997). Following a yeast two-hybrid screen of a rat cDNA library it was 
described as a RBCC protein interacting with PKC (RBCK1) (Tokunaga et al., 1998a) and 
finally it was found as a UbcM4-interacting protein (UIP28) in a murine system (Martinez-
Noel et al., 1999). In addition, another start codon was identified in the mRNA of RBCK1 10 
codons upstream of the original initiation site and the resulting protein was dubbed HOIL-1L 
(Kirisako et al., 2006). However, there is very limited data on differential expression patterns 
or functions of the two forms and the terms RBCK1 and HOIL-1 are widely used to refer to 
the longer form even by protein databases. In this thesis the 510 aminoacid form of the 
protein will be referred to as HOIL-1. Structurally, this protein includes an N-terminal UBL-
domain, an NZF, two RING domains and an IBR domain (Figure 10), making it part of the 
RBR-family (Kirisako et al., 2006; Marin et al., 2004). The structures of the UBL- and NZF 
domain were solved and it was shown that the UBL assumes a ubiquitin fold followed by an 
-helical segment (Uekusa et al., 2011) while the NZF contains a zinc-coordinating core and 
an additional -helical NZF tail. This combination allows it to bind to M1-linked ubiquitin 
specifically by interacting with the Ile44 patch on the distal ubiquitin and a Phe4 centred 
hydrophobic patch on the proximal ubiquitin (Sato et al., 2011). Functionally, different 
activities have been reported for HOIL-1. It was described to shuttle between nucleus and 
cytoplasm and to possess transcriptional activity (Tatematsu et al., 1998; Tatematsu et al., 
2005; Tokunaga et al., 1998b). Reported targets include estrogen receptor (ER) alpha and 
cyclin B1 which mediate an effect of HOIL-1 on cell cycle progression and on proliferation in 
ER positive breast cancer cells (Gustafsson et al., 2010). This transcriptional activity was 
reported to be inhibited by the splice variant RBCK2, which lacks the RING domains of 
HOIL-1 and by tethering its active counterpart in the cytoplasm prevents it from acting as a 
transcription factor (Tokunaga et al., 1998b; Yoshimoto et al., 2005). Furthermore, 
transcriptional activity was described to be enhanced by PKA and to be repressed by MEK1 
or MEKK1 (Tatematsu et al., 1998). Finally, phosphorylation by PKC was reported to cause 
auto-ubiquitination of HOIL-1 leading to its proteasomal degradation (Tatematsu et al., 
2008). This ability to attach supposedly K48-linked chains to target proteins is the other 
activity by which HOIL-1 affects signalling. Targets include the transcription factors Bach-1 
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(Zenke-Kawasaki et al., 2007) and interferon regulatory factor (IRF3) (Zhang et al., 2008) as 
well as TAB2 and TAB3 (Tian et al., 2007). Degradation of these proteins was reported to 
cause an inhibitory effect of HOIL-1 on the antiviral interferon production and on NF-B 
signalling, respectively (Tian et al., 2007; Zhang et al., 2008). Like the transcriptional activity 
the ability of HOIL-1 to act as an E3 is regulated by interaction with RBCK2 and by 
phosphorylation by PKC which was reported to lead to cleavage and thus inactivation of 
HOIL-1 (Nakamura et al., 2006; Tatematsu et al., 2008).  
2.3.3  HOIP 
HOIP which is also known as RNF31, zinc IBR finger UBA domain (ZIBRA) or putative 
ARIADNE like ubiquitin ligase (PAUL) was identified as a potential E3 ligase which is highly 
expressed on the mRNA level in different kinds of cancers (Thompson et al., 2004) and as an 
interactor of the muscle-specific receptor tyrosine kinase (MuSK) (Bromann et al., 2004). 
Like HOIL-1 it contains two RING-domains and an IBR-domain which makes it a member of 
the RBR-family of E3 ligases (Marin et al., 2004). In addition, HOIP contains a ZnF-, two NZF- 
and a UBA-domain (Figure 10). It was reported that HOIP associates with the atypical 
orphan receptor DAX-1 and in complex with this protein acts as a corepressor at the 
promoters of the StAR and CYP19 genes by interacting with the nuclear orphan receptor 
steroidogenic factor 1 (SF-1). Thus HOIP was suggested to regulate metabolism and steroid 
hormone synthesis and was also implicated in the transcriptional regulation of the Wnt 
pathway (Ehrlund et al., 2009; Ehrlund et al., 2012). Furthermore, HOIP was found to be 
recruited to the CD40-RSC and experiments using cells deficient in HOIP or expressing a 
variant lacking E3 activity showed that HOIP is required for NF-B- and JNK-activation by this 
receptor (Gerlach et al., 2011; Hostager et al., 2010; Hostager et al., 2011).  
2.3.4 LUBAC 
In 2006 it was found that HOIL-1 and HOIP interact and form an E3-complex of 
approximately 600 kDa. The interaction was mapped to their UBL- and UBA-domains 
respectively (Kirisako et al., 2006) and structural analysis revealed that the two domains 
bind to each other in a non-canonical manner using different surfaces than the ones usually 
involved in UBL-UBA-interactions (Yagi et al., 2012). The distinguishing property of this E3-
complex is that it can generate M1-linked ubiquitin chains as demonstrated by its ability to 
use lysine-less (K0) but not methylated ubiquitin as a substrate. Due to this role in 
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generating linear ubiquitin chains, the complex was dubbed linear ubiquitin chains assembly 
complex (LUBAC) (Kirisako et al., 2006). It was found that the E3-activity of the complex 
resides in the RING-domains of HOIP but not HOIL-1 (Kirisako et al., 2006). As described in 
section 2.1.2.2.8 linear chains were first described to have a role in proteasomal 
degradation and LUBAC was thereby implicated in the regulation of the RIG-I pathway and 
of conventional PKC (Inn et al., 2011; Kirisako et al., 2006; Nakamura et al., 2006; Prakash et 
al., 2009; Thrower et al., 2000; Zhao and Ulrich, 2010). Later it was found that LUBAC is a 
positive regulator of NF-B activation in the context of different stimuli such as TNF, IL-1 
and genotoxic stress (Haas et al., 2009; Niu et al., 2011; Tokunaga et al., 2009) and that it 
also regulates other signalling pathways such as the activation of JNK downstream of TNF-
stimulation (Haas et al., 2009). 
 
 
Figure 10: Schematic representation of the domain structures of SHARPIN, HOIL-1 and HOIP. There is 
significant sequence homology (45 % identity) between the carboxyl terminus of SHARPIN and the amino 
terminus of HOIL-1 (Lim et al., 2001), each of which contains a UBL- and an NZF-domain. Both HOIL-1 and HOIP 
contain an RBR-motif making them members of the RBR-family of E3s (Marin et al., 2004). It was found that 
these two proteins interact via their UBL- and UBA-domains respectively thereby forming the E3 complex 
referred to as LUBAC (Kirisako et al., 2006). ZnF: zinc finger; NZF: Npl4 zinc finger; UBL: ubiquitin-like domain; 
UBA: ubiquitin-associated domain; IBR: in-between RING domain. RING: really interesting new gene. 
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3 Aims 
The identification of peptides for SHARPIN together with HOIL-1 and HOIP in the mass-
spectrometric analysis of the native TNF-RSC raised the question whether it is a functional 
component of this complex. 
This study therefore aimed to investigate whether SHARPIN, along with the other two novel 
components found by mass-spectrometry, i.e. HOIL-1 and HOIP, is recruited to TNF-
receptors in a stimulation-dependent manner and to unravel which other components of 
the complex this recruitment depends on. In this context the question how SHARPIN 
influences TNF-induced signalling was to be answered.  
Furthermore, the presence of SHARPIN alongside the LUBAC-components HOIL-1 and HOIP 
together with the similarity of its sequence to that of HOIL-1 indicated the possibility that 
SHARPIN might affect the activity of LUBAC. To test this hypothesis it was to be investigated 
whether SHARPIN interacts with this E3-complex. In case such an interaction was identified, 
a potential role for SHARPIN as a modulator of LUBAC’s activity was to be analysed.  
In brief the aims of this study were to 
1. investigate the mechanism by which SHARPIN, HOIL-1 and HOIP are recruited to the 
TNF-RSC 
2. test the influence of SHARPIN on TNF-induced signalling 
3. analyse a potential role of SHARPIN as an active part or an inhibitor of LUBAC 
4. further characterise the activity of LUBAC 
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4 Materials and Methods 
4.1 Materials 
4.1.1  Chemicals and reagents 
All chemicals and biologically reactive reagents were purchased from Roth, Sigma/Aldrich 
(Fluka), Merck (Calbiochem), Invitrogen (Gibco; Molecular Probes), AppliChem, Pierce, 
Honeywell (Riedel-de Häen) or Amersham Biosciences in pA quality unless indicated 
otherwise. 
4.1.2  Specific inhibitors 
4.1.2.1 Inhibitors used in the purification of recombinant proteins 
All protease inhibitors used in the purification of recombinant proteins were purchased 
from Sigma. Specifically the following inhibitors were used: AEBSF, Aprotinin, E-64, 
Leupeptin and Pepstatin. 
4.1.2.2  Inhibitors used in the lysis of eukaryotic cells 
Proteases were inhibited by using the Complete Protease Inhibitor Cocktail obtained from 
Roche; Phosphatase Inhibitor Cocktail from Sigma was employed to impair the activity of 
phosphatases. 
4.1.3 Buffers and solutions 
4.1.3.1 General buffers 
- 1x PBS:      137 mM NaCl 
8.1 mM Na2HPO4 
2.7 mM KCl 
1.5 mM KH2PO4 
pH 7.4 
4.1.3.2 Buffers used in the cloning and purification of recombinant proteins 
- TAE buffer (10x):     400 mM Tris/HCl 
200 mM Acetic Acid 
10 mM EDTA 
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- Bacteria lysis buffer (GST-purification):  1x PBS 
70 μM AEBSF 
5 μM E-64 
1.2 μg/mL Aprotinin 
1 μM Pepstatin 
1 mM DTT  
- GST-wash buffer:     1x PBS 
      1 mM DTT 
- GST-elution buffer:    1x PBS 
50 mM reduced glutathione 
- PreScission cleavage buffer:   50 mM Tris-HCl 
150 mM NaCl 
1 mM EDTA 
1 mM DTT 
pH 7.0 
- Dialysis buffer (ligands)    50 mM Trizma Base 
100 mM NaCl 
0.02 % Tween 20 (v/v) 
2 mM DTT 
0.5 M L-Arginine 
- Dialysis buffer (other proteins):  1x PBS 
      1 mM DTT 
- Bacteria lysis buffer (His-tagged proteins): 50 mM  Tris/HCl 
      200 mM NaCl 
      100 mM KCl 
      10 %  Glycerol (v/v) 
      0,5 %  Triton X100 
      2 mM  β-Mercaptoethanol         
      70 µM  AEBSF 
      5 µM  E-64 
      1.2 µg/mL Aprotinin 
      1 µM  Pepstatin A 
- His-wash buffer    50 mM Tris/HCl 
      300 mM NaCl 
      25 mM imidazole 
      pH 7.5 
- His-elution buffer    50 mM Tris/HCl 
      300 mM NaCl 
      500 mM imidazole 
      pH 7.5 
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4.1.3.3. Buffers used for freezing, transfecting and lysing eukaryotic cells 
- Freezing medium:    90 % FCS (v/v) 
10 % DMSO (v/v) 
- 2x HBS:     50 mM HEPES 
280 mM NaCl 
1.5 mM Na2HPO4 x 2 H2O 
pH 7.0 
- IP-lysis buffer:     30 mM Trizma Base  
120 mM NaCl 
2 mM EDTA 
2 mM KCl 
10 % Glycerol (v/v) 
1 % Triton X-100 (v/v) 
pH 7.4 
+ Complete protease inhibitor cocktail 
4.1.3.4. Buffers used for gelfiltration 
- Lysis buffer gelfiltration:   50 mM Tris/HCl (pH 7.5) 
1 mM MgCl2 
1 mM DTT  
+ Complete protease inhibitor cocktail 
- Running buffer gelfiltration:   50 mM Tris/HCl (pH 7.5) 
1 mM MgCl2 
1 mM DTT  
150 mM NaCl 
+ Complete protease inhibitor cocktail 
 
4.1.3.5. Buffers for SDS-PAGE and western blotting 
- Running buffer (MOPS)   1:20 dilution of 20x MOPS (Invitrogen) 
- Transfer buffer:     192 mM Glycine 
25 mM Trizma Base 
0.01 % EDTA (w/v) 
20 % Methanol (v/v) 
- Blocking buffer:     1x PBS 
5 % milk powder (w/v) 
0.05 % Tween-20 (v/v) 
- Wash buffer:     1x PBS 
0.05 % Tween-20 (v/v) 
- Stripping buffer:    50 mM Glycine 
pH 2.3  
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4.1.3.6. Buffers for Luciferase assays 
- Passive lysis buffer:     1:5 dilution of 5x passive lysis buffer (Promega) 
- Luciferase assay buffer A:    20 mM HEPES 
33.3 mM DTT 
8 mM MgCl2 
130 μM EDTA 
530 μM ATP 
470 μM Luciferin 
270 μM Coenzyme A 
pH 7.8 
 
- Luciferase assay buffer B:   15 mM Na4P2O7 
7.5 mM NaOAc 
400 mM NaSO4 
10 mM CDTA 
25 μM APMBT 
1 % Methanol (v/v) 
2 μM Benzyl-Coelenterazin 
pH 5.0 
- MTT solution:     2.5 mg/mL MTT in PBS 
4.1.3.7 Buffers for ubiquitin-related in-vitro assays 
- Pull-down buffer:     150 mM NaCl 
50 mM Trizma Base (pH 7.5) 
5 mM DTT 
0.1 % NP-40 (v/v) 
- Ubiquitylation buffer:    20 mM Trizma Base (pH 7.5) 
5 mM MgCl2 
2 mM DTT 
- DUB dilution buffer:     150 mM NaCl 
25 mM Tris (pH 7.5) 
10 mM DTT 
- 10x DUB reaction buffer:    500 mM NaCl 
500 mM Tris (pH 7.5) 
50 mM DTT    
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4.1.4 Antibodies 
4.1.4.1  Primary antibodies 
Table 1: Primary antibodies. WB: western blotting; IP: immunoprecipitation 
antibody isotype Source application(s) 
anti-Actin (A5441) mIgG1 Sigma WB 
anti-cIAP2 rat Gift from John Silke WB 
anti-cIAP Pan (MAB3400) mIgG2a R&D Systems WB 
anti-FLAG (M2) mIgG1 Sigma WB, IP 
anti-GAPDH mIgG1 Abcam WB 
anti-GST goat GE Healthcare WB 
anti-HOIL-1 mIgG2a Produced in the lab WB, IP 
anti-HOIP rabbit Sigma WB, IP 
anti-HOIP rabbit Eurogentech WB 
anti-IB (C-15) mIgG1 Santa Cruz WB 
anti-myc (9E10) mIgG1 Abcam WB, IP 
anti-NEMO (FL419) rabbit Santa Cruz WB 
anti-NEMO (B3) mIgG1 Santa Cruz WB 
anti-pIB (5A5) mIgG1 Cell Signaling WB 
anti-pJNK (98F2) 
(98F2)  
 
(98F2)  
 
(98F2)  
 
(98F2)  
 
rabbit Cell Signaling WB 
anti-pp38(3D7) rabbit Cell Signaling WB 
anti-RIP1 mIgG1 Pharmingen IP 
anti-RIP1 (clone 38) mIgG2a BD Biosciences WB 
anti-SHARPIN mIgG1 Produced in the lab WB, IP 
anti-SHARPIN rabbit Gift from Ivan Dikic WB 
anti-TNF-R1 (H-5) mIgG2b Santa Cruz WB, IP 
anti-TNF-R1 (ab19139) rabbit Abcam WB 
anti-TNFR2 rabbit Cell Signaling IP 
anti-TNFR2 rat Pharmingen WB 
anti-TRADD (clone 37) mIgG1 BD Biosciences WB 
anti-TRADD (H-278) rabbit Santa Cruz WB 
anti-TRAF2 (C-20) rabbit Santa Cruz WB 
anti-TRAF2 (AP1040) rabbit Calbiochem WB 
anti-TRAF6 IgG1 Cell Signaling WB 
anti-TRAF6 rabbit Epitomics WB 
anti-UBE2D3 IgG1 Abnova WB 
anti-Ubiquitin (FK1) mIgM Biomol WB 
anti-Ubiquitin (FK2) mIgG1 Biomol WB 
anti-Ubiquitin (#07-375) rabbit Millipore WB 
anti-V5 (V5-10) rabbit MBL WB, IP 
anti-V5 mIgG2a Santa Cruz WB 
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4.1.4.2 Secondary antibodies 
- Goat-anti-mIgG1-HRP (SouthernBiotech) 
- Goat-anti-mIgG2a-HRP (SouthernBiotech) 
- Goat-anti-mIgG2b-HRP (SouthernBiotech) 
- Goat-anti-mIgM-HRP (SouthernBiotech) 
- Goat-anti-rat-HRP (SouthernBiotech) 
- Rabbit-anti-goat-IgG-HRP (Santa Cruz) 
- Goat-anti-rabbit-IgG-HRP (SouthernBiotech) 
4.1.5 Beads for precipitations 
- anti-Myc agarose (Sigma)  
- anti- NEMO beads (Santa Cruz) 
- anti-V5 Agarose (clone V5-10) (Sigma)  
- FLAG M2 affinity Gel (Sigma)  
- glutathione beads (GE Healthcare) 
- Protein G Sepharose (GE Healthcare) 
- ubiquitin-coupled agarose (Boston Biochem) 
4.1.6 Recombinant proteins 
- K48-linked tetra-ubiquitin (Enzo Life Sciences) 
- K63-linked tetra-ubiquitin (Enzo Life Sciences) 
- linear tetra-ubiquitin (Enzo Life Sciences) 
- PreScission Protease (GE Healthcare) 
- Thrombin (GE Healthcare) 
- TRAF2 (Signal Chem) 
- USP2 catalytic domain (Enzo Life Sciences) 
- UBE1 (Enzo Life Sciences) 
- E2s (Enzo Life Sciences) 
4.1.7 Commercially available kits and solutions 
- ABsolute QPCR ROX Mix (ABgene) 
- BCA Protein Assay (Pierce) 
- ECL Western Blotting Detection (GE Healthcare) 
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- ECL Western Blotting Detection Plus (GE Healthcare) 
- Chemoluminescent Substrate SuperSignal West Dura (Pierce) 
- Chemoluminescent Substrate SuperSignal West FEMTO (Pierce) 
- E.Z.N.A. Plasmid Mini Kit (Omega Bio-Tek) 
- E.Z.N.A. Plasmid Maxi Kit (Omega Bio-Tek) 
- QIAquick Gel Extraction kit (Qiagen) 
- QIAquich PCR purification kit (Qiagen) 
- RevertAidTMH Minus first strand cDNA synthesis kit (Fermentas) 
- TNT Quick coupled Transcription/Translation System (Promega) 
- TrypanBlue (Serva) 
- pcDNA3.1V5/His TOPO Directional Expression kit (Invitrogen) 
- SuperScript III Reverse Transcriptase (Invitrogen) 
- tissue lysates (IMGENEX) 
4.1.8 Bacteria strains 
DG1 chemically competent cells (Eurogentech) were used for plasmid amplification and 
expression of recombinant proteins was performed in BL21(DE3) cells (Invitrogen). 
4.1.9 Cell culture media and antibiotics 
- Ampicillin (Roth) 
 - β-mercaptoethanol (Invitrogen) 
- Dulbecco’s Modified Eagle Medium (Invitrogen)  
- Hygromycin B (Boehringer) 
- Insulin (Sigma) 
- Penicillin/Streptomycin (Invitrogen) 
- RPMI 1640 (Invitrogen)  
- Sodium Pyruvate (Invitrogen)  
- Trypsin/EDTA solution (Invitrogen) 
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4.1.10 Cell lines 
Table 2: Cell lines 
cell line Description reference 
HEK 293T 
Human embryonic kidney cells transformed with 
sheared adenovirus 5 DNA. 
(Graham et al., 1977) 
HEK293-  
NF-B 
Cell line purchased from Panomics that was 
obtained by cotransfection of a luciferase reporter 
construct containing multiple copies of the NF-B 
response element and a hygromycin selection 
marker into HEK293 cells, followed by hygromycin 
selection. 
Panomics 
HeLa 
Cell line isolated from an adenocarcinoma of the 
cervix in 1952. 
(Scherer et al., 1953) 
HT1080 
Sarcoma cell line, derived from a 35-year-old male 
with fibrosarcoma. 
(Rasheed et al., 1974) 
HaCat 
Cell line resulting from spontaneous in-vitro 
transformation of keratinocytes from histologically 
normal skin. 
(Boukamp et al., 1988) 
Saos-2 
Osteosarcoma cell line with epithelial morphology 
that was isolated from an 11-year-old female 
patient. 
(Fogh et al., 1977a; 
Fogh et al., 1977b) 
IGROV-1 
Cell line originating from an ovarian carcinoma of a 
47-year-old woman. 
(Benard et al., 1985) 
DKO-4 
Colorectal adenocarcinoma cell line derived from 
DLD-1 cells by targeted disruption of its mutant 
Ki-Ras allele. 
(Shirasawa et al., 1993) 
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DU145 
Cell line that was originally derived from a human 
prostate adenocarcinoma that metastasized to 
the brain. 
(Stone et al., 1978) 
A549 
This line was initiated in 1972 by culturing of lung 
carcinomatous tissue from a 58-year-old male. 
(Giard et al., 1973) 
MCF-7 
Cell line obtained by pleural effusion from a 
female patient with metastatic breast cancer. 
(Brooks et al., 1973) 
JA-3 
The Jurkat cell line was first established from the 
peripheral blood of a 14-year old boy suffering 
from T cell leukemia. 
(Schneider and Schwenk, 
1977; Schneider et al., 
1977) 
Raji 
Human lymphoblast-like cell line which was 
established from a Burkitt’s lymphoma of the left 
maxilla of an 11-year-old male. 
(Pulvertaft, 1964) 
U937 
Cell line derived from malignant cells obtained 
from the pleural effusion of a patient with 
histiocytic lymphoma. Terminal monocytic 
differentiation can be induced. 
(Sundstrom and Nilsson, 
1976) 
THP-1 
Cell line with distinct monocytic markers that was 
derived from the peripheral blood of a patient 
with acute monocytic leukemia. 
(Tsuchiya et al., 1980) 
MEF 
Wt and knockout MEFs were generated from E15 
embryos in accordance with standard procedures 
and were infected with SV40 large T antigen-
expressing lentivirus. Cells with inducible 
expression of cIAP1 or TRAF2 were described 
previously. 
(Feltham et al., 2010; 
Mace et al., 2008; Vince 
et al., 2009) 
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4.1.11 Additional materials 
- Cuvettes (Greiner Bio One) 
- Cryogenic vials (Nunc) 
- Dialysis Membrane 12,000-14,000 MWCO (Roth) 
- GSTrap FF (GE Healthcare) 
- HisTrap FF (GE Healthcare) 
- Hybond ECL Nitrocellulose Membrane (Amersham Bioscience) 
- NuPAGE 4-12 % Bis-Tris Gels (Invitrogen) 
- 4x LDS-Sample buffer (Invitrogen) 
- PCR tubes (StarLab) 
- Plastic pipettes (5 mL, 10 mL and 25 mL) (StarLab) 
- Pipette tips (0.1-10, 1-200, 101-1000 μL) (StarLab)  
- 50 mL Reagent Reservoir (Corning Inc.) 
- Safe-Lock Reaction Tubes (1.5mL, 2 mL) (Eppendorf) 
- SeeBlueTM Plus2 Pre-Stained Standard (Invitrogen) 
- SmartLadder DNA Standard (Eurogentech) 
- Sterile filter (0.22 μm and 0.45 μm pore size) (Millipore) 
- Superdex 200 10/300 GL column (GE Healthcare) 
- Tissue culture equipment (TPP) 
- Whatman paper (Schleicher&Schuell) 
- X-Ray film HyperfilmTM ECL (Amersham Bioscience) 
4.1.12 Instruments 
- Biofuge Stratos (Heraeus) 
- Blotting equipment X cell IITM (Novex) 
- Electrophoresis chamber (Biorad) 
- GelSystem Flexi 4040 Biostep 
- Hyper Processor X-Ray film Developer (Amersham Bioscience) 
- Incubator Stericult 200 (Forma Scientific) 
- Microscope Axiovant 25 (Zeiss) 
- Mithras Luminometer LB 940 (Berthold Technologies) 
- Multifuge 3S-R (Heraeus) 
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- Multiskan Ascent (Thermo Labsystems) 
- Multitron Incubator Shaker (Appropriate Technical Resources) 
- NanoDrop Spectrophotometer ND-1000 (NanoDrop Technologies) 
- Photometer Ultrospec 3100 pro (Amersham Bioscience) 
- Sonifier (Branson Ultrasonics Corporation) 
- Mastercycler Pro (Eppendorf) 
- Äkta Purifier (GE Healthcare) 
- peristaltic pump P1 (Pharmacia Fine Chemicals) 
 
4.2 Methods  
4.2.1  Methods in Molecular Biology 
4.2.1.1 RNA purification 
Total RNA was isolated using Trizol (Invitrogen) according to the manufacturer’s 
instructions. Trizol was removed by addition of 0.2 mL chloroform followed by isopropanol 
precipitation. The concentration and purity of RNA was determined with a ND-1000 
Spectrophotometer (NanoDrop). 
4.2.1.2 cDNA preparation 
A reverse transcription was performed on 5 μg total RNA for 1 h at 42°C using the 
RevertAidTM H Minus first strand cDNA synthesis kit (Fermentas) according to the 
manufacturer’s instructions. 
4.2.1.3 Quantitative Real-time PCR 
Quantitative Real-time PCR was performed with the ABI PRISM 7900 HT Sequence Detection 
System (Applied Biosystems) using the ABsoluteTM QPCR ROX Mix (ABgene). The 
ProbeFinder software (Roche) was used to design the optimal assay, comprising the 
respective labelled probe of the Universal ProbeLibrary (Roche) and gene-specific primers. 
For the RT-PCR reaction, cDNA was diluted 1:10. Amplification was carried out in stages of 
incubation at 95°C for 15 min following 40 cycles of 95°C for 15 s and 60°C for 60 s. The 
mRNA levels were measured as double determinations and normalised with reference to 
the amount of housekeeping gene transcripts (GAPDH or HPRT1). The following gene-
specific primers were used: HOIP: cttctgtgtgcgctgcaa and ttctggaagtcctcacagctc;  
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HOIL-1: gcctgaggtctccccaac and ggtgacggtgtgcatctg; SHARPIN: cggaagcctccacactca and 
tccctgccagctcttctc; GAPDH: agccacatcgctcagaca and gcccaatacgaccaaatcc; HPRT1: 
tgaccttgatttattttgcatacc and cgagcaagacgttcagtcct.  
4.2.1.4 Polymerase Chain Reaction (PCR) 
All PCRs were set up in a volume of 50 μL, which contained 1-50 ng plasmid-DNA or cDNA as 
template, 0.4 μM of each oligonucleotide, 200 μM of each dNTP, 2.5 U Polymerase in 1x 
Polymerase Buffer. The polymerase used was PfuUltra (Stratagene). If possible, the 
synthetic oligonucleotides were designed with 40-60 % GC content, no internal structure or 
complementarity at the 3’-ends. Annealing temperatures were chosen ~5-10°C lower than 
the melting temperature Tm and elongation times were calculated based on an elongation 
rate of 1 kb/min.  
The following oligonucleotides were used: 
Table 3: Oligonucleotides used in PCR reactions. Restriction sites are underlined, stop codons are in bold print 
and reverse primers are presented in upper case. 
insert vector Primers 
restriction 
sites used 
SHARPIN 
pcDNA3.1
D/V5-His-
TOPO 
- CACCatggcgccgccagcg 
- GGTGGAAGCTGCAGCAAGGG 
TOPO 
cloning 
SHARPIN pGEX6-p2 
- atggcgccgccagcgggc 
- atatGCGGCCGCtcaGGTGGAAGCTGCAGCAAGGGGGTCC 
SmaI + NotI 
SHARPIN-
V5 
pGEX6-p2 
- atggcgccgccagcgggc 
- atatGCGGCCGCtcaCGTAGAATCGAGACC 
SmaI + NotI 
HOIL-1 
pcDNA3.1
D/V5-His-
TOPO 
- CACCatggacgagaagaccaagaaagc 
- GTG GCA GTT CTG ACA GCT TGG 
TOPO 
cloning 
HOIL-1 pGEX6-p2 
- atggacgagaagaccaagaaagc 
- atatGCGGCCGCtcaGTG GCA GTT CTG ACA GCT TGG 
SmaI + NotI 
HOIL-1-
V5 
pGEX6-p2 
- atatGAATTCatatggacgagaagaccaagaaagc 
- atatATTTAAATtcaCGTAGAATCGAGACCGAGGAGAGG 
EcoRI + SwaI 
(PCR) / SmaI 
(vector) 
HOIP pGEX6-p2 
- atgccgggggaggaag 
- atatGCGGCCGCtcaCTTCCGCCTGCGGG 
SmaI + NotI 
HOIP-V5 pGEX6-p2 
- atatGAATTCatatgcccgggggaggaagagg 
- atatATTTAAATtcaCGTAGAATCGAGACCGAGGAGAGG 
EcoRI + SwaI 
(PCR) / SmaI 
(vector) 
HOIP ZnF 
only 
pGEX6-p2 
- agtgctcatttgccctggcactgtgc 
- atatGCGGCCGCtcaACAGCCTCGGGGCCGATCACAGG 
SmaI + NotI 
HOIP 
NZF1 
only 
pGEX6-p2 
- gcacggggtcggtgggcc 
- atatGCGGCCGCtcaGGCCAGCCGAGGTCGCTCACATATGG 
SmaI + NotI 
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HOIP 
NZF2 
only 
pGEX6-p2 
- agagtcaagtctggtactgtattcactgtacc 
- atatGCGGCCGCtcaGGGGCTACTAGTCCGGTTGC 
SmaI + NotI 
cIAP1 pGEX6-p2 
- atgcacaaaactgcctccc 
- atatGCGGCCGCtcaAGAGAGAAATGTACGAACAGTACCC 
SmaI + NotI 
cIAP2 pGEX6-p2 
- atgaacatagtagaaaacagcatattcttatcaaatttg 
- atatGCGGCCGCtcaTGAAAGAAATGTACGAACTGTACCCTT    
SmaI + NotI 
RNF5 pGEX6-p2 
- atggcagcagcggaggaggagg 
- atatGCGGCCGCtcaaatactgagcagccaaaaaaagaagaagatgg 
SmaI + NotI 
PARKIN pGEX6-p2 
- atgatagtgtttgtcaggttcaactcc 
- atatGCGGCCGCtcaCACGTCGAACCAGTGGTC 
SmaI + NotI 
PARKIN 
RBR only 
pGEX6-p2 
- atgcggaacatcacttgcattacg 
- atatGCGGCCGCtcaCCACTCGCAGCCAC 
SmaI + NotI 
ARIH1 
RBR only 
pGEX6-p2 
- atggcacaggatatgccttgtc 
- atatGCGGCCGCtcaCCATGGGCCAAGACAC 
SmaI + NotI 
ARIH2 pGEX6-p2 
- atgtcagtggacatgaatagccag 
- atatGCGGCCGCtcaGGTGTCATGGAAATCTTTCAGCAG 
SmaI + NotI 
ARIH2 
RBR only 
pGEX6-p2 
- atgcctcaccactgtgcag 
- atatGCGGCCGCtcaCCAATCTCCTAGACACATCC 
SmaI + NotI 
RNF19A pGEX6-p2 
- atgcaagaacaagaaataggttttatctctaaatataatg 
- atatGCGGCCGCtcaAATTTCAGTCTGAATTGCAACTTTTAATTCC 
SmaI + NotI 
RNF144B pGEX6-p2 
- atgggctcagctggtagg 
- atatGCGGCCGCtcaGGTTGTGGATGGGTCGTG 
SmaI + NotI 
RNF216 pGEX6-p2 
- atggaagagggaaacaacaatgaag 
- atatGCGGCCGCtcaGAAGCGATGCCGCGG 
SmaI + NotI 
RNF14 pGEX6-p2 
- atgtcgtcagaagatcgagaagc 
- atatGCGGCCGCtcaGTCTTCTACCTCATCTTCCCAAATATCG 
SmaI + NotI 
PTEN 
pcDNA3.1
D/V5-His-
TOPO 
- CACCatgacagccatcatcaaagagatcgttagc 
- GAC TTT TGT AAT TTG TGT ATG CTG ATC TTC ATC AAA AGG 
TOPO 
cloning 
ABIN-1 
pcDNA3.1
D/V5-His-
TOPO 
- CACCatggaagggagaggaccgtaccg 
- CTG AGG CCC CTC ACG GTC ATT TTT TGG 
TOPO 
cloning 
 
4.2.1.5 Site-directed Mutagenesis 
To introduce deletions or point mutations by PCR, primers containing the point mutation 
were designed. These oligonucleotides contained the desired mutations with ~10-15 bases 
of correct sequence on both sides. Following the PCR, the reaction was treated with DpnI 
endonuclease for 1 hour at room temperature to cut unmethylated DNA. The linearised, 
mutated plasmid was then transformed into competent bacteria (Section 4.2.1.10). 
 
 
 
4. Material and Methods 
  
71 
 
The oligonucleotides used to introduce mutations were: 
 Table 4: Oligonucleotides used to introduce mutations. Restriction sites are underlined; introduced 
mutations are shown in upper case and bold print. 
 
4.2.1.6 DNA digestion and restriction analysis 
Sequence-specific cleavage of DNA molecules was performed using specific restriction 
endonucleases of the FastDigest® system obtained from Fermentas. Restriction reactions 
were incubated at 37°C for 1 hour. 
4.2.1.7 Agarose gel electrophoresis of nucleic acids 
The analysis or separation of DNA fragments was performed by agarose gel electrophoresis. 
Gels were prepared by dissolving 1-2 % agarose (w/v) in TAE buffer. DNA fragments were 
resolved by electrophoresis which was performed in a gel chamber filled with TAE buffer at 
10 Volts per cm of electrodal distance. After electrophoretic separation the gel was 
incubated for 30 min in TAE buffer + ethidium bromide (400 ng/mL) and DNA fragments 
were visualised by UV light ( = 254 nm). 
4.2.1.8 Gel extraction of DNA fragments 
The appropriate bands were cut out from the agarose gel and the isolation of DNA was 
achieved using the QIAquick Gel Extraction kit (Qiagen) according to manufacturer’s 
protein mutation  primers 
SHARPIN 
deletion of 
UBL-domain 
- caggatggggaccctgctttcctc 
- ggggccaggtgggaagcaggcctc 
SHARPIN 
deletion of 
NZF-domain 
- acttgggacccccttgctgcagcttc 
- tggactgggcaggctggaggcagc 
SHARPIN C353,356S 
- ccagctggtcctCtccttcctCcaccttcatcaatgcc 
- ggcattgatgaaggtgGaggaaggaGaggaccagctgg 
SHARPIN C367,370S 
- ccagaccgccctggctCtgagatCtgtagcacccagagg 
- cctctgggtgctacaGatctcaGagccagggcggtctgg 
HOIP 
deletion of 
the UBA-
domain 
- cgcctagagcccttccgccag 
- gccatgacgatccagccaggc 
HOIP C699,702S 
- cgcttgcttgcccaggagtCtgccgtgtCtggctgggccctgccccac  
- gtggggcagggcccagccaGacacggcaGactcctgggcaagcaagcg 
HOIP C871,874S 
- ggaaaacggcattgactCccccaaatCcaagttctcgtacgcc 
- ggcgtacgagaacttgGatttggggGagtcaatgccgttttcc  
HOIP C885S 
- cgagagcctagagccag 
- atatgcatgcTgcctcctc 
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instructions. DNA was eluted in 30-50 L ddH2O and directly employed in following 
applications. 
4.2.1.9 Ligation of DNA fragments 
Digested vector and insert were mixed in ratios ranging from 1:3 to 1:7. The ligation 
reaction was carried out in 11 μL total volume containing 1 μL T4 DNA ligase (NEB), 1 μL 
PEG4000 and 1.1 μL 10x Ligase buffer (NEB). The reaction volume was brought up to 11 μL 
with ddH2O. Ligation reactions were incubated at room temperature for at least 1 hour and 
between 2 and 5 μL were directly used to transform competent bacteria. 
4.2.1.10 Transformation of competent E. coli bacteria 
Competent bacteria were thawed on ice and an appropriate amount of plasmid DNA or of a 
ligation reaction were added to the bacteria followed by incubation on ice for 30 min. After 
a heat shock that was achieved by incubating the bacteria at 42°C for 1 min the bacteria 
were cooled on ice for 5 min. 300 μL SOC medium were added and the bacteria suspension 
was incubated at 37°C for 1 hour. Afterwards, bacteria were plated on LB agar plates 
containing the antibiotic required for selection and incubated at 37°C overnight. 
4.2.1.11 Isolation of Plasmid-DNA 
For plasmid isolation on an analytical scale 5 mL LB medium (+ antibiotic) were inoculated 
with a single bacterial colony and incubated at 37°C overnight. Next, the plasmid DNA was 
isolated using the QIAprep Spin Mini Kit (Qiagen) according to the manufacturer’s 
instructions. For the production of larger amounts of plasmid DNA, 400-500 mL LB medium, 
supplemented with an appropriate antibiotic, were inoculated and the culture was grown at 
37°C and under constant shaking (170rpm) overnight. The preparation of plasmid DNA was 
carried out with the E.Z.N.A. Plasmid purification Maxi kit (Omega bio-tek) as per 
manufacturer’s protocol. 
4.2.2 Methods of Cell Biology 
4.2.2.1 Cell culturing conditions 
All adherent cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10 % fetal bovine serum (FBS) in a humidified atmosphere containing 
10 % CO2 at 37 °C.  For MCF-7 cells 1 % pyruvate and 0.1 % human insulin were added to the 
cultivation medium, while the medium for DKO-4 and HaCat cells was supplemented with 
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2 mM Glutamine. A 1x Trypsin/EDTA solution was used to regularly detach and dilute the 
adherent growing cells. Suspension cells were maintained in RPMI with 10 % FBS at 5 % CO2 
and 37°C. Cell density was determined with a Neubauer chamber slide. Cells were 
centrifuged with a refrigerated centrifuge (Heraeus Multifuge 3 S-R) for 4 min at 300 x g and 
4°C. 
4.2.2.2 Freezing and thawing of eukaryotic cells 
For freezing, cells were harvested, pelleted and resuspended in freezing medium at a 
concentration of approximately 2x106 cells/mL. The cryogenic vials were then slowly cooled 
down to -80°C and transferred to liquid nitrogen for long-term storage.  
Cells were thawed rapidly to 37°C and fresh culture medium was added immediately. Cells 
were centrifuged and resuspended in fresh medium and transferred to cell culture flasks.  
4.2.2.3 Transfection of adherent cells with plasmid DNA or siRNA 
HEK293 NF-B cells were transfected using FuGene 6 (Roche Applied Science) according to 
the manufacturer’s protocol. HEK293T cells were transfected by the calcium phosphate 
method. For this purpose, 450 μL H2O were added to a solution of plasmid DNA and 50 μL 
CaCl2 (2 M). 500 μL HBS (2x) were added dropwise to the DNA/ CaCl2 mix. After 30 min 
incubation at room temperature, the transfection mixture was added slowly to the cell 
medium which had previously been supplemented with Chloroquine at a concentration of 
25 M. Transient knockdowns were performed using siRNAs obtained from Dharmacon 
(Thermo Fisher) which were transfected using Dharmafect I (Thermo Fisher) according to 
the manufacturer’s protocol. Briefly, per six-well, 1.5 μL Dharmafect were mixed with 
200 μL DMEM without FBS for 10 min at room temperature. Subsequently, 2.2 μL siRNA 
with a concentration of 20 μM were added and incubated for 30 min at RT. The mix was 
added dropwise to the cells and 1 mL of culture medium was added. For the knockdown of 
SHARPIN and HOIL-1 the respective siRNA smartpools were employed whereas for HOIP a 
single siRNA (#4) was used. The shRNA for HOIL-1 had the sequence 
5'-CCACAACACTCATCTGTCAAA-3´. 
4.2.2.4 Inducible Protein Expression 
cIAP1/2-deficient MEFs reconstituted with an inducible lentiviral system for the expression 
of wild-type or mutant cIAP1 as well as TRAF2/5-deficient MEFs containing an inducible 
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system for TRAF2 mutants were kindly provided by John Silke (Mace et al., 2008; Vince et 
al., 2009). Expression of the respective proteins and their mutants was induced by the 
addition of 4-hydroxy-tamoxifen at a final concentration of 20 nM for 20 hours.  
4.2.2.5 Treatment with Smac mimetics 
SM-164 (Smac059) was synthesised and kindly provided by Pierfausto Seneci and Leonardo 
Manzoni (Cossu et al., 2009). Before TNF stimulation, cells were pre-treated with SM-164 at 
a final concentration of 100 nM in cell culture medium for 2 hours at 37°C. 
4.2.3 Biochemical methods 
4.2.3.1 Determination of protein content 
To determine the protein concentration of cell lysates, the bicinchoninic acid (BCA)- 
containing protein assay was applied (Pierce). For this purpose, 2.5 μL of the lysate was 
incubated in 0.5 mL BCA solution at 60°C for 20 min, followed by measuring light absorption 
at 540 nm. 
4.2.3.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Separation of proteins was performed using 4-12 % Bis-Tris-NuPAGE gels from Invitrogen. 
Samples were mixed with LDS Sample buffer containing a final concentration of 200 mM 
DTT and heated for 10 min at 75°C. The SeeBlueTM Plus2 Pre-Stained marker (Novex) was 
used as a molecular weight standard. The electrophoretic separation was carried out at a 
constant voltage of 125 V for 10 min and subsequently 185 V for 55 min using MOPS as a 
running buffer. For samples resulting from in-vitro ubiquitylation assays the second 
separation step was reduced to 47 min at 175 V.  
4.2.3.3 Western blotting 
Western blotting was performed using the NOVEX gel-system based on the method of 
Towbin (Towbin et al., 1979). Proteins from SDS-PAGE gels were transferred onto 
nitrocellulose membranes (Amersham Pharmacia) by application of a constant voltage of 
30 V and a maximum current of maximum 200 mA per gel for 2 hours and 15 minutes. 
Afterwards, membranes were incubated for 1 hour with blocking buffer at room 
temperature to occupy non-specific protein binding sites. 
Subsequently, membranes were subjected to immunoprobing with primary and secondary 
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horseradish-peroxidase (HRP)-conjugated antibodies. Proteins were visualised using the 
ECL® detection system (Amersham Biosciences). 
4.2.3.4 Stripping of immunoblot membranes 
If nitrocellulose membranes had to be incubated with alternative antibodies, bound 
immunoglobulins were removed by incubating the nitrocellulose membranes with stripping 
buffer at room temperature for 12 min. The membranes were then rinsed with PBST, 
followed by incubation in blocking solution and probing as described in 4.2.3.3. 
4.2.3.5 Quantification of band intensities 
Intensities of the bands obtained by western blotting were quantified using the ImageJ 
software. Briefly, using the rectangle selection tool a rectangle (higher than wide) was 
drawn around the band of interest. This box was then copied until all bands to be analysed 
were selected. In a profile plot, the peak representing the actual band was separated from 
the background using the straight line selection tool. The area under these peaks as given by 
the programme was taken as the intensity of the respective band. These intensities were 
used to normalise the intensities of the HOIL-1 bands in lysates and IPs to the intensities of 
the bands corresponding to ACTIN in the lysates and SHARPIN in the IP respectively. Based 
on these normalised values the down-regulation of HOIL-1 in the lysates was compared to 
the percentage that remained associated with SHARPIN. 
4.2.3.6 Generation and in-vitro translation of SHARPIN and HOIP mutants 
For in vitro binding assays, V5-His-tagged versions of SHARPIN, HOIP and different deletion 
mutants (HOIP C terminus (residues 1–654), HOIP UBA (deletion of residues 564–615), 
HOIP N-terminus (residues 494–end), SHARPIN UBL (deletion of residues 219–289), 
SHARPIN NZF (deletion of residues 348–377), SHARPIN NZFmut1 (point mutations of 
cysteines 353 and 356 to serine) and SHARPIN NZFmut2 (point mutations of cysteines 367 
and 370 to serine) were generated by PCR and cloned into pcDNA3.1 (Invitrogen). The 
specific point-mutants were obtained by site-directed mutagenesis. All mutations and 
deletions were verified by sequencing and the proteins were generated in vitro using the 
TNT Quick Coupled Transcription/Translation System (Promega) according to the 
manufacturer’s instructions. Briefly, 1.2 μg of each expression vector was added to an 
aliquot of the TNT Quick MasterMix and incubated in a reaction volume of 50 μL at 30°C for 
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80 min. Equal protein production was controlled by western blotting (input: 1 μL of reaction 
mix). 
4.2.3.7 Expression and Purification of GST-tagged recombinant proteins 
Recombinant proteins and their mutants (SHARPIN-UBL-only (residues 218–314), HOIP-ZnF- 
only (residues 298–329), HOIP-NZF1-only (residues 350–379), HOIP-NZF2-only (residues 
408-438), Parkin-RBR-only (residues 234-453), ARIH1-RBR-only (residues 181-379), ARIH2-
RBR-only (residues 136-330)) were expressed from a pGEX-6P2-vector (GE Healthcare Life 
Sciences). The DNA constructs were transformed into E. coli BL21(DE3) (Invitrogen) and 
500 mL LB/Amp medium were inoculated with 10 mL overnight culture of a single BL21 
colony and grown until an OD600 of approximately 0.6. Protein expression was induced with 
1 mM IPTG (Isopropyl--D-thiogalactoside). For proteins containing many zinc-coordinating 
domains the growth medium was supplemented with 200 mM ZnSO4. The bacteria 
suspension was incubated at 18°C and 170 rpm for 16 hours, centrifuged at 4600 rpm and 
4°C for 15 min, and the supernatant was discarded. The bacterial pellet was resuspended in 
10 mL Bacteria lysis buffer and the lysate was incubated on ice for 15 min after addition of 
lysozyme (50 μg/mL). The bacteria were sonicated six times for 20 s, incubated on ice for 
10 min and centrifuged at 15000 rpm and 4°C for 30 min. The supernatant was then filtered 
using 0.45 μm syringe filters and applied to a 1 mL GSTrap column (GE Healthcare) which 
had been equilibrated with 10 mL PBS + 1 mM DTT.  After application of the sample which 
was performed at a flow rate of 0.5 mL/min, the column was washed with 10 mL GST-wash 
buffer. Elution of the GST fusion proteins was carried out at 4°C using 10 mL GST-elution 
buffer and the eluate was collected in 1 mL fractions.  Alternatively, 160 u PreScission (GE 
Healthcare Life Sciences) were loaded onto the column in 1 mL cleavage buffer and 
incubated for at least 4 hours at 4°C. Protein elution was determined by Coomassie staining. 
Protein containing fractions were dialysed in 5 L of dialysis buffer overnight. If the protein 
had been eluted using the elution buffer the GST-tag could be removed by incubation with 
1 u PreScission protease per 100 g protein.  
4.2.3.8 Expression and Purification of human HF-TNF 
His-Flag-tagged TNF was expressed from a pQE32 expression vector (Qiagen). Protein 
expression was performed as described above and the bacterial pellet was resuspended in 
bacterial lysis buffer for His-tagged proteins. Lysis and sample preparation were performed 
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as described for GST-tagged proteins and His/FLAG-TNF (HF-TNF) was purified using a 
HisTrap FF Agarose column (GE Healthcare Life Sciences) according to manufacturer's 
instructions. The expression and purification of HF-TNF was controlled by SDS-PAGE and 
Coomassie staining. Dialysed fractions, containing HF-TNF in dialysis buffer containing L-
Arginine were stored at -80°C. 
4.2.3.9 TNF-RSC precipitation 
For analytical RSC analysis, 2-5 x 107 U937 or HeLa cells per sample were either treated with 
1 g FLAG-tagged TNF per mL stimulation medium or left untreated. Cells were then lysed in 
IP-lysis buffer for 30 min at 4°C on a head-to-head shaker. Afterwards, the lysates were 
centrifuged at 15.000 x g for 30 min, protein content was assessed using the BCA-assay 
(section 4.2.3.1) and protein concentrations for the different samples were adjusted. 0.5 μg 
FLAG-TNF was added to the non-stimulated control. FLAG-TNF was precipitated using M2 
beads (Sigma) for 16 hours. Alternatively, 2 g anti-TNFR1 or anti-TNFR2 antibody were 
precoupled to ProteinG beads for at least 2 hours at room temperature, unbound antibody 
was washed off and the antibody-coupled beads were used to precipitate the TNF-RSC. In all 
cases the beads were washed 5 times with 1 mL IP-lysis buffer and eluted with SDS-Sample 
buffer. The TNF-RSC were analysed by immunoblotting using the indicated antibodies. 
4.2.3.10 Treatment of the TNF-RSC with recombinant USP2 
The TNF-RSC was precipitated from 2x108 U937 cells as described under 4.2.3.9. Following 
the precipitation, the beads were washed 5x in DUB reaction buffer and split into 4 samples. 
As controls, one sample was left untreated and one was incubated in 1x DUB reaction buffer 
for 2 hours at 37°C. The remaining two samples were subject to DUB treatment as described 
previously (Komander et al., 2009b). For this purpose, the catalytic domain of USP2 (Enzo 
Life Sciences) was diluted to a concentration of 0.2 g/L in DUB dilution buffer and pre-
incubated for 10 min at room temperature. The TNF-RSC coupled beads were treated with 
2 or 4 g of the activated DUB in a total volume of 30 L for 2 hours at 37°C. The reaction 
was stopped by addition of reducing sample buffer and analysed by western blotting. 
4.2.3.11 Size exclusion chromatography 
HeLa cells were lysed in lysis buffer for gelfiltration by repeated passing through a syringe 
needle. After adding an equal volume of lysis buffer containing 300 mM NaCl, lysates were 
4. Material and Methods 
  
78 
 
centrifuged at 100,000 g for 60 min to obtain S100 lysates. S100 lysates were separated via 
a Superdex 200 10/300 GL column (GE Healthcare Life Sciences) in gelfiltration running 
buffer using an ÄKTA chromatography system (GE Healthcare Life Sciences). 
4.2.3.12 Protein interaction studies 
For in-vivo interaction studies, 7 x 106 HEK293T cells were transfected with 5 μg of the 
respective DNAs by standard calcium phosphate transfection. Cells were harvested 24 hours 
post transfection and lysed in 1 mL IP-lysis buffer for 30 min at 4°C. Subsequently, lysates 
were centrifuged at 15,000 x g for 30 min. Beads coupled to antibodies specific for a tag or 
one of the transfected proteins itself were used for immunoprecipitations which were 
performed at 4°C for 16 hours. The beads were washed 5 times with IP-lysis buffer and the 
proteins were eluted in 35 μL 2x LDS sample buffer containing DTT as a reducing agent. 
Precipitated proteins were analysed by immunoblotting. 
4.2.3.13 Ubiquitin pull-down assays 
Lysates from unstimulated HeLa or U937 cells were incubated with control beads or 
ubiquitin-coupled agarose (Boston Biochem) at 4°C overnight. The beads were washed and 
dried and the proteins were eluted using 2x LDS Sample buffer. Binding was assessed by 
western blotting. The mapping of the ubiquitin binding domain in SHARPIN was performed 
in a similar manner. Here the ubiquitin-coupled beads were used to precipitate in-vitro 
translated SHARPIN or mutants thereof. Investigation of linkage specificity was performed 
by incubating 10 μg of purified C-terminally V5-tagged SHARPIN, HOIL-1 or HOIP with anti-
V5-beads in 600 μL Pull-down buffer (PDB) at 4°C for 6 hours. Beads were washed three 
times with PDB, split into aliquots and incubated at 4°C overnight with 2 μg recombinant 
K48-, K63- or linear-linked ubiquitin chains in 450 μL PDB. The beads were washed five times 
with PDB. The bound proteins were eluted using 2x LDS sample buffer and subsequently 
subjected to SDS-PAGE and immunoblotting using ubiquitin specific antibodies. 
4.2.3.14 NF-B Luciferase assay 
HEK293-NF-B cells were seeded into 6-well plates and cultured for 10 to 12 hours in DMEM 
+ 10 % FCS before transfection. Cells were cotransfected with 1 g/well of the pCMV-RLuc 
plasmid (Stratagene) and the plasmids encoding the respective LUBAC components using 
FuGENE 6 (Roche). Alternatively transient knockdown was performed as described in 
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section 4.2.2.3. 16 to 24 hours after transfection with plasmid DNA or 72 hours after siRNA 
transfection, cells were detached and seeded in 96 well plates. The next day cells were 
stimulated with TNF for 4 hours or left untreated. Afterwards, cells were lysed with 1x 
Passive lysis buffer (Promega) and the luminescence was measured using a microplate 
reader (Mithras LB940; Berthold Technologies). Firefly luciferase data were either 
normalised to values obtained in a MTT-viability assay (knock-down experiments) or to 
Renilla luciferase activity (over-expression experiments). 
4.2.3.15 MTT-viability assay 
The MTT [3-(4,5-Dimethylthiazol-2-yl) 2,5-diphenyl-tetrazoliumbromide] method is based on 
the reduction of the yellow soluble tetrazolium salt by mitochondrial dehydrogenases of the 
respiratory chain leading to the formation of blue formazan crystals (Gerlier and Thomasset, 
1986). Cells were seeded on a 96 well plate in parallel with those required for the luciferase 
assay. After the addition of 25 L MTT solution, the cells were incubated at 37°C for 2 hours. 
Afterwards, the medium was discarded and the MTT reaction was stopped by adding 100 L 
of an acetic acid solution (5 % acetic acid in isopropanol). The reduction of the substrate was 
assessed by measuring the absorption at a wavelength of 570 nm. 
4.2.3.16 In-vitro ubiquitylation assay 
For in-vitro ubiquitylation assays, 0.8 mg recombinant E3 were incubated with 5 g 
ubiquitin (wild-type, His-tagged or K0), 200 ng E1 (UBE1), 300 ng E2, 1x ERS (Boston 
Biochem) in ubiquitylation buffer. If TRAF2 was used as an E3, sphingosine-1-phosphate was 
added to a final concentration of 100 nM. After 2 hours incubation at 37°C the reaction was 
stopped by adding reducing sample buffer. The samples were analysed by western blotting. 
For in-vitro ubiquitylation of potential target proteins 293T cells were transfected with 
plasmids encoding a tagged version of the respective protein using calcium phosphate and 
proteins were immunoprecipitated using beads coupled to antibodies specific for either the 
tag or the protein itself. The beads were washed, dried and added to the reaction mix. The 
assay was performed as described above. 
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5 Results 
5.1 SHARPIN, HOIL-1 and HOIP are recruited to TNFR1 upon stimulation 
A first step in the investigation of the three novel components identified by mass 
spectrometry was to verify their presence in the TNF-RSC and to test whether they are 
recruited in a stimulation-dependent manner or if they are already associated with 
unstimulated receptors. For this purpose U937 cells were stimulated with His-FLAG (HF)-TNF 
for different times and the receptor complex was precipitated by an anti-FLAG 
immunoprecipitation. To control for unspecific, stimulation-independent binding or a direct 
interaction between LUBAC and TNFR1, TNF was also added post lysis to the lysate of 
untreated cells. Analysis by western blotting revealed that recruitment of SHARPIN, HOIL-1 
and HOIP is a stimulation-dependent event (Figure 11).  
 
Figure 11: SHARPIN, HOIL-1 and HOIP are recruited to the TNF-RSC in a stimulation-dependent manner. 
5x10
7 
U937 cells per sample were stimulated with 1g/mL HF-TNF for the indicated times. The TNF-RSC was 
precipitated using anti-FLAG beads and analysed by western blotting for the presence of both the three novel 
proteins and of bona-fide components of this complex using specific antibodies. The asterisk indicates an 
unspecific band recognised by the anti-SHARPIN-antibody. 
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It also showed that the three proteins are already present after two minutes of stimulation 
and are recruited with similar kinetics. Their levels reach a maximum at five minutes and 
start decreasing after about 15 minutes. This coincides with the recruitment of other 
components like RIP1, cIAP1/2 and NEMO, which also reach maximal levels, and in the case 
of RIP1 and cIAP1/2 maximal modification after five minutes and which start disappearing 
from the complex after 30 minutes of stimulation. The kinetics of recruitment for TRADD 
seem to be slightly different. The latter protein seems to reach its maximum levels already 
at two minutes of stimulation whereas. Overall this result shows that, together with other 
components of the TNF-RSC, SHARPIN, HOIL-1 and HOIP are recruited to the TNF receptor in 
a stimulation-dependent manner.  
As the mass spectrometric analysis was performed on the TNF-RSC isolated from U937 cells, 
a cell line which expresses both TNFR1 and TNFR2 (Haridas et al., 1998; Shu et al., 1996), the 
question arose which of the two receptors is essential for the recruitment of SHARPIN, 
HOIL-1 and HOIP. In line with the finding that soluble TNF fully activates TNFR1 but not 
TNFR2 (Grell et al., 1998; Grell et al., 1995; Krippner-Heidenreich et al., 2002), only peptides 
for TNFR1 were identified in the mass-spectrometric analysis of the TNF-RSC which had 
been precipitated using soluble TNF (Gerlach et al., 2011; Haas et al., 2009). This provides a 
good indication that SHARPIN, HOIL-1 and HOIP are recruited to TNFR1 rather than TNFR2. 
However, for a more direct analysis of this aspect, the TNF-RSC precipitated from U937 cells 
was compared to that of HeLa cells which, in contrast to U937 cells, only express TNFR1 
(Haridas et al., 1998; Shu et al., 1996);  PhD thesis Dr. C. H. Emmerich). In spite of much 
lower expression levels of HOIL-1 in HeLa cells, SHARPIN, HOIL-1 and HOIP were detectable 
in the TNF-RSC isolated from these cells (Figure 12), indicating that TNFR2 is not essential for 
their presence in TNF-precipitations. 
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Figure 12: SHARPIN, HOIL-1 and HOIP are recruited to the TNF-RSC of both U937 and HeLa cells. U937 or 
HeLa cells were stimulated with 1g/mL TNF for ten or thirty minutes. After lysis, protein levels were adjusted 
to the same levels and the TNF-associated complex was pulled out in an anti-FLAG immunoprecipitation. The 
resulting TNF-RSC was analysed by western blotting using the indicated antibodies. 
To further investigate this point, lysates of U937 cells stimulated with TNF for five, fifteen or 
thirty minutes were divided into two parts and each fraction was subject to precipitation of 
either TNFR1 or TNFR2 using specific antibodies. Comparable levels of TRAF2, a protein that 
was described to associate with both TNFR1 and TNFR2 (Shu et al., 1996), were detectable 
in both receptor complexes after fifteen minutes (Figure 13). In the precipitation of TNFR1, 
TRAF2 was already present after five minutes and could hardly be detected anymore after 
thirty minutes. On the other hand, the levels of TRAF2 detectable in the TNFR2-complex 
after five minutes were very low but the association remained stable at thirty minutes. A 
similar picture could be observed for cIAPs, additional components common to the two 
receptor complexes (Shu et al., 1996), although the levels recruited to TNFR2 were lower 
than the ones detectable on TNFR1. This indicates that the kinetics of complex formation 
differ between the two receptors, with TNFR2 showing a slight delay in recruitment of 
intracellular proteins. Another difference between the two complexes is constituted by the 
fact that SHARPIN, HOIL-1 and HOIP, like RIP1, a specific component of the TNFR1- but not 
the TNFR2-associated complex (Hsu et al., 1996a), could only be detected in the 
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precipitation of TNFR1. Overall, these findings establish that SHARPIN, HOIL-1 and HOIP are 
recruited to TNFR1. However, a potential recruitment to TNFR2, especially under conditions 
in which this receptor is efficiently stimulated by membrane-bound TNF, cannot be fully 
excluded on the basis of these results.  
 
Figure 13: SHARPIN, HOIL-1 and HOIP are not present in the TNFR2-SC. U937 cells were stimulated with TNF 
for the indicated times. Lysates were separated into two parts and subject to precipitation using antibodies 
specific for TNFR1 or TNFR2, respectively. The proteins associated with the two receptors were analysed by 
western blotting. Black rhombi indicate the position of the heavy chain and unspecific bands recognised by the 
anti-SHARPIN and anti-TRAF2-antibodies respectively are marked by asterisks. 
5.2 Down-regulation of SHARPIN, HOIL-1 or HOIP inhibits TNF-signalling 
Having identified SHARPIN, HOIL-1 and HOIP as components of the TNF-RSC, the next step 
was to analyse the functional relevance of this recruitment for downstream signalling 
events. To this end, expression levels of the three proteins were down-regulated by RNA 
interference in HEK293-NF-B cells, a cell line that stably expresses luciferase under a 
NF-B-responsive promotor. Following the knockdown-procedure, a part of the cells was 
taken to determine the efficiency of the down-regulation. The rest of the cells were 
stimulated with different concentrations of TNF. As shown in Figure 14, down-regulation of 
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any of the three proteins decreased luciferase expression following TNF-stimulation with 
knockdown of HOIP being the most efficient in inhibiting TNF-induced NF-B activation. At 
100 ng/mL TNF HOIP knockdown decreased luciferase-activity to 44 % of the control 
whereas RNAi for SHARPIN and HOIL-1 led to a reduction to 66 % and 49 %, respectively.  
 
Figure 14: Down-regulation of SHARPIN, HOIL-1 or HOIP reduces TNF-induced NF-B activation.  HEK293-
NF-B cells were transfected with siRNAs targeting SHARPIN, HOIL-1 or HOIP, respectively. A: TNF-induced 
NF-B activation was assessed in a luciferase-reporter assay, following stimulation with the indicated 
concentrations of TNF for four hours.  Values were normalised to the values obtained in a MTT-viability assay 
and values reached for stimulation with 100 ng/mL TNF were set to 100 %. Results are shown as mean +/- 
SEM, n=4. B: Knockdown efficiency was determined by qPCR. Results for one representative experiment are 
shown. 
In line with this, phosphorylation of p38, JNK and IB were almost completely abolished 
when HOIP expression was down-regulated in HeLa cells (Figure 15A), indicating that not 
only the activation of NF-B but also that of other TNF-induced signalling pathways is 
affected by down-regulation of this component. Knockdown of SHARPIN or HOIL-1 was not 
as efficient in blocking the different pathways. However, the phosphorylations indicating the 
activation of the different signalling cascades were also slightly decreased. This suggests 
that of the three, HOIP is the most important for TNF-induced signalling. However, a 
pronounced decrease in the protein levels of SHARPIN and especially HOIL-1 can be 
observed when HOIP is down-regulated by siRNA (Figure 15A). This is unlikely to be an off-
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target effect of the siRNA, as the qPCR analysis did not show an effect of the siRNA on the 
mRNA levels of SHARPIN or HOIL-1 (Figure 15B). Furthermore a similar down-regulation on 
protein- but not on mRNA level was described to occur in mouse embryonic fibroblasts 
(MEFs) deficient for SHARPIN or HOIL-1 (Gerlach et al., 2011; Tokunaga et al., 2011). Overall 
this demonstrates that a decrease in levels of SHARPIN, HOIL-1 or HOIP but especially their 
co-down-regulation efficiently inhibits TNF-induced signalling cascades. This suggests that 
recruitment of the three proteins to TNFR1 is an event essential for TNF-induced signalling 
to occur at its full strength. 
 
Figure 15: Other TNF-induced signalling cascades are also affected by down-regulation of SHARPIN, HOIL-1 
and HOIP. A: Protein levels of SHARPIN, HOIL-1 and HOIP were down-regulated in HeLa cells using RNA 
interference. Cells were then stimulated with 25 ng/mL TNF for five or fifteen minutes and events indicating 
the activation of signal transduction were analysed using western blotting. B: Down-regulation of SHARPIN and 
HOIL-1 by HOIP knockdown is not an off-target effect. As determined by qPCR the knockdown of either 
SHARPIN, HOIL-1 or HOIP does not lead to co-down-regulation of the other two on mRNA-level. 
5.3 Recruitment of SHARPIN, HOIL-1 and HOIP to the TNF-RSC is 
interdependent and requires the presence of cIAP1/2 
To follow up this finding, the recruitment of SHARPIN, HOIL-1 and HOIP to the TNF-RSC was 
to be investigated further with the aim of identifying the mechanism of recruitment. By 
analysing the TNF-RSC precipitated from MEFs deficient for individual components of this 
complex, it was established that HOIL-1 requires the presence of cIAPs for its recruitment 
(Haas et al., 2009). To test whether the same was true for SHARPIN and HOIP, HeLa cells 
were treated with the Smac-mimetic compound SM-164, a substance that leads to the auto-
ubiquitination and degradation of cIAP1 and cIAP2 (Lu et al., 2008). The TNF-RSC was 
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isolated from these cells and compared to that of cells that had been treated with DMSO as 
a control. This comparison revealed that in absence of cIAP1/2 neither HOIL-1 nor SHARPIN 
or HOIP are recruited (Figure 16).  
 
Figure 16: SHARPIN, HOIL-1 and HOIP are recruited to the TNF-RSC in a cIAP-dependent manner. HeLa cells 
were pre-treated for two hours with the Smac-mimetic compound SM-164 (100 nM) which leads to 
degradation of cIAP1 and cIAP2. The TNF-RSC was precipitated following TNF-stimulation using an anti-TNFR1-
antibody and compared to that of control treated cells (DMSO).  
As cIAPs are E3s able of generating ubiquitin-chains on RIP1, themselves and potentially 
other components of the TNF-RSC (Bertrand et al., 2008; Lopez and Meier, 2010; 
Varfolomeev et al., 2008; Wertz et al., 2004), the question arose whether this activity is 
required for recruitment of the three proteins. To test this, MEFs deficient for cIAP1 and 
cIAP2 that contain a tamoxifen-inducible construct encoding either wild-type cIAP1 or 
mutants of this protein that cannot dimerise (F610, V576E) or bind their corresponding E2 
(V567A/D57) (Feltham et al., 2011; Feltham et al., 2010; Mace et al., 2008) were treated 
with 20 nM 4-hydroxy-tamoxifen (4-HT). As can be seen in Figure 17A, this efficiently 
induced the expression of cIAP1 or its mutants. In Figure 17B the result of a TNF-RSC 
precipitation from reconstituted cells is shown. Even though re-expression of wild-type 
cIAP1 was not efficient enough to fully rescue RIP1 ubiquitination, it was sufficient for 
HOIL-1 recruitment to occur. In contrast, none of the mutants was able to restore RIP1 
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modification or HOIL-1 recruitment, indicating that not only presence of cIAPs but also their 
activity is required for either of these events to occur. Due to technical limitations in the 
detection of SHARPIN and HOIP in the murine system, recruitment of these proteins was not 
investigated in this assay.  
 
Figure 17: Recruitment of HOIL-1 to the TNF-RSC depends on the activity of cIAP. A: Expression of cIAP1 was 
induced in cIAP1/2
-/- 
MEFs containing constructs for the re-constitution with either wild-type (wt) cIAP1 or 
mutants of this protein that are unable to dimerise (V576E, F610A) or to bind the corresponding E2 
(V567A/D570A) (Feltham et al., 2011; Feltham et al., 2010; Mace et al., 2008) by incubation with 20nM 4-
hydroxy-tamoxifen. B: The TNF-RSC was precipitated from cIAP1/2
-/- 
MEFs reconstituted with different cIAP1 
mutants and the recruitment of HOIL-1 was analysed by western blotting. 
Making use of a similar inducible system, in which expression of TRAF2 or its mutants can be 
switched on using tamoxifen, it was shown that cIAP requires presence of TRAF2 and 
specifically of a cIAP-interaction motif (CIM) within TRAF2 for its recruitment to the TNF-RSC 
whereas the RING-domain of TRAF2 is dispensable (Figure 18). These results also indicate 
that the RING-domain of TRAF2 is insufficient to mediate the modification of RIP1 and that 
TRAF2 instead serves a role in recruiting cIAP1, which in turn is responsible for 
ubiquitinating RIP1. 
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Figure 18: cIAP requires a cIAP-interaction motif (CIM) within TRAF2 for its recruitment to the TNF-RSC. 
TRAF2/5
-/-
 MEFs reconstituted with constructs for the tamoxifen-inducible expression of TRAF2 mutants (Vince 
et al., 2009), were used to precipitate the TNF-RSC in presence or absence of 4-HT. Modification of RIP1 and 
recruitment of cIAP in presence of the different mutants was assessed by western blotting. 
Together this indicates that recruitment of HOIL-1 and potentially of SHARPIN and HOIP 
depends on the activity of cIAPs, which in turn are recruited to the TNFR-complex via their 
interaction with TRAF2. As cIAPs generate ubiquitin chains and this activity is required for 
recruitment of HOIL-1, it was next investigated whether SHARPIN, HOIL-1 and HOIP have 
ubiquitin-binding properties. As a first approach to this question, ubiquitin-coupled agarose 
beads were compared to control beads in their ability to precipitate SHARPIN, HOIL-1 and 
HOIP from unstimulated lysates of HeLa (Figure 19A, left panel) or U937 (Figure 19A, right 
panel) cells. It could be shown that all three proteins associate specifically with ubiquitin-
coupled but not with the control beads. To further investigate this property of SHARPIN, 
HOIL-1 and HOIP recombinant versions of the three proteins with an N-terminal GST- and a 
C-terminal V5-tag were produced in E.coli. After it had been used for purification, the GST-
tag was removed and the proteins were precipitated via their C-terminal V5-tag. The 
predominant non-proteolytic ubiquitin linkage reported to be generated by cIAPs are K63-
linked chains. Therefore, K63-linked tetra-ubiquitin was added to immobilised SHARPIN, 
HOIL-1 and HOIP and the co-precipitation of K63-linked ubiquitin chains was analysed by 
western blotting (Figure 19B). Association of ubiquitin with all three proteins but not with 
anti-V5-beads alone was detectable, indicating that SHARPIN, HOIL-1 and HOIP all have the 
ability to bind K63-linked ubiquitin. However, it can be observed that although the levels of 
HOIP are much lower than those of SHARPIN and HOIL-1, the amount of ubiquitin co-
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precipitated with the former protein is the highest. This suggests that HOIP has a greater 
overall affinity for ubiquitin or that SHARPIN and HOIL-1 preferentially bind other ubiquitin 
chain types.  
  
Figure 19: SHARPIN, HOIL-1 and HOIP can bind to ubiquitin. A: Control beads and ubiquitin-coupled agarose 
were compared in their capacity to precipitate SHARPIN, HOIL-1 and HOIP from lysates of unstimulated HeLa 
(left panel) or U937 cells (right panel). Association of the three proteins with the two types of beads was 
analysed by western blotting. B: C-terminally V5-tagged forms of SHARPIN, HOIL-1 and HOIP were coupled to 
anti-V5 beads, K63-linked tetra-ubiquitin (Ub4 K63) was added and co-precipitation was determined on 
western blot level. 
Indeed, a recent report demonstrated that the NZF-domain of HOIL-1 shows a strong 
specificity for linear chains (Sato et al., 2011). In order to investigate whether a similar 
preference exists for SHARPIN, the recombinant protein was precipitated using a specific 
antibody. K48-, K63- or linearly linked tetra-ubiquitin chains were added and co-
precipitation was assessed by western blotting (Figure 20). This analysis revealed that K63-
linked and linear chains were co-precipitated with SHARPIN, whereas binding of K48-
linkages could not be detected (Figure 20A). It is important to note that different linkage 
types are not equally well detectable with antibodies recognising total ubiquitin 
(Figure 20B). 
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Figure 20: SHARPIN shows a preference for K63- and M1-linked tetra-ubiquitins. A: Untagged recombinant 
SHARPIN purified from E.coli was precipitated using a specific antibody and tetra-ubiquitin of different linkage 
types was added as indicated. To assess binding of the different linkages, precipitations were separated by 
SDS-PAGE and the corresponding western blots were probed with two anti-ubiquitin-antibodies (clones FK1 
and FK2, Biomol) and an anti-SHARPIN antibody. B: Ubiquitin-chains of different lengths and linkage types 
were resolved by SDS-PAGE, transferred to membranes by western blotting and the corresponding 
membranes were probed with different anti-ubiquitin antibodies. Equivalent loading was verified by staining 
with PonceauS. 
Although no band representing K48-linked tetra-ubiquitin was visible in the lanes 
corresponding to co-precipitation of this linkage type in the western blots shown in Figure 
20A, a strong band was present in the input samples, suggesting that the lack of detectable 
co-precipitation of K48-linkages was not due to a problem with antibody specificity. Instead 
it indicates a preference of SHARPIN K63- and linearly linked ubiquitins which is in line with 
a recent publication (Sato et al., 2011). The ubiquitin-binding motifs of HOIL-1 and HOIP 
were allocated to their NZF- and NZF1- domains, respectively (Ikeda et al., 2011). To map 
the parts of SHARPIN involved in ubiquitin binding, ubiquitin-coupled agarose beads were 
used to precipitate in vitro-translated versions of SHARPIN, in which deletion- or point-
mutations had been introduced (Figure 21A). This assay showed that both the wild-type 
protein and a mutant in which the UBL-domain had been deleted (UBL) efficiently bound 
to the ubiquitin-beads (Figure 21B). In contrast, much lower levels of mutants in which the 
NZF-domain had been deleted (NZF) or in which specific residues within that domain had 
been mutated (NZF1mut: C353,356S; NZF2mut: C367,370S) were found to be associated 
with the beads. This indicates that SHARPIN binds ubiquitin mainly via its NZF domain.  
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Figure 21: SHARPIN binds to ubiquitin via its NZF-domain. A: Schematic representation of SHARPIN and 
mutant employed in C. B: Ubiquitin-coupled agarose beads were used to assess the binding of V5-tagged in-
vitro translated versions of SHARPIN to ubiquitin. Cysteines 353 and 356 were mutated to serine in NZFmut1 
and NZFmut2 is a C367,370S mutant of SHARPIN. Co-precipitation was analysed by western blotting. 
The observations that SHARPIN, HOIL-1 and HOIP are recruited to the TNF-RSC with similar 
kinetics (Figure 10) and that all three proteins require cIAPs and potentially ubiquitin chains 
generated by this E3 for their presence in the TNFR-associated complex (Figures 16-21), led 
me to investigate whether their recruitment is interdependent.  
 
Figure 22: SHARPIN and HOIP are still recruited to the TNF-RSC in absence of HOIL-1. The TNF-RSC was 
isolated using an anti-TNFR1-antibody from HeLa cells in which expression of HOIL-1 was stably down-
regulated by shRNA. Levels of SHARPIN and HOIP in the complex were compared to those associated with the 
receptor in control cells by western blotting. The asterisk indicates an unspecific band that is recognised by the 
anti-SHARPIN antibody. 
To assess the role of HOIL-1 in association of SHARPIN and HOIP with the TNF-induced 
signalling complex, expression of HOIL-1 was stably down-regulated in HeLa cells using 
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shRNA. The TNF-RSC isolated from these cells was then compared to that of control cells 
(Figure 22). Comparative western blotting shows that, even though HOIL-1 expression was 
efficiently down-regulated, the levels of SHARPIN and HOIP remain within the same range as 
in control cells indicating that HOIL-1 is dispensable for their recruitment. 
A similar approach was taken to investigate a potential role for SHARPIN as an adaptor for 
HOIL-1 and HOIP. Again, the levels of the other two proteins within the TNF-RSC were not 
markedly reduced in comparison to the control (Figure 23). In addition, a similar analysis in 
SHARPIN-deficient MEFs, isolated from cpdm mice, supports a SHARPIN-independent 
mechanism of recruitment for HOIL-1 and HOIP (Gerlach et al., 2011). 
 
Figure 23: Knockdown of SHARPIN does not prevent recruitment of HOIL-1 and HOIP to the TNF-RSC. 
SHARPIN-expression was transiently down-regulated in HeLa cells by siRNA. Following stimulation with HF-
TNF, the TNF-RSC was pulled out using anti-FLAG-beads and levels of complex-components present in the 
precipitation were analysed by western blotting. Asterisks mark cross-reactive bands detected by the anti-
SHARPIN and anti-HOIP antibodies, respectively. 
Lastly, HOIP was transiently down-regulated using RNA interference in HeLa cells and 
recruitment of all three proteins to the TNF-RSC was analysed by western blotting. As shown 
in Figure 24, absence of HOIP prevented the association of SHARPIN and HOIL-1 with the 
complex, demonstrating that HOIP acts an adaptor for the other two.  
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Figure 24: HOIP is required for the recruitment of SHARPIN and HOIL-1 to the TNF-RSC. HOIP expression was 
down-regulated in HeLa cells using RNA interference and the TNF-RSC was precipitated and analysed as in 
Figure 13. Asterisk marks an unspecific band detected by the anti-SHARPIN antibody. 
 
5.4 SHARPIN, HOIL-1 and HOIP form a stimulation-independent complex 
This central role of HOIP raised the question whether SHARPIN, HOIL-1 and HOIP form a 
complex in the absence of stimulation, which is then recruited to the TNF-RSC as a pre-
formed unit. To address this, lysates of unstimulated HeLa cells were separated by 
gelfiltration chromatography and protein containing fractions (Figure 25, upper panel) were 
analysed by western blotting for the presence of SHARPIN, HOIL-1 and HOIP. An 
unseparated lysate control was included on all blots to ensure equal exposure times. While 
especially HOIP and SHARPIN partially eluted in the fractions corresponding to the 
molecular weights of their monomeric forms (fractions 22-25 and 33+34, respectively), all 
three proteins were also present in high molecular weight fractions (fractions 13-17), 
suggesting that even in the absence of a stimulus they are present in a pre-formed protein 
complex (Figure 25, lower panel). On the other hand the unspecific band recognised by the 
anti-SHARPIN antibody remained in the low molecular weight fractions. This is in line with a 
previous report showing that HOIL-1 and HOIP are present in a complex of about 600 kDa in 
unstimulated HeLa and SH-SY5Y cells and that exogenous co-expression of HOIL-1 and HOIP 
shifts both proteins to these high-molecular weight fractions (Kirisako et al., 2006).  
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Figure 25: SHARPIN, HOIL-1 and HOIP co-elute in high molecular-weight-fractions. S100 lysates of 
unstimulated HeLa cells were separated on a Superdex 200 10/300 GL column (GE Healthcare Life Sciences). 
The upper panel represents the elution profile with elution volume and fraction numbers being shown on the 
horizontal axis, whereas the vertical axis presents protein content in arbitrary units. The lower panel shows 
analysis of protein containing fractions by western blotting. 
To further test the possibility of a stimulation-independent interaction of SHARPIN with 
HOIL-1 and HOIP, an N-terminally myc-tagged version of SHARPIN, was over-expressed in 
HEK293T cells either alone or in combination with C-terminally V5-tagged forms of HOIL-1 
and HOIP. Immunoprecipitation with anti-V5 coupled beads followed by western blotting 
revealed that SHARPIN was co-precipitated with HOIL-1 and even more strongly with HOIP 
(Figure 26A). In order to verify this interaction in a more physiological setting, U937 cells 
were left untreated or stimulated with TNF for five minutes. The lysates of these cells were 
split into five parts of which three were used to precipitate SHARPIN, HOIL-1 and HOIP using 
specific antibodies, respectively, whereas the other two served as controls for unspecific 
binding to the beads or the antibodies. As shown in Figure 26B, precipitation of any of the 
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three proteins also pulled out the other two and the levels of the co-precipitated protein did 
not change upon TNF-stimulation. This demonstrates that in an unstimulated state 
endogenous SHARPIN, HOIL-1 and HOIP are associated with each other. However, this data 
was insufficient to judge whether the interaction between the three is direct. To clarify 
whether another factor is required to mediate the association of the three, recombinant 
versions of SHARPIN, HOIL-1 and HOIP were precipitated using specific antibodies and co-
precipitation of the other two was analysed by western blotting (Figure 26C).  
 
Figure 26: SHARPIN, HOIL-1 and HOIP interact in a direct and stimulation-independent manner. A: V5-tagged 
forms of HOIL-1 and HOIP were over-expressed in HEK293T cells either alone or in combination with SHARPIN 
and precipitated using anti V5-beads. Co-precipitation of SHARPIN was assessed on western blot level. B: U937 
cells were stimulated with TNF for five minutes or left untreated. Lysates were split into five parts and 
precipitations using empty beads, an isotype control (IgG2a) or anti-SHARPIN, anti-HOIL-1 or anti-HOIP 
antibodies. Presence of the three proteins in the different pulldowns was determined by western blotting. C: 
Recombinant forms of SHAPRIN, HOIL-1 or HOIP were added to either the precipitations of the respectively 
other two or to beads containing the specific antibodies used for pull-down but not their specific antigen. The 
heavy chain as detected by PonceauS staining is used as a loading control. Black rhombi mark bands 
representing the heavy chain.  
Both HOIL-1 and HOIP were associated with SHARPIN (lanes 3 and 4) but were not 
detectable on beads coupled to the anti-SHARPIN antibody (lanes 1+2), indicating that a 
specific and direct interaction occurs between the proteins. Similarly, interaction of 
SHARPIN and HOIL-1 with recombinant HOIP (lanes 7+8) and of SHARPIN and HOIP with 
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HOIL-1 (lanes 11+12) could be detected. These results demonstrate that SHARPIN, HOIL-1 
and HOIP can associate with each other in a direct manner and that this interaction occurs 
in cells in a stimulation-independent manner. However, the data are not sufficient to 
distinguish between the existence of one complex containing all three proteins and that of 
different complexes containing only two of the proteins, respectively. Since SHARPIN and 
HOIL-1 show high sequence similarity (Lim et al., 2001) it seemed possible that HOIP 
associated with either of the two in a tissue- or cell line specific manner. Expression of 
HOIL-1 in a variety of tissues (Tokunaga et al., 1998b) and its association with HOIP in 
several cell lines (Kirisako et al., 2006; Tokunaga et al., 2009) were reported.  
To test, whether SHARPIN shows a similar expression pattern, lysates of different human 
tissues were analysed by western blotting. Although quantitative statements are not 
possible due to different expression levels of GAPDH and ACTIN in the tissues analysed, the 
western blot depicted in Figure 27 shows that SHARPIN is widely expressed across tissues.  
 
Figure 27: SHARPIN is widely expressed in normal human tissues. Lysates of normal human tissues 
(IMGENEX) were analysed by western blotting for the presence of SHARPIN. Membranes were probed with 
anti-GAPDH and anti-ACTIN antibodies as a loading control. 
To test whether SHARPIN, HOIL-1 or HOIP exclusively binds only one of the other two in 
certain tissues, fourteen cell lines of different tissue origins (table 1) were used to 
precipitate each of the three proteins using specific antibodies respectively.  
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Table 5: Origin of cell lines used in Figure 28. Information according to ATCC, Benard et al and Boukamp et al. 
(Benard et al., 1985; Boukamp et al., 1988). 
 
Although expression levels seem to differ slightly between cell lines, with very low levels of 
HOIL-1 in HEK293T and HeLa cells being the most notable difference, precipitation of any of 
the three proteins led to the co-precipitation of the other two in all cell lines tested 
(Figure 28). 
While a tissue-specific formation of different dipartite complexes cannot be fully excluded 
on the basis of this result, it is a clear indication that stimulation-independent association of 
SHARPIN, HOIL-1 and HOIP is not a cell type specific event. Based on these results, a further 
investigation of the interactions between the three proteins was undertaken. 
cell line disease organ / cell type
HEK 293T -
human embyonic
kindey
HeLa adenocarcinoma cervix
HT1080 fibrosarcoma connective tissue
HaCat - skin/keratinocyte
Saos-2 osteosarcoma bone
IGROV-1 carcinoma ovary
DKO-4
colorectal 
adenocarcinoma
colon
Du145 carcinoma prostate
A549 carcinoma lung
MCF-7 adenocarcinoma
mammary gland, 
breast
JA-3 acute T cell leukemia T lymphocyte
Raji Burkitt's lymphoma B lymphocyte
U937 histiocytic lymphoma
monocyte / 
macrophage
THP-1
acute monocytic
leukemia
monocyte
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Figure 28: SHARPIN, HOIL-1 and HOIP co-precipitate in a variety of cell lines. Lysates of the indicated fourteen 
cell lines of different tissue origins were employed to assess protein levels of SHARPIN, HOIL-1 and HOIP by 
western blotting (lower right panel) or to precipitate each of the three proteins using specific antibodies. 
Association of the remaining two proteins with beads coupled to the third was again analysed on western blot 
level.   
It can be noted in Figure 26A that more SHARPIN was co-precipitated with HOIP than with 
HOIL-1. To follow up on this point, HOIP expression was down-regulated using siRNA and 
the amount of HOIL-1 bound to SHARPIN, which was pulled out using a specific antibody, 
was estimated by western blotting (Figure 29A). In absence of detectable HOIP, the amount 
of HOIL-1 associated with SHARPIN was clearly decreased. However, as observed previously 
(Figure 15), down-regulation of HOIP severely affected the levels of SHARPIN and HOIL-1. To 
account for this co-down-regulation and to be able to judge whether there is a role for HOIP 
in mediating the interaction between SHARPIN and HOIL-1, the bands representing HOIL-1 
were quantified using the ImageJ software (Figure 29B and C). The intensities were then 
normalised to those representing ACTIN in the lysates or SHARPIN in the 
immunoprecipitations. When the band intensities of the control were set to 100 % in both 
lysates and precipitations the amount of HOIL-1 in HOIP knockdown cells was reduced to 
29 % and 18 %, respectively. This shows that although the absence of HOIP already leads to 
a down-regulation of HOIL-1 (by 71 %) in total cell extracts the interaction between 
SHARPIN and HOIL-1 is even further influenced by the absence of HOIP (82 % reduction) 
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compared to control cells. Although it cannot be distinguished if a direct binding between 
SHARPIN and HOIL-1 is taking place in the knockdown situation or if the remaining HOIP is 
sufficient to mediate this association, this result indicates that HOIP increases the 
interaction between the other two. 
 
Figure 29: HOIP enhances the interaction between SHARPIN and HOIL-1 in HeLa cells. Expression levels of 
HOIP were down-regulated in HeLa cells and SHARPIN was precipitated using a specific antibody. A: Western 
blot showing the co-precipitation of HOIL-1 in presence or absence of HOIP. B and C: Quantification of bands 
from A and calculation of relative HOIL-1 levels in immunoprecipitations and lysates. 
This was confirmed by co-precipitation of recombinant HOIL-1 with V5-tagged SHARPIN in 
absence or presence of increasing amounts of HOIP. Again, a weak direct interaction 
between HOIL-1 and SHARPIN could be detected and an increase in this association was 
observed in the presence of HOIP indicating that this protein can mediate the interaction 
between the other two (Figure 30). 
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.  
Figure 30: HOIP increases the interaction of HOIL-1 and SHARPIN in vitro.  10g of recombinant V5-tagged 
SHARPIN per sample were used to couple the protein to beads. 3g of HOIL-1 were added to either empty 
beads (first lane) or to the SHARPIN-coupled beads in the absence of HOIP (second lane) or in presence of 
different amounts (0.05g, 0.5g, 5g) of HOIP. Co-precipitation was assessed on western blot level.  
This provides additional evidence for the existence of a tripartite complex. Furthermore, it 
raised the question as to how HOIP binds to SHARPIN and HOIL-1 at the same time. The 
interaction between HOIL-1 and HOIP was reported to be mediated via their UBL- and UBA-
domains respectively (Kirisako et al., 2006). In order to map which parts of HOIP are 
involved in binding SHARPIN, in-vitro-translated versions of HOIP lacking the UBA-domain, 
the N-terminus or the C-terminus (Figure 31A), were tested for their ability to bind 
recombinant SHARPIN.  
 
Figure 31: The NZF2-domain in the N-terminal part of HOIP is sufficient to mediate the interaction with 
SHARPIN. A: Schematic representation of HOIP mutants employed in B. B: In-vitro translated mutations of 
HOIP lacking the UBA-domain, the N-terminus or the C-terminus were tested for their ability to bind 
recombinant SHARPIN in a co-precipitation assay using a specific anti-SHARPIN antibody (left panel). Right 
panel: recombinant forms of the ZnF, NZF1 and NZF2 domain of HOIP were pulled down via their N-terminal 
GST-tag, recombinant SHARPIN was added and binding was assessed by western blotting.  
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As shown in Figure 31B deletion of its N-terminus abolished co-precipitation of HOIP, 
indicating that this part is essential for the association with SHARPIN. To further allocate the 
SHARPIN-binding motif to one of the three zinc-fingers present in the N-terminal part of 
HOIP, GST-tagged versions of these domains were purified from E.coli, coupled to 
glutathione-beads and tested for co-precipitation of SHARPIN (Figure 31C). This experiment 
revealed that the NZF2-domain was sufficient to pull down recombinant SHARPIN, whereas 
no binding of this protein to the ZnF- or NZF1-domain could be detected. 
To identify the corresponding domain in SHARPIN that is recognised by HOIP’s NZF2, 
recombinant HOIP was coupled to beads using a specific antibody and co-precipitation of in-
vitro-translated SHARPIN mutants (Figure 32A) was analysed by western blotting. As shown 
in Figure 32B, binding efficiency was greatly reduced when the UBL-domain of SHARPIN was 
deleted.
 
Figure 32: Deletion of SHARPIN’s UBL-domain prevents its interaction with HOIP. A: Schematic 
representation of SHARPIN and of mutants employed in this assay. B: Recombinant HOIP was pulled down 
using a specific antibody and tested for its capacity to co-precipitate mutants of SHARPIN in which the UBL-
domain or the NZF had been deleted or in which zinc-coordinating cysteines had been mutated to serine 
(NZFmut1= C353,356S; NZFmut2= C367,370S).  
Indeed a GST-tagged recombinant form of this domain was sufficient to bind V5-tagged 
HOIP in precipitations performed using glutathione- (Figure 33, left panel) or anti-V5-beads 
(Figure 33, right panel). 
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Figure 33: The UBL-domain of SHARPIN is sufficient to mediate the interaction with HOIP. Anti-V5-beads were 
used to precipitate recombinant HOIP and co-precipitation of GST-only or a GST-tagged form of SHARPIN’s 
UBL-domain was analysed by western blotting (left panel). The reciprocal experiment was performed using 
glutathione-beads to precipitate GST-only or the N-terminally GST-tagged UBL-domain of SHARPIN. Binding of 
HOIP was determined using a specific antibody on western blot level. Precipitation of GST and the UBL-domain 
was controlled by PonceauS-staining. 
Taken together, it could be shown that the interaction between HOIP and SHARPIN is 
mediated via their NZF2- and UBL-domains, respectively. 
5.5 LUBAC exclusively generates linear ubiquitin chains in vitro 
A high-molecular weight complex consisting of HOIL-1 and HOIP was previously described to 
act as an E3 generating linear ubiquitin chains (Kirisako et al., 2006). Furthermore, this 
activity was correlated to the ability of inducing NF-B activation upon over-expression 
(Haas et al., 2009; Tokunaga et al., 2009). To investigate the effect SHARPIN has on the 
processes mediated by LUBAC, the three proteins were ectopically expressed in 
HEK293-NF-B cells and the resulting luciferase expression was assessed in an activity assay. 
As shown in Figure 34, none of the proteins induced NF-B activation when expressed on its 
own and neither did the combination of SHARPIN and HOIL-1. However, combination of 
HOIP with either SHARPIN, HOIL-1 or both induced luciferase expression, providing evidence 
that also in the context of LUBAC’s activity SHARPIN fulfils a role similar to that of HOIL-1.  
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Figure 34: Over-expression of HOIP in combination with SHARPIN and/or HOIL-1 induces NF-B activation in 
a luciferase-reporter assay. HEK293-NF-B cells were transfected with SHARPIN, HOIL-1 and HOIP either alone 
or in combination. Luciferase-expression was measure in a luciferase-assay and normalised to renilla-activity. 
Fold inductions in the relative luminescence units (RLU) were calculated and results are shown as mean +/- 
SEM; n=5 (left panel). The right panel shows a representative western blot to control for successful over-
expression of the three proteins. 
To be able to directly investigate its role in the generation of linear ubiquitin chains by 
LUBAC, an in-vitro ubiquitination assay using recombinant proteins and mono-ubiquitin as a 
model substrate was set up. By stopping the reaction after the times indicated in 
Figure 35A, the incubation time necessary for efficient chain formation was established. The 
assay showed that the combination of HOIL-1 and HOIP, in line with it being previously 
described to act as an E3 (Kirisako et al., 2006), was active in generating ubiquitin chains as 
seen by the appearance of poly-ubiquitin conjugates after twenty and more strongly after 
forty minutes (Figure 35A, lanes 7+8). This conjugation was specifically mediated by HOIL-1 
and HOIP because even after sixteen hours the combination of E1 and E2 was unable to 
catalyse the reaction in the absence of an E3 (lane 1+2). Based on the signal strength for the 
ubiquitin-chains generated and on practicability an incubation time of two hours was 
deemed optimal and therefore applied in all following experiments of this type. Having set 
up the system to analyse it, SHARPIN’s ability to promote the formation of ubiquitin 
conjugates was assessed (Figure 35B). Again, combinations of HOIP with SHARPIN and/or 
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HOIL-1 but not the combination of SHARPIN and HOIL-1 or HOIP alone were active. Thus, 
the capacity to promote formation of poly-ubiquitin conjugates correlated well with the 
ability or inability of these combinations to induce NF-B activation as established in 
Figure 34.  
 
Figure 35: HOIP generates ubiquitin chains when complexed with SHARPIN and/or HOIL-1. A: An in-vitro 
assay was performed as described under 4.2.3.16. Incubation time for in-vitro ubiquitination assays was 
optimised by stopping the reaction catalysed by the E3-complex consisting of HOIL-1 and HOIP after the 
indicated times. Formation of ubiquitin polymers was determined on western blot level. B: Different 
combinations of untagged HOIP and GST-tagged SHARPIN were tested for their ability to mediate the 
conjugation of ubiquitin moieties in the presence or absence of E1 and E2 in an in-vitro assay as described 
under A.  
The E3-complex consisting of HOIL-1 and HOIP, LUBAC, was found to be able to generate 
ubiquitin chains from K0-ubiquitin, in which all lysine residues were mutated to arginine, 
and it was concluded that these chains are linked via the N-terminal methionine (Kirisako et 
al., 2006). It can be observed in Figure 35B, that the bands for the ubiquitin conjugates 
generated by SHARPIN-containing E3-combinations run at the same apparent molecular 
weight as the ones generate by HOIL-1 and HOIP. This indicates that these chains are also 
M1-linked because different linkage types, especially of lower order ubiquitin oligomers, can 
be distinguished due to their different electrophoretic mobilities (Komander et al., 2009b). 
For the purpose of assessing more directly if SHARPIN supports the formation of linear 
chains or if it shifts linkage specificity towards a different type, the active E3-combinations 
identified in Figure 35B were compared to TRAF6 in their ability to use N-terminally His-
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tagged ubiquitin, in which the N-terminal aminogroup of M1 is rendered inaccessible by the 
conjugation of six histidine-residues while all lysine residues remain unchanged, as a 
substrate. Although all E3s were active in promoting the formation of ubiquitin-chains using 
wild-type ubiquitin, conjugation of His-ubiquitin could only be observed for TRAF6 
(Figure 36A). This demonstrates that HOIP in combination with SHARPIN and/or HOIL-1 is 
not only able to generate linear ubiquitin chains but is restricted to catalysing the formation 
of only this linkage type. In line with this strict linkage specificity, addition of increasing 
amounts of His-tagged ubiquitin reduces the formation of poly-ubiquitin chains by HOIL-1 
and HOIP (Figure 36B), indicating that N-terminally tagged ubiquitin acts as a competitive 
inhibitor of LUBAC.  
 
Figure 36: All LUBAC combinations exclusively generate linear linkages. A: HOIP in combination with SHARPIN 
and/or HOIL-1 was compared to TRAF6 in its ability to generate ubiquitin chains from wild-type (wt Ub) or His-
tagged (His Ub) ubiquitin in an in-vitro ubiquitination assay. B: Increasing amounts of His-tagged ubiquitin (0.5, 
1, 2, 10g) were added to reactions of an in vitro-assay of HOIL-1 and HOIP generating polyubiquitin 
conjugates. 
Overall, this data shows that LUBAC is unable to generate any linkage type other than linear 
chains and that SHAPRIN is both a structural and a functional component of this E3 complex. 
The term LUBAC will hence be used from here onwards to refer to the tripartite, linear 
ubiquitin chain generating  complex consisting of SHARPIN, HOIL-1 and HOIP.  
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In addition, in Figure 36B an additional band can be noticed in the anti HOIL-1 blot thus 
creating a pattern that resembles the appearance of HOIL-1 in cell lysates 
(Figures 10, 13, 28). This gave rise to questions concerning the identity, location and 
function of this modification.  
5.6 Modifications of LUBAC components 
A common principle in the regulation of enzymes is the addition of post-translational 
modifications. In several previous analyses it can be noticed that LUBAC-components are 
indeed modified (e.g. Figures 10, 13, 15 and 22). The fact that LUBAC is an E3 together with 
the sizes of the modified proteins in relation to their unmodified forms suggests that the 
type of modification could potentially be ubiquitination. To test this hypothesis, the TNF-RSC 
was precipitated from U937 cells and the precipitate was split into four parts of which two 
were treated with different amounts of the catalytic domain of USP2 (Figure 37). This 
deubiquitinase was described to remove a wide range of ubiquitin linkages while not 
affecting modifications with the ubiquitin-like protein NEDD8 (Kim et al., 2011). Treatment 
with USP2 was efficient as can be seen by the almost complete de-modification of RIP1 and 
cIAP2. Furthermore, modifications of SHARPIN, HOIL-1 and HOIP were also removed by 
DUB-treatment, indicating that LUBAC-components are indeed ubiquitinated within the 
TNF-RSC.  
 
 
 
 
Figure 37: Treatment with the catalytic domain 
of USP2 removes modifications form LUBAC 
components present in the TNF-RSC.  2x10
8
 
U937 cells were stimulated with TNF for five 
minutes. The TNF-RSC was isolated using M2-
beads, the precipitate was split into four parts 
of which one was left untreated, one was 
incubated in DUB-buffer for two hours at 37˚C 
and the remaining two were treated with 2 or 4 
g of the catalytic domain (CD) of USP2 (Enzo 
Life Sciences), respectively. Reactions were 
stopped by addition of reducing sample buffer 
and protein modifications were analysed on 
western blot level. 
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The strength of the band representing modified HOIL-1 in relation to its unmodified form, as 
observed in several experiments, indicates that a higher percentage of this protein is 
modified as compared to SHARPIN and HOIP. Based on this distribution I chose to 
investigate the modification of HOIL-1 in more detail. To study the influence of TNF-
stimulation and to investigate a potential role for SHARPIN and HOIP in mediating this 
modification, HeLa cells in which expression of HOIP (Figure 38A) or SHARPIN (Figure 38B) 
had been down-regulated by siRNA, were treated with TNF for five or fifteen minutes and 
the corresponding lysates were analysed on western blot level. No significant change can be 
observed in the upper band of HOIL-1 upon stimulation with TNF, indicating that HOIL-1 
modification is a stimulation-independent event. However, down-regulation of SHARPIN or 
HOIP led to a clear decrease in this modification (Figure 38A and B). To be able to directly 
compare the effects the down-regulation of the two proteins has on HOIL-1 modification, 
HeLa (Figure 38C, left panel) and A549 cells (Figure 38C, right panel) were transfected with 
siRNAs targeting SHARPIN or HOIP. Again, it could be observed that a decrease of HOIP 
protein levels was accompanied by a strong reduction in the HOIL-1 modification. In HeLa 
cells knockdown of SHARPIN also led to a decrease in the intensity of the band representing 
a modification on HOIL-1, albeit to a lesser degree than down-regulation of HOIP. In 
contrast, in A549 cells this modification seems to be largely unaffected by a decrease in 
SHARPIN levels. This suggests that SHARPIN may have a, potentially cell line specific, role in 
mediating the modification of HOIL-1 but that it is not able to modify HOIL-1 on its own. 
Presence of HOIP on the other hand is essential for HOIL-1 modification to occur. 
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Figure 38: Modification of HOIL-1 depends on HOIP and potentially SHARPIN. A, B: Expression of HOIP (A) or 
SHARPIN (B) was transiently down-regulated in HeLa cells using siRNA. Cells were stimulated with TNF 
[1g/mL] for five or fifteen minutes and the indicated proteins were analysed by western blotting. C: SHARPIN 
and HOIP were knocked down in HeLa (left panel) or A549 cells (right panel). HOIL-1 modification and 
knockdown efficiency were determined on western blot level. 
To further clarify the type of the HOIL-1 modification and to assess the need for HOIP’s 
activity in generating it, an in-vitro assay was performed. The fact that a modification of 
HOIL-1 can also be observed in this in-vitro system (Figure 39) provides further evidence 
that it is a ubiquitination, as other potential modifiers are not present here. 
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Figure 39: Modification of HOIL-1 can be observed in an in-vitro ubiquitination assay. Recombinant HOIL-1 
was combined with the indicated forms of HOIP and SHARPIN, a ubiquitination assay was performed in 
presence of either wild-type or His-tagged ubiquitin and activity of LUBAC as well as HOIL-1 modification were 
assessed by western blotting. 
In contrast to the observations made in cell lines (Figure 38) it could be noted that HOIL-1 
was modified to some extent even in the absence of SHARPIN and HOIP (Figure 39, lane 2) 
and addition of SHARPIN alone was sufficient to increase the intensity of the band 
representing this modification (lane 3). A similar enhancement could be observed when 
inactive mutants of HOIP, alone or in combination with SHARPIN, were added to HOIL-1 
(lanes 6-9) or when LUBAC’s activity was blocked by His-tagged ubiquitin (lanes 11 and 12). 
In the last two lanes a slight increase in the distance between the bands representing the 
two forms of HOIL-1 could be observed which corresponds to the size difference between 
wild-type and His-tagged ubiquitin. This provides further evidence that HOIL-1 is indeed 
mono-ubiquitinated. When active LUBAC was created by adding wild-type HOIP to HOIL-1 in 
absence of presence of SHARPIN (lanes 4 and 5) a laddering pattern indicates that not only 
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one but several ubiquitin moieties are added to HOIL-1 in this case, which is in contrast to 
the observations made in cell lines where HOIL-1 modification seems to be restricted to 
mono-ubiquitination.  
In spite of the differences between the in-vitro system and the events occurring in cell lines, 
the HOIL-1 modification was sufficiently similar between the two for the in-vitro assay to be 
deemed a suitable system for performing a first characterisation of this ubiquitination 
event. In order to locate the modification site within HOIL-1, I made use of the fact that 
Thrombin cleaves this protein at aminoacid 183. This cleavage creates an N-terminal 
fragment if around 21 kDa that contains the N-terminal aminogroup as well as the -amino-
groups of eight lysine residues as potential ubiquitination sites. Another twelve lysines are 
contained in the C-terminal part which has a predicted molecular weight of approximately 
39 kDa (Figure 40A). To determine which of the two parts comprises the modification sites a 
C-terminally V5-tagged recombinant version of HOIL-1 was subject to an in-vitro 
ubiquitination assay, resulting in modification of the protein. After completion of the 
reaction, each sample was split into two parts of which one was left untreated 
(lanes 1, 3, 5, 7, 9) whereas Thrombin was added to the second part (lanes 2, 4, 6, 8, 10). As 
the anti-HOIL-1 antibody was raised against a peptide in the N-terminal part of this protein, 
both the N-terminal and the C-terminal fragment could be detected after cleavage by 
western blotting using the anti-HOIL-1 and an anti-V5 antibody respectively. This analysis 
revealed that no band was detectable at a molecular weight that could have resulted from 
the addition of a 7kDa ubiquitin molecule to the N-terminal fragment. On the other hand a 
clear double-band was visible in the anti-V5 blot, demonstrating that HOIL-1 is modified 
within its C-terminal part in vitro.  
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Figure 40: HOIL-1 is modified within its C-terminal part in vitro. A: Schematic representation of C-terminally 
V5-tagged HOIL-1 and the cleavage fragments generated by Thrombin. B: An in-vitro ubiquitination assay was 
performed as in Figure 36. After completion of the reaction, each sample was split into two parts of which one 
was treated with Thrombin for another two hours at 37˚C. Afterwards modification of HOIL-1 was assessed on 
western blot level using an anti-HOIL-1 antibody to detect the N-terminal and an anti-V5 antibody to show the 
C-terminal fragment. aa: aminoacid 
Two recent studies reported on the mass-spectrometry based identification of 
ubiquitination sites on a proteome-wide level (Kim et al., 2011; Wagner et al., 2011). In 
combination the two reports found lysines 158, 174, 254 and 342 of HOIL-1 to be modified. 
Because K158 and K174 are N-terminal of the Thrombin cleavage site and because K342 was 
identified by only one of the two studies whereas K254 was reported to be modified by both 
publications, the latter residue seemed to be the most likely candidate for the residue to be 
targeted by mono-ubiquitination. Site-directed mutagenesis was therefore employed to 
generate a mutant of HOIL-1 (referred to as K254R) in which this lysine, that is located 
between its NZF- and RING1-domains, was replaced by an arginine. In an in-vitro assay 
comparing recombinant forms of wild-type and mutant HOIL-1 both variants showed 
equivalent levels of modification when ubiquitin was present in the reaction (Figure 41). The 
band representing this modification could be observed in both the anti-HOIL-1 and the anti-
ubiquitin blot, further confirming that HOIL-1 is ubiquitinated. The lack of a difference 
between wild-type and mutant HOIL-1 in modifiability suggests that K254 is not the 
modification site of HOIL-1 required for its mono-ubiquitination. 
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Figure 41: Mutation of lysine 254 to arginine is insufficient to prevent modification of HOIL-1. Recombinant 
forms wild-type HOIL-1 or a mutant in which lysine 254 had been replaced by arginine (K254R) were employed 
in an in-vitro ubiquitination assay in the presence or absence of ubiquitin and/or SHARPIN. Modification of 
HOIL-1 was assessed by probing the corresponding western blot with the indicated antibodies. 
Another observation that can be made here is the presence of an additional band in the 
anti-ubiquitin blot that only becomes apparent when SHARPIN is added and that runs at an 
apparent molecular weight of just below 51 kDa. It could therefore correspond to a mono-
ubiquitinated form of SHARPIN, which would be in line with a modification of SHARPIN 
present in the TNF-RSC that was shown to be sensitive to DUB-treatment (Figure 37). 
Overall, these data indicate that all three LUBAC components are subject to modifications 
that due to their size and their DUB-sensitivity are likely to be ubiquitinations. Whereas 
modification of HOIP seems to be a stimulation-dependent event as seen by the appearance 
of additional bands following TNF-stimulation (Figure 10), ubiquitination of HOIL-1 is already 
present in an unstimulated state but depends on presence of HOIP and to a lesser degree of 
SHARPIN (Figure 38). The location of the HOIL-1 modification occurring in vitro could be 
mapped to its C-terminal part although the identification of the exact ubiquitination site will 
require further investigation (Figures 40 and 41). 
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5.7 LUBAC modifies NEMO in vitro and differs from other E3s in its 
linkage specificity 
The ability of LUBAC to induce NF-B activation when over-expressed and its role in TNF-
induced signalling together with its activity as an E3 suggested that its effect on signal 
transduction is accomplished by modification of proteins relevant to the respective 
signalling cascades. To investigate which protein may be a target, different components of 
the TNF-RSC were ectopically expressed in HEK293T cells and precipitated via their 
respective tags or using specific antibodies. The immobilised proteins were then divided into 
five parts and incubated with the different LUBAC-combinations in an in-vitro ubiquitination 
assay (Figure 42). 
 
Figure 42: All three LUBAC-combinations modify NEMO in vitro. Different components of the TNF-RSC and 
PTEN, a protein that was described to interact with SHARPIN (He et al., 2010), were precipitated from 
transfected or untreated HEK293T cell. Precipitates were split into five samples that were either left untreated 
or employed as a substrate in an in-vitro ubiquitination assay using different combinations of untagged 
recombinant HOIP or SHARPIN and GST-tagged HOIL-1 as E3s. Modification was assessed on western blot level 
by probing the membrane with an antibody specific for the potential target. Activity of all three LUBAC 
combinations was demonstrated by probing with an anti-ubiquitin antibody. 
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Detection of bands at higher molecular weights by the antibody specific for the respective 
target protein in LUBAC-treated samples, that were not present in the 
immunoprecipitations left untreated (Figure 42, first lanes) or incubated with E1 and E2 only 
(second lanes) indicated that a modification mediated by LUBAC and not by an E3 co-
precipitated with the target was taking place. This analysis revealed that all three LUBAC 
versions were capable of ubiquitinating NEMO in vitro whereas none of the other TNF-RSC 
components or PTEN, a protein that was described previously to be inhibited by SHARPIN 
(He et al., 2010), was modified to a significant extent. The identification of NEMO as a target 
of all LUBAC-combinations is in line with a report describing modification of this protein by 
HOIL-1 and HOIP (Tokunaga et al., 2009) and could also be corroborated by the mass-
spectrometry based finding that linearly ubiquitinated forms of NEMO are present in the 
native TNF-RSC (Gerlach et al., 2011). 
Because HOIL-1 and HOIP belong to the RING-in-between-RING (RBR)-family of E3s (Marin 
et al., 2004) I next investigated whether the property of exclusively generating linear 
ubiquitin chains is an intrinsic characteristic of this protein family. For this purpose, the RBR-
ubiquitin ligases Parkin (PARK2), ARIH2 (ariadne homolog2, also known as TRIAD1), RNF19A 
(Dorfin), RNF144B (ring finger protein 144B or IBR domain-containing protein 2 (IBRDC2)), 
RNF216 (also known as triad domain-containing protein 3 (TRIAD3) or zinc finger protein 
inhibiting NF-kappa-B (ZIN)) and RNF14 (androgen receptor-associated protein 54 (ara54) or 
TRIAD2) (Figure 43) were produced in E.coli. 
 
Figure 43: Schematic representation of RBR-family members. Proteins and their domains are not drawn to scale. UBL: 
ubiquitin-like; UIM: ubiquitin-interacting motif; TM: trans-membrane; TIM: TRAF-interaction motif; PRO-RICH: Proline-rich, 
Modified from (Marin et al., 2004).  
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The purified proteins were then tested for their ability to use wild-type or His-tagged 
ubiquitin as a substrate. Figure 44A shows that, in contrast to LUBAC, these E3s were not 
compromised in their activity by the N-terminal tag in ubiquitin, indicating that they are able 
to use lysine residues to conjugate ubiquitin moieties. However, this result does not exclude 
the possibility that linear linkage can be formed by these E3s when that option is available.  
 
Figure 44: Other members of the RBR-family can employ His-tagged but not lysine-less ubiquitin as a 
substrate in in-vitro ubiquitination assays. A: Different members of the RBR-family were compared to HOIP in 
combination with SHARPIN or HOIL-1 in in-vitro ubiquitination assays preformed as described in Section x 
using wild-type (wt) or His-tagged (His) ubiquitin as a substrate as indicated. B: Recombinant forms of the RBR-
domains of ARIH1, PARKIN (without a tag) or ARIH2 (GST-tagged) were compared to LUBAC in their capacity to 
generate ubiquitin chains from wild-type (wt), lysine-less (K0) or His-tagged  (His) ubiquitin. The E2 employed 
in the different reaction is indicated. Combinations of E2 and E3 were chosen based on maximal activity in 
previous assays. 
To investigate this aspect and to exclude effects like the auto-inhibitory influence of Parkin’s 
UBL domain (Chaugule et al., 2011) the RBR-domains of ARIH1 (also known as human 
homolog of Drosophila ariadne-1 (HHARI)), ARIH2 and Parkin were purified and 
ubiquitination assays were performed using wild-type, lysine-less (K0) or His-tagged 
ubiquitin. As expected, the combination of HOIL-1 and HOIP was able to generate 
polyubiquitin from wild-type or K0- but not from tagged ubiquitin (Figure 44B). On the other 
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hand the RBR-domains of the other family members still showed activity in spite of the N-
terminal tag on ubiquitin but were not able to generate ubiquitin-polymers from lysine-less 
ubiquitin to a significant degree. This does not exclude that formation of linear linkages can 
be catalysed by some members of the RBR-family, but it proves that not all proteins 
belonging to this group are capable of or even restricted to generating chains of this linkage 
type. To test whether the linear linkages identified in the native TNF-RSC by mass 
spectrometry (Gerlach et al., 2011) were definitely generated by LUBAC or whether a 
different E3 known to be present in this complex shows the same linkage specificity, 
recombinant forms of cIAP1, cIAP2 and TRAF2 were compared to LUBAC in an in-vitro assay. 
 
Figure 45: Other E3s present in the TNF-RSC are largely unaffected in their capacity to generate poly-
ubiquitin by an N-terminal tag on ubiquitin. Recombinant forms of cIAP1, cIAP2 and TRAF2 were compared to 
the different LUBAC combinations in an in-vitro ubiquitination assay. Their capacity to generate ubiquitin 
conjugates from wild-type (wt) or N-terminally tagged (His) ubiquitin was assessed by western blotting. 
100 nM sphingosine-1-phosphate was added to TRAF2 containing reactions as a cofactor. 
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Because it was reported that TRAF2 requires sphingosine-1-phosphate as a cofactor, this 
substance was added to the reactions containing this E3. In spite of this, only a faint smear 
representing the formation of higher-order ubiquitin conjugates by TRAF2 is visible on the 
western blot shown in Figure 45. Overall this blot shows that all LUBAC combinations are 
again unable to employ tagged ubiquitin as a substrate, whereas chain formation and auto-
ubiquitination by the other E3s is largely unaffected.  
To further corroborate the seemingly unique linkage specificity of LUBAC, another in-vitro 
ubiquitination assay using different E3s in combination with either UBE2D3 or the UBE2N-
UBE2V1-complex was performed (Figure 46A). Mass-spectrometric analysis showed that the 
UBE2N-UBE2V1-complex indeed exclusively generates K63-linked chains when employed 
alone or in combination with any of the E3s investigated (Figure 46B). When combined with 
UBE2D3, cIAP1, cIAP2, TRAF6 and RNF5, of which the latter two are E3s so far not described 
to play a role in TNF-signalling that were used as a control in this assay, promoted the 
formation of K48- and K63- but not of linear chains. By contrast, the LUBAC-combinations 
exclusively generated M1-linkages further confirming the notion that among the E3s tested, 
LUBAC exhibits a special linkage specificity.  
 
Figure 46: LUBAC has a unique linkage specificity. An in-vitro ubiquitination was performed using different E3s 
in combination with either UBE2D3 or the UBE2N/UBE2V2 complex. 10 % of each sample were used to control 
for ubiquitin-conjugation on western blot level (A). The rest was analysed by mass spectrometry for the 
presence of peptides specific for certain linkages types (B).   
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This result also draws attention to the fact that the E2 participating in the generation of 
ubiquitin chains by RING-class E3s is usually the critical factor in determining linkage 
specificity (Nagy and Dikic, 2010). In order to assess the influence of the E2 on ubiquitin 
conjugation mediated by HOIP in combination with SHARPIN or HOIL-1, in-vitro 
ubiquitination assays were performed with a panel of E2s, either alone or in combination 
with these two LUBAC-versions (Figure 47). 
 
Figure 47: LUBAC is active with a panel of different E2s.  The indicated E2s were employed in an in-vitro 
ubiquitination assay as described under section x either alone or in combination with complexes of HOIP and 
SHARPIN or HOIL-1. Conjugation of ubiquitin moieties was assessed by western blotting. 
In accordance with the model that E3s mediate the interaction between substrate and E2 
and substantially increase the rate of ubiquitin discharge from an E2’s active site (Ye and 
Rape, 2009), most E2s were unable to generate ubiquitin-conjugates of more than two 
ubiquitin moieties on their own (left panel of Figure 47). The exception in this was the 
UBE2N-UBE2V1-complex, which in line with the literature (Hofmann and Pickart, 1999, 
2001) and the results shown in Figure 46 indicates that this E2-complex mediates formation 
of K63-linked chains even in the absence of an E3. The other two panels of Figure 47 show 
that HOIP complexed with SHARPIN or HOIL-1 can employ all E2s tested in the generation of 
ubiquitin chains. Inferring from the position of the corresponding bands on the western 
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blot, all chains seem to be linear polyubiquitin conjugates irrespective of the E2 involved in 
their formation. Reactions including UBE2N-UBE2V1, where bands corresponding to both 
presumably linear and K63-linked chains can be observed constitute an exception to this 
observation. This result shows that linkage specificity is an intrinsic property of LUBAC that 
is unaffected by the E2 it collaborates with.  
5.7 LUBAC works via a HECT-like mechanism and its activity is required 
for TNF-induced NF-B activation 
In addition, the data shown in Figure 47 provides evidence that LUBAC is active in 
combination with UBE2L3, an E2 that lacks lysine-reactivity (Wenzel et al., 2011a) and which 
therefore cannot transfer ubiquitin directly onto a substrate. Instead UBE2L3 needs to 
transfer ubiquitin moieties to a cysteine-residue within the catalytic centre of an E3, which 
in turn confers it onto the target protein. This limitation prevents UBE2L3 from working with 
RING-E3s as these do not usually have a catalytic cysteine that could accept the ubiquitin. 
However, a recent publication showed that apart from HECT-ligases also members of the 
RBR-family are capable of forming a thioester-intermediate between ubiquitin and a 
catalytic cysteine (Wenzel et al., 2011a). RBR-E3s that have this catalytic residue within their 
RING2-domain can therefore work via a HECT-like mechanism. To investigate whether 
LUBAC has similar properties, it was compared to different RING-class E3s in an in-vitro 
assay using either UBE2D3 or UBE2L3 as an E2 (Figure 48). In line with UBE2L3 exhibiting 
exclusively cysteine-reactivity, it was unable to act as an E2 for the RING-domain containing 
E3s cIAP1, cIAP2 and TRAF6 as seen by the lack of formation of polyubiquitin chains as well 
as the absence of auto-ubiquitination observed when the respective E3s were combined 
with UBE2D3. On the other hand, ubiquitin conjugation by all three LUBAC combinations 
was supported by both UBE2D3 and UBE2L3, suggesting that like ARIH1 and Parkin (Wenzel 
et al., 2011a) LUBAC also works via a HECT-like mechanism. 
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Figure 48: UBE2L3 is active with the different LUBAC combinations but not with RING-class E3s. UBE2D3 and 
UBE2L3 were compared in an in-vitro ubiquitination assay as described in section 4.2.3.16. Generation of 
ubiquitin chains by the two E2s in combination with the three LUBAC-versions or with different RING-class E3s 
(cIAP1, cIAP2, TRAF6) was analysed by western blotting.  
Interaction studies (Figures 26A, 29 and 30) as well as functional assays (Figure 34 and 
(Figure 35B) indicate that HOIP is the central component of LUBAC both structurally and 
functionally. It was therefore hypothesised that a potential catalytic cysteine should be 
located in HOIP and more specifically within its RING2-domain. The consensus sequence 
surrounding the catalytic centre of RBR-family members as published by Wenzel et al. 
(Wenzel et al., 2011a) was therefore compared to the RING2-domain of HOIP (Figure 49A). 
UBE2:
E3: - cI
A
P
1
 
cI
A
P
2
 
T
R
A
F6
SH
A
R
P
IN
 +
 H
O
IP
 
H
O
IL
-1
 +
 H
O
IP
 
SH
A
R
P
IN
 +
 H
O
IL
-1
 +
 
H
O
IP
 
Ubiquitin
cIAP1/2
TRAF6
SHARPIN
HOIL-1
HOIP
97
97
97
97
64
64
64
51
51
51
39
39
28
19
14
D
3
L3 D
3
L3 D
3
L3D
3
L3 D
3
L3 D
3
L3 D
3
L3
5. Results 
  
121 
 
 
Figure 49: C885 of HOIP is required for LUBAC's activity. A: Alignment of the consensus sequence (in blue) 
surrounding the catalytic cysteine in RBR-family members as published by (Wenzel et al., 2011a) with the 
RING2-domain of HOIP (in grey). Identical residues are shown in black. Green letters in italics indicate that the 
aminoacids present in HOIP can also be found in at least one other family member at this position. Residues 
different from all other RBR-E3s analysed are shown in red bold print. B: Interaction of HOIP C885S with 
SHARPIN and HOIL-1 was compared to that of the wild-type (wt) protein. The indicated proteins were over-
expressed in HEK293T cells followed by precipitation of HOIP variants via their V5-tag and western analysis for 
co-precipitation of SHARPIN and HOIL-1. C: Co-precipitation of SHARPIN, HOIL-1 and UBE2D3 with the two 
forms of HOIP in a pulldown using a specific HOIP antibody was investigated using recombinant proteins.  e.v.: 
empty vector 
Although seven of the thirty-six aminoacids aligned did not correspond to either the 
consensus sequence or the residues present in any of the other RBR-E3s, the overall 
similarity was sufficient for a potential catalytic cysteine to be identified as C885. A mutant 
of HOIP in which this residue was replaced by serine was therefore created. By over-
expression of V5-tagged versions of wild-type HOIP or the C885S-mutant together with 
SHARPIN or HOIL-1 followed by precipitation using an anti-V5 antibody, it was found that 
mutation of cysteine 885 does not prevent HOIP from interacting with the other two 
proteins (Figure 49B). This result was corroborated by using recombinant proteins (Figure 
49C). In this assay it was also established that mutated HOIP can still interact with UBE2D3, 
the E2 supplied in most ubiquitination-assays, in vitro. In spite of these intact interactions, 
HOIP C885S was unable to catalyse formation of ubiquitin chains when combined with 
either SHARPIN or HOIL-1 (Figure 50). In this inability it resembles another HOIP mutant, in 
which some of the zinc-coordinating cysteine residues of both RING1 (C699 and C702) and 
RING2 (C871 and C874) had been mutated. This shows that cysteine 885 within the RING2-
domain of HOIP is essential for its activity. Together with LUBAC’s capacity of generating 
poly-ubiquitin when combined with UBE2L3, this suggests that LUBAC works via a HECT-like 
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mechanism that probably involves the formation of a thioester between ubiquitin and 
cysteine 885 within HOIP.  
 
Figure 50: HOIP C885S is inactive in in-vitro ubiquitination assays when combined with SHARPIN or HOIL-1. 
HOIP C885S and HOIP C699,702,871,874S (RING1/2mut)  were compared to wild-type HOIP in an in-vitro 
ubiquitination assay. 
To address whether this activity of HOIP is required in TNF-induced NF-B activation, V5-
tagged versions of HOIP that were either unchanged or contained mutations in the RING-
domains, were expressed in HEK293-NF-B cells (Figure 51, right panel). NF-B activation 
was assessed in a reporter-assay following TNF-stimulation (Figure 51, left panel). Forms of 
HOIP that contained mutations in the RING2-domain, in RING1 and RING2 or in cysteine 885 
significantly reduced the luciferase-activity measured after TNF-stimulation, indicating that 
an intact RING2 domain and presence of C885 are required and that mutants with changes 
in these features exert a dominant-negative effect on TNF-induced signalling.  
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Figure 51: Mutants of HOIP containing alterations in the RING2-domain have a dominant-negative effect on 
TNF-induced NF-B activation. V5-tagged mutants of HOIP were over-expressed in HEK293 NF-B cells and 
luciferase-activity was analysed in a luciferase-assay following stimulation with TNF. Values were normalised to 
renilla-activity and the control was set to 100 %. Results are presented as mean +/- SEM; n=9 and significance 
was calculated using a student’s t-test (left panel). Over-expression of the different HOIP mutants was verified 
by western blotting and the results of two representative experiments are shown (right panel). RING1mut: 
HOIP C699,702S; RING2mut: HOIP C871,874S; RING1/2mut: HOIP C699,702,871,874S.  
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6 Discussion and Outlook 
TNF is a key inflammatory cytokine with great physiological relevance and diverse effects 
ranging from pro-inflammatory to immune-regulatory functions. On a cellular level, TNF can 
induce the production of pro-inflammatory cytokines, cell proliferation, differentiation or 
cell death (Chen and Goeddel, 2002; Hayden and Ghosh, 2008; Kovalenko and Wallach, 
2006; Wajant et al., 2003). In initiating these diverse outcomes, TNF relies on two surface 
receptors, TNFR1 and TNFR2 (Wajant et al., 2003). Since both receptors belong to the TNFR-
superfamily, a group of proteins that generally lack enzymatic activity within their 
intracellular domains (Aggarwal, 2003), they recruit cytoplasmic proteins upon stimulation, 
which in turn initiate downstream signalling events. The receptor-associated multi-protein 
complexes, referred to as receptor signalling complexes (RSCs), represent the apex of all 
signal transduction cascades emanating from the TNF-receptors. Events occurring within 
this assembly of proteins are therefore critical determinants of cellular fate and important 
regulators of diverse biological processes. Hence, it is essential to comprehend the 
composition of these complexes on a molecular level. For this purpose the TNF-RSC was 
isolated by a modified tandem affinity procedure and analysed by mass spectrometry (Haas 
et al., 2009). Next to almost all proteins previously described to form part of the TNF-RSC 
this analysis revealed the presence of three novel components, i.e. SHARPIN, HOIL-1 and 
HOIP, in this complex (Gerlach et al., 2011). Two of these three proteins had been described 
to form an E3 complex that mediates the formation of ubiquitin chains linked via the 
N-terminal methionine (M1) (Kirisako et al., 2006) and that is thus referred to as linear 
ubiquitin chain assembly complex (LUBAC). In this thesis, SHARPIN could be identified as a 
third structural and functional component of LUBAC. Furthermore, it was shown that this 
pre-formed complex is recruited to the TNF-RSC in a stimulation- and cIAP-dependent 
manner and that all potential LUBAC-variants exclusively generate linear ubiquitin chains via 
a HECT-like mechanism.  
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6.1  The role of SHARPIN, HOIL-1 and HOIP in the context of TNF-signalling 
6.1.1 Isolation of the TNF-RSC verifies the stimulation-dependent recruitment of 
SHARPIN, HOIL-1 and HOIP to this complex and shows modification of 
different complex components 
A kinetic study performed on the TNF-RSC of U937 cells showed that the three novel 
components identified by mass spectrometry are not present on unstimulated receptors but 
are recruited in a manner that depends on receptor crosslinking by its ligand. In this 
stimulation-dependency of their recruitment as well as the kinetics of their appearance and 
disappearance from the complex, SHARPIN, HOIL-1 and HOIP resemble each other and most 
other components of the RSC. Only TRADD seems to reach its maximal levels slightly earlier 
than the other proteins, which is in line with a direct interaction between the DD of this 
protein with those present in TNFR1 (Hsu et al., 1995) and with a role for the former as an 
adaptor for other complex constituents like TRAF2 and potentially RIP1 (Hsu et al., 1996a; 
Hsu et al., 1996b; Shu et al., 1996; Tsao et al., 2000). Apart from mere presence of proteins, 
the level of modifications they carry can be an indicator for stage and stability of the 
receptor-complex. The most obvious modifications observed in the TNF-RSC are the 
ubiquitination of RIP1 and cIAP, which like the levels of most components reach a maximum 
after five minutes of stimulation. Both modifications are most likely mediated mainly by the 
E3-activity of cIAP as indicated by the findings that the RING-domain of TRAF2 is not 
sufficient or required for RIP1 ubiquitination to occur and that reconstitution of cIAP1/2-/- 
MEFs with inactive forms of cIAP1 cannot restore this modification. This is in line with 
previous publications that cIAPs can directly target RIP1 in vitro, whereas TRAF2 can not. 
However, the identification of four different types of ubiquitin linkages on RIP1 by mass 
spectrometry (Gerlach et al., 2011) suggests that RIP1 may be modified by several E3s and 
that one of these ligases is LUBAC. The modification of cIAP is likely to be an auto-
ubiquitination, as a similar alteration occurs in in-vitro assays in the absence of another E3. 
This would again be in accordance with literature (Bertrand et al., 2008; Dueber et al., 2011; 
Feltham et al., 2010) but as in the case of RIP1 the contribution of one or several other E3s 
cannot be excluded. Furthermore, the modifications present on RIP1 and cIAP do not seem 
to exclusively consist of ubiquitin-molecules. This is indicated by the finding that the 
catalytic domain of USP2, a DUB that cleaves a wide variety of ubiquitin chains and that is 
able to return all LUBAC components to their apparently unmodified state, cannot 
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completely remove the modifications from RIP1 and cIAP. This shows that USP2 is able to 
also remove the first ubiquitin unit from the target protein and that the remaining 
modification is hence unlikely to be a ubiquitination. The size difference of approximately 
7 kDa of this remaining modification in relation to the unaltered proteins makes a 
modification with a UBL-molecule seem likely. However, no data are available to date to 
support this notion and further investigation, for example by treatment with deconjugating 
enzymes specific for other modifications or by a mass-spectrometry based approach will be 
required to clarify the identity and function of these modifications.  
In addition, smaller shifts in the bands representing the non-ubiquitinated forms of RIP1 and 
TRAF2 can be observed in the TNF-RSC after 15 minutes of stimulation. Due to the fact that 
RIP1 has kinase activity (Hsu et al., 1996a) and that TRAF2 was previously described to be 
subject to that kind of modification (Blackwell et al., 2009; Li et al., 2009a; Thomas et al., 
2009; Zhang et al., 2011), these additional bands might represent phosphorylations of the 
two proteins. Phosphorylation of TRAF2 by PKC was reported to promote its ubiquitination 
with K63-linked chains and to favour the recruitment of the TAB/TAK- and IKK-complexes (Li 
et al., 2009a). However, the upward shift in TRAF2 that could correspond to its 
phosphorylation is only observed after 15 minutes whereas the levels of NEMO, the subunit 
responsible for the recruitment of the IKK-complex (Ea et al., 2006; Wu et al., 2006), reach a 
maximum already after 5 minutes. This could be in line with another report describing the 
phosphorylation of TRAF2 as an event involved in the later stages of IKK-activation 
(Blackwell et al., 2009). Yet, in this context it was reported to form part of a secondary 
cytoplasmic complex, whereas the potentially modified form of TRAF2 observed here is still 
associated with the receptor.  
In case of RIP1 an activity as a serine-threonine kinase that can mediate its auto-
phosphorylation was described (Hsu et al., 1996a). However, it was also shown that this 
kinase activity is dispensable for the activation of the NF-B- and p38-pathways in the 
context of TNF-signalling (Lee et al., 2004). On the other hand, activity of RIP1 is required in 
necroptosis-induction (Holler et al., 2000; Vandenabeele et al., 2010) and in this context 
phosphorylation of RIP1 by RIP3 or possibly another so far unidentified kinase was reported 
(Cho et al., 2009; He et al., 2009). However, modification of RIP1 observed in these studies 
occurs at much later times and again takes place in a secondary complex, suggesting that 
this event differs from the modification seen in the receptor-associated complex. Here, a 
6. Discussion and Outlook 
  
127 
 
shift in the position of the bands representing RIP1 becomes apparent after 15 minutes and 
increases after 30 minutes. At the same time a decrease in the ubiquitination of RIP1 or a 
dissociation of this protein from the complex can be observed. It therefore seems possible 
that RIP1 phosphorylation favours its deubiquitination, a process considered important for 
the formation of secondary death-inducing complexes (O'Donnell et al., 2007). Overall, 
further investigation is required to unravel the identity and function of the non-ubiquitin 
modifications present on TNF-RSC components such as RIP1, TRAF2 and cIAP. It could be 
speculated that they have a role in the disassembly of the receptor-complex and are hence 
required in the termination of signals emanating from stimulated receptors. Another 
possibility is that they function in regulating and maintaining the balance between pro-
survival and death-inducing signalling outputs. 
6.1.2 TNFR1 versus TNFR2 
The identification of SHARPIN, HOIL-1 and HOIP as proteins that are present in TNF-
precipitations from U937 cells raised the question which of the two TNF-receptors 
expressed on the surface of these cells (Haridas et al., 1998; Shu et al., 1996) they are 
recruited to. Generally, most of the manifold effects induced by TNF are mediated via the 
more widely expressed TNFR1 (Wajant et al., 2003). Yet, independent and non-redundant 
roles for TNFR2 as well as cross-talk between the two receptors exist (Faustman and Davis, 
2010; MacEwan, 2002). TNFR1 and TNFR2 recruit distinct but overlapping sets of 
intracellular proteins upon stimulation. Several lines of evidence presented here, including 
the isolation of the TNF-RSC from HeLa cells which do not express TNFR2 (Haridas et al., 
1998; Shu et al., 1996); PhD thesis Dr. C.H. Emmerich) and the precipitation of TNFR1 and 
TNFR2 using specific antibodies, indicate that LUBAC components are recruited to TNFR1 
rather than TNFR2, when soluble TNF is employed as a stimulus. It was shown previously 
that membrane-bound TNF is vastly superior to its soluble form in activating TNFR2 (Grell et 
al., 1998; Grell et al., 1995; Krippner-Heidenreich et al., 2002) and that it may therefore lead 
to not only quantitatively but qualitatively different responses. Based on this and on the 
finding that recruitment of LUBAC to TNFR1 depends on cIAPs which are also associated 
with TNFR2 (Rothe et al., 1995a), it seems possible that SHARPIN, HOIL-1 and HOIP can be 
recruited to TNFR2 when this receptor is efficiently activated. Additional studies using 
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membrane-bound TNF or a cross-linked version of this ligand that mimics membrane 
association, in both wild-type and TNFR1-deficient cells are required to test this hypothesis.  
6.1.3 Mechanism of LUBAC’s recruitment 
In a setting where protein levels of cIAP1 and cIAP2 were down-regulated either genetically 
or by treatment with a Smac-mimetic compound, it could be shown that recruitment of 
LUBAC in HeLa cells or HOIL-1 in MEFs depended on the presence cIAP1/2. As it was 
demonstrated that SHARPIN, HOIL-1 and HOIP form a stimulation-independent complex and 
are therefore recruited in an interdependent-manner, the finding that the activity of cIAP is 
essential for the recruitment of HOIL-1 in MEFs can be extended to the other two LUBAC 
components. This requirement for cIAP’s activity implied a role for ubiquitin in the 
recruitment process. Indeed, all three LUBAC-components can bind to ubiquitin, with HOIP 
displaying the strongest association with K63-linked tetraubiquitin in an in-vitro setting. 
Based on these results and published observations, the following mechanism of recruitment 
seems likely (Figure 52): Upon crosslinking of TNFR1 by trimeric TNF or higher order 
oligomers thereof, the adaptor protein TRADD is recruited via homotypic interaction of its 
DD with that of TNFR1 (Hsu et al., 1995). Although RIP1 can also directly interact with the 
receptor in a DD-dependent manner (Ermolaeva et al., 2008; Haas et al., 2009; Pobezinskaya 
et al., 2008) its recruitment may also be mediated or increased by TRADD (Hsu et al., 
1996a). The latter protein also serves as an adaptor for TRAF2 (Hsu et al., 1996b), which in 
turn has a cIAP-interaction motif that is essential for the recruitment of cIAP1 and cIAP2 by 
binding to their BIR1-domains (Samuel et al., 2006; Varfolomeev et al., 2008; Vince et al., 
2009). Structural studies have revealed that a TRAF2 trimer interacts with one cIAP2 
molecule in an asymmetric manner (Zheng et al., 2010). Once recruited to the TNF-RSC 
cIAPs modify several components, including RIP1, with ubiquitin chains, the majority of 
which serve non-proteolytic functions at this stage as they mainly act as recruitment 
platforms for further components of the RSC (Bertrand et al., 2008; Ea et al., 2006; 
Varfolomeev et al., 2008; Wertz et al., 2004). This includes the TAB/TAK-complex which is 
recruited via TAB2 that specifically binds K63-linked ubiquitin-linkages via its NZF-domain 
(Kulathu et al., 2009) and the IKK-complex that can associate with K63- and possibly K11-
linked chains via its regulatory subunit NEMO. The primary association of LUBAC with the 
receptor complex is likely to also be mediated by K63-linked chains, which are recognised by 
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the NZF1-domain of HOIP (Ikeda et al., 2011). It can be assumed that this initial recruitment 
is sufficient for LUBAC to modify its targets within the complex. These include but are not 
necessarily restricted to NEMO and RIP1 (Gerlach et al., 2011). The linear linkages could 
stabilise the presence of LUBAC in the complex as the NZF-domains of SHARPIN and 
especially HOIL-1 were shown to preferentially or even exclusively bind ubiquitin chains of 
this linkage type (Sato et al., 2011).  The finding that the NZF-domains of these proteins are 
required for LUBAC’s ability to induce NF-B but not for the generation of ubiquitin chains 
(Ikeda et al., 2011; Sato et al., 2011; Tokunaga et al., 2009) suggests that this interaction 
with the complex or with potential target proteins is an important aspect of the role 
SHARPIN and HOIL-1 play in the context of LUBAC’s function. Furthermore, linear ubiquitin 
increases the recruitment of IKK-complexes as NEMO’s UBAN domain shows an affinity to 
this linkage type that is about 100-fold higher than that to K63-linked chains (Lo et al., 2009; 
Rahighi et al., 2009). Overall this suggests that LUBAC is recruited to the TNF-RSC by binding 
of its central component, HOIP, to cIAP-generated ubiquitin chains. This may not be 
restricted to K63-linked chains as a study based on a ubiquitin-replacement strategy 
reported that this linkage type is dispensable for TNF-signalling (Xu et al., 2009a) and by the 
finding that cIAPs can mediate the formation of different linkage types (Dynek et al., 2010; 
Feltham et al., 2012). The interaction of LUBAC-components and especially of HOIP with 
differentially linked ubiquitin will therefore have to be investigated. Once an interaction 
with the TNF-receptor complex has been established by HOIP, SHARPIN and HOIL-1 that are 
not essential to this initial recruitment may have a function in stabilising this association and 
in retaining LUBAC in the TNF-RSC at later stages. Finally, direct protein-protein interactions 
between LUBAC and other components of the TNF-RSC, such as the binding of HOIP to 
NEMO (Tokunaga et al., 2009) may contribute to LUBAC being recruited to and retained in 
the TNF-RSC although they do not seem to be essential or sufficient to mediate the 
recruitment process (Haas et al., 2009). 
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Figure 52: Schematic representation the process involved in recruiting LUBAC to the TNF-RSC. Upon 
crosslinking by TNF, TNFR1 recruits TRADD and RIP1 to its intracellular death-domain. TRADD serves as an 
adaptor of TRAF2 which in turn recruits cIAPs. Once recruited to the TNF-RSC cIAP attaches ubiquitin chains of 
different linkage types to components of the TNF-RSC including RIP1 and itself (1). These chains allow for the 
recruitment of the TAB-TAK- and IKK-complexes as well as LUBAC. LUBAC then attaches linear ubiquitin chains 
to RIP1, NEMO and possibly other targets (2). This increases the recruitment of IKK-complexes and allows for 
the activation of IKK to occur. This involves phosphorylation of IKKan event that may be mediated by trans-
auto-phosphorylation or by TAK1 (3). 
6.1.4 The Role of LUBAC in TNF-induced signal transduction 
Using both knockdown approaches and the over-expression of dominant-negative mutants 
of HOIP, it could be shown in this thesis that presence and activity of LUBAC are required for 
full activation of TNF-induced signalling. While depletion of HOIP led to a stronger reduction 
in the activation of signalling pathways initiated by TNF than down-regulation of SHARPIN or 
HOIL-1, it was insufficient to fully block signal transduction. The same is true for over-
expression of inactive forms of HOIP which again reduced but did not abolish TNF-induced 
NF-B activation. In both cases it is not possible to distinguish whether the remaining level 
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of active LUBAC is sufficient to mediate signalling or whether LUBAC-independent signalling 
pathways exist. The latter possibility is supported by the finding that TNF can still activate 
the NF-B- and MAPK-pathways in cells derived from cpdm mice, which due to a 
spontaneous mutation lack SHARPIN expression (Seymour et al., 2007) as well as in HOIL-1-/- 
MEFs in which HOIL-1 is genetically deleted (Gerlach et al., 2011; Ikeda et al., 2011; 
Tokunaga et al., 2011; Tokunaga et al., 2009). Even in HOIP-deficient cells, signal 
transduction by CD40, a receptor that also requires LUBAC in its downstream signalling 
(Gerlach et al., 2011) is still possible to a certain extent (Hostager et al., 2011). Taken 
together this indicates that LUBAC is not essential for TNF-signalling but is required for 
signal transduction to occur at its full strength. Although investigation of TNF-induced signal 
transduction in HOIP-deficient cells is required to corroborate this notion, these results 
suggests a role for LUBAC in fine tuning signalling output rather than as an on/off-switch for 
signals emanating from the TNF-RSC. Because LUBAC acts as an E3 and influences TNF-
induced signal transduction it is likely that LUBAC exerts its effect on signalling by modifying 
components of the respective pathways. Its recruitment to the TNF-RSC (Gerlach et al., 
2011; Haas et al., 2009) as well as its effect not only on NF-B activation but also on MAPK-
cascades (Gerlach et al., 2011; Haas et al., 2009; Ikeda et al., 2011) suggests that LUBAC 
targets proteins within this complex that represents the apex of all TNF-induced signalling 
pathways rather than ubiquitinating downstream effectors. In an in-vitro ubiquitination 
assay testing nine TNF-RSC components, only NEMO could be identified as a target for all 
LUBAC-variants. However, this does not exclude that other proteins which were not 
modified by LUBAC in vitro may be targets in vivo, as conformations or previous 
modifications present in the context of the TNF-RSC may not be sufficiently mimicked in the 
in-vitro situation. The modification of NEMO with linear ubiquitin could be verified by mass 
spectrometry (Gerlach et al., 2011). In the same experimental setup M1-linkages were 
found together with RIP1 on a 2D-gel, indicating that this protein is modified with linear 
chains too. In both cases LUBAC is likely to be the relevant E3 as no other ubiquitin ligase 
could so far be shown to generate ubiquitin chains of this linkage type (Verhelst et al., 
2011). There is a report on cIAPs being able to use lysine-less ubiquitin as a substrate 
(Bertrand et al., 2011). However, results presented in this thesis suggest that they do not 
make use of this ability if other possibilities in form of accessible internal lysine residues are 
available. TRAF2, the other E3 known to be present on the TNF-RSC showed very low if any 
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activity in an in-vitro ubiquitination assay even in the presence of S1P, which was reported 
to be an essential co-factor for this ligase (Alvarez et al., 2010). This lack of activity is in line 
with a publication that concluded, based on the structure of the RING- and first zinc-finger 
domains of TRAF2, that this E3 is unable to interact with UBE2N or related E2s and that it 
therefore cannot act as a functional ligase. Taken together these findings suggest that all 
linear linkages present in the TNF-RSC are generated by LUBAC and that NEMO and RIP1 are 
targets of this E3-complex. This could be fully clarified by investigating these modifications 
in the presence or absence of active LUBAC. For this purpose the native TNF-RSC isolated 
from cells in which expression of HOIP has been ablated by a knockout strategy or replaced 
by an inactive mutant in a knockin approach could be compared to that precipitated from 
wild-type cells by mass spectrometry. Absence of M1-linkages on NEMO and RIP1 in cells 
exclusively expressing an inactive form of HOIP would provide the final proof that not only 
LUBAC’s presence but also its activity is required for the ubiquitination of these proteins. It 
has not been fully elucidated how linear ubiquitin chains favour the activation of TNF-
induced signal transduction but several explanations for the connection between linear 
ubiquitination and the regulation of signalling are conceivable. Linear chains on RIP1 and 
NEMO may act as a recruitment platform for other ubiquitin-binding proteins which display 
a preference for this linkage type including NEMO itself. Indeed absence of LUBAC severely 
decreases the association between NEMO and the TNF-RSC (Haas et al., 2009). However, 
linear chains may not only increase the amount of IKK-complexes that are recruited to the 
TNF-RSC but binding of NEMO to ubiquitin attached to another NEMO molecule may also 
result in clustering of these kinase complexes (Rahighi et al., 2009) thereby creating a 
proximity between the kinase-subunits that allows trans-auto-phosphorylation, an event 
that has been implicated in the activation of IKKs (Tang et al., 2003a). Furthermore, it was 
reported that binding to linear ubiquitin induces a conformational change in NEMO (Rahighi 
et al., 2009) which could translate to similar changes in the kinase subunits of the IKK-
complex, again favouring their activation. In addition, the activity of LUBAC leads to an 
overall stabilisation of the TNF-RSC (Haas et al., 2009). This effect that probably depends, at 
least partially, on the modification of RIP1 and NEMO, results in RIP1, TRAF2, cIAP and TAK1 
being retained in the TNF-RSC for a longer period of time and consequently extends the 
half-life of this complex thereby allowing enhanced and prolonged activation of 
downstream signalling. This stabilisation is likely to be caused not only by the linkage 
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specificity of UBDs present in complex components but also by linear ubiquitin chains being 
more refractory to disassembly mediated by DUBs recruited to this complex (Komander et 
al., 2009b). DUBs associated with the TNF-RSC include A20, CYLD, Cezanne and USP21 
(Harhaj and Dixit, 2011) and of these only CYLD and USP21 were shown to cleave linearly 
linked ubiquitin with considerable activity (Komander et al., 2009b; Ye et al., 2011). Binding 
of UBDs to linear chains could make them even more resistant to DUB-mediated cleavage. 
Further to the aforementioned possibilities, LUBAC could also influence signalling by its 
ubiquitination of NEMO. This modification was reported to occur at K285 and K309 and 
reconstitution of NEMO-deficient cells with a mutant in which these lysines had been 
replaced by arginines (K285,309R) was insufficient to rescue NF-B activation induced by 
LUBAC over-expression or IL-1-stimulation (Tokunaga et al., 2009). Mechanistically, this 
modification on the regulatory subunit of the IKK-complex may not only serve as a 
recruitment platform favouring clustering and trans-activation of kinase-complexes but 
might also itself induce a conformational change in NEMO and consequently in the 
associated kinases. Overall, LUBAC could regulate TNF-induced signalling by a tripartite 
mechanism. The first leg of this mechanism is constituted by provision of a binding platform 
that allows recruitment and possibly clustering of downstream components, the second 
aspect is the stabilisation of the TNF-RSC and thirdly LUBAC may induce activating 
conformational changes in the IKK-complex by directly ubiquitinating its regulatory subunit.  
In addition to its positive regulatory effect on TNF-signalling a role for LUBAC in signal 
termination can be envisioned. In this context it is possible that linear chains also recruit 
ABIN-1 and Optineurin which, like NEMO, have a UBAN-domain that was shown to bind M1-
linkages with much higher affinity than K63-linked chains (Lo et al., 2009; Rahighi et al., 
2009). As these proteins were shown to act as adaptors for A20 and CYLD, two DUBs 
implicated in terminating TNF-signalling (Harhaj and Dixit, 2011; Heyninck et al., 1999; 
Mauro et al., 2006; Nagabhushana et al., 2011; Regamey et al., 2003), linear ubiquitin chains 
could also have a role in preventing prolonged signalling. The specific recognition of linear 
ubiquitin chains by particular UBDs will have to be analysed in more depth, additional 
LUBAC targets will have to be identified and the sensitivity of M1-linkages attached to 
certain targets towards cleavage by DUBs will have to be compared to that of chains linked 
via specific lysine residues, if the mechanism by which LUBAC regulates TNF signalling is to 
be fully elucidated.  
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6.2 Functional investigation of LUBAC as an E3-complex 
6.2.1 LUBAC exists as a preformed complex 
HOIL-1 and HOIP were previously reported to form a stimulation-independent protein 
complex of about 600 kDa that, due to its activity as an E3 ligase with exclusive linkage 
specificity, is referred to as LUBAC (Kirisako et al., 2006). Here it could be shown that 
SHARPIN co-elutes with HOIL-1 and HOIP in the high-molecular weight fractions of a 
gelfiltration chromatography and that it directly interacts with the original LUBAC 
components even in the absence of a stimulus. Further evidence for the association 
between the three proteins stems from the observation that down-regulation or absence of 
one of them decreases the protein expression levels of the other two (Gerlach et al., 2011; 
Tokunaga et al., 2011). As no such down-regulation can be observed on the mRNA-level it 
can be concluded that the interaction between SHARPIN, HOIL-1 and HOIP is required to 
maintain their stability on the protein level. The interaction between SHARPIN, HOIL-1 and 
HOIP does not seem to be tissue- or cell line-specific and even though a weak binding 
between SHARPIN and HOIL-1 could be detected, the association seems to be mediated 
mainly via HOIP. Although further data obtained from HOIP-deficient cells are required to 
verify the direct interaction between SHARPIN and HOIL-1, the existence of SHARPIN-HOIL-1 
dimers cannot be excluded and a potential function for this dimeric complex will need to be 
investigated. This combination of proteins could either have an inhibitory role by preventing 
SHARPIN and HOIL-1 from forming active complexes with HOIP or it might itself act as an E3. 
In line with the latter idea HOIL-1 was reported to act as a ubiquitin-ligase conjugating K48-
linked ubiquitin to IRP2 (Yamanaka et al., 2003) and possibly other substrates (Tian et al., 
2007; Zenke-Kawasaki et al., 2007; Zhang et al., 2008). However, this is in is in contrast to 
data obtained in this thesis which show that no activity of HOIL-1 could be detected in in-
vitro ubiquitination assays. On the other hand, Parkin, which is very similar to HOIL-1 in its 
domain structure, was described to be subject to an auto-inhibition. In this protein the auto-
inhibitory back-folding of its UBL-domain needs to be relieved by binding of a cofactor or a 
substrate before Parkin can efficiently catalyse the formation of ubiquitin chains (Chaugule 
et al., 2011). It is possible that HOIL-1 is regulated in a similar fashion and that interaction 
with SHARPIN, or another yet to be identified cofactor, enables it to act as a ubiquitin ligase. 
If SHARPIN and HOIL-1 were to have E3-activity, an additional factor is likely to be required 
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as indicated by the observation that the combination of the two proteins can neither 
generate ubiquitin chains in vitro nor induce NF-B upon over-expression. 
However, data on the co-precipitation of SHARPIN and HOIL-1 in the presence or absence of 
HOIP clearly indicate that the latter protein increases the interaction between the former 
two. This demonstrates that tripartite complexes exist in which the central component HOIP 
interacts with both SHARPIN and HOIL-1 by binding their respective UBL-domains. The 
binding of SHARPIN could be mapped to the NZF2-domain of HOIP, which was reported to 
interact with HOIL-1 via its UBA-domain in an atypical manner (Kirisako et al., 2006; Yagi et 
al., 2012). The use of different domains of HOIP for interacting with its binding partners 
seems to be suitable to support simultaneous interactions with two different proteins. On 
the other hand, UBA-domains can serve as dimerisation- and as ubiquitin-binding motifs 
(Bayrer et al., 2005; Bertolaet et al., 2001; Kozlov et al., 2007; Raasi et al., 2005) and the 
UBA-domain of HOIP may therefore contribute to the interaction with SHARPIN even 
though is not sufficient to mediate it as can be concluded from the observation that deletion 
of this domain only slightly decreases the co-precipitation of HOIP with SHARPIN. A 
structural study of the UBA-domain present in XIAP suggested that different surfaces are 
involved in dimerisation and ubiquitin-binding thereby allowing the domain to fulfil both 
functions at the same time (Tse et al., 2011). Using a similar mechanism, two HOIP 
molecules could dimerise while each associating with the UBL-domains of SHARPIN or 
HOIL-1, respectively. The finding that LUBAC has a molecular weight of around 600 kDa 
(Kirisako et al., 2006), shows that several copies of SHARPIN, HOIL-1 and HOIP need to 
associate. Indeed it was reported that at least three molecules of HOIP are present in LUBAC 
(Tokunaga et al., 2011). Based on the respective molecular weights of approximately 40 kDa, 
57 kDa and 120 kDa for SHARPIN, HOIL-1 and HOIP, several possibilities for the formation of 
the high-molecular weight complex exist and the stoichiometry has not been resolved. It can 
however be assumed that the ability to dimerise via their coiled-coil (Lim et al., 2001), RING- 
(Tatematsu et al., 2008) or UBA-domains allows SHARPIN, HOIL-1 and HOIP to mediate the 
association of the higher order protein assemblies that is required for the formation of 
LUBAC. The interactions between individual proteins within this E3-complex are displayed 
schematically in Figure 53. 
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Figure 53: Schematic representation of the interactions between individual LUBAC-components. HOIP interacts with the 
UBL-domains of SHARPIN and HOIL via its NZF2- and UBA-domains, respectively.  Arrows indicate interactions between the 
proteins. ZnF: Zinc Finger; NZF: Npl4 zinc finger; UBL: Ubiquitin-like domain; UBA: Ubiquitin-associated domain; IBR: in-
between RING domain. RING: really interesting new gene. 
6.2.2 SHARPIN, HOIL-1 and HOIP form an E3-complex with exclusive linkage 
specificity. 
Beside the interaction studies that identified SHARPIN as a structural component of LUBAC, 
activity assays show that it is not only important for the stability of HOIL-1 and HOIP on the 
protein level (Gerlach et al., 2011; Tokunaga et al., 2011) but can also support HOIP in the 
formation of ubiquitin chains. In spite of the fact that SHARPIN lacks an RBR-domain no 
qualitative differences in the ubiquitin conjugation could be detected between SHARPIN-
HOIP and HOIL-1-HOIP-complexes. This suggests that chain formation is mediated by HOIP 
whereas SHARPIN and HOIL-1 have an auxiliary or regulatory role. Indeed, both published 
data and results obtained in this study support this notion by showing that mutations in the 
RING-domains of HOIP but not in those of HOIL-1 abolish LUBAC’s ability to generate 
ubiquitin chains and to activate NF-B upon over-expression (Haas et al., 2009; Kirisako et 
al., 2006; Tokunaga et al., 2009). In contrast to HOIP’s RING-domain and the UBL-domains of 
SHARPIN and HOIL-1, the NZF-domains of the latter two proteins are required for LUBAC 
ability to induce NF-B but not for its ubiquitin chain generating activity (Ikeda et al., 2011; 
Sato et al., 2011; Tokunaga et al., 2009). This suggests that SHARPIN and HOIL-1 do not only 
need to interact with HOIP but that they may also fulfil additional functions in LUBAC’s 
activity. Possible roles for SHARPIN and HOIL-1 might lie in the determination of linkage- or 
target specificity displayed by the different LUBAC variants. However, the chains generated 
by HOIP do not differ in their electrophoretic mobility independently of the binding partner 
involved in formation of the active LUBAC. In addition, assays based on the use of ubiquitin 
mutants or the mass-spectrometric analysis of LUBAC-generated polyubiquitin show that all 
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LUBAC-variants exclusively generate linear linkages even when other possibilities for 
conjugation of ubiquitin moieties, in the form of internal lysine residues, are available and 
an E2 without a strict linkage specificity such as UBE2D3 is used. In this preference LUBAC 
differs from all other E3s investigated so far (Verhelst et al., 2011), even if certain other 
ubiquitin ligases as for example cIAP seem to be able to use the N-terminal methionine as a 
conjugation point when forced to do so  by the absence of alternative attachment points 
(Bertrand et al., 2011). Furthermore, comparison to other members of the RBR-family 
indicates that the linkage specificity is not an intrinsic property of this sequence of RING-
domains. It is possible that certain members of this subclass of RING-E3s can mediate the 
formation of linear linkages in the presence of a suitable partner or cofactor, but in the 
assays performed here RBR-family members were able to employ N-terminally tagged but 
not K0-ubiquitin in the generation of ubiquitin conjugates. This is in line with publications 
that report that the RBR-family member Parkin generates K63- and K48-linked chains (Doss-
Pepe et al., 2005; Lim et al., 2006) and that report on the generation of lysine-linked 
polyubiquitin by other proteins of this family (Marteijn et al., 2009; Nakhaei et al., 2009). 
Although HOIP is not very active as an E3 on its own, it seems that this central component of 
LUBAC is responsible for restricting the activity to the conjugation of ubiquitin molecules via 
their N- and C-terminus (Kirisako et al., 2006). A possible hypothesis is that by binding the 
nascending ubiquitin chain via their NZF-domains SHARPIN and HOIL-1 force it to adopt a 
conformation in which only the N-terminal methionine is accessible as an attachment point 
to HOIP, thereby determining linkage specificity. In case of HOIL-1 this does not seem to be 
the case as the electrophoretic mobility of chains generated by HOIP and HOIL-1 lacking 
their NZF-domains does not differ from those generated by the wild-type proteins. Similarly, 
deletion of SHARPIN’s NZF-domain seems to decrease the overall ubiquitin chains 
generation by LUBAC but does not change the linkage type (Tokunaga et al., 2011). 
Concerning target specificity, NEMO could be identified as a common target for all LUBAC 
variants and hence no data on different target specificities exhibited by SHARPIN- or HOIL-1 
containing LUBAC-combinations exist so far. Yet, due to the differences between SHARPIN- 
and HOIL-1-deficient cells especially in the response to cell death induction by TNF (Ikeda et 
al., 2011), it seems likely that the two proteins might direct HOIP’s activity to overlapping 
but distinct sets of target proteins. On the other hand, LUBAC-independent functions of 
monomeric SHARPIN or HOIL-1 might contribute to these differences as well. Thus, further 
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differentiation between LUBAC-dependent and potential LUBAC-independent effects of 
SHARPIN, HOIL-1 and HOIP will be necessary. Several reports on such complex-independent 
functions exist (Bayle et al., 2006; Ehrlund et al., 2009; He et al., 2010; Jung et al., 2010; 
Rantala et al., 2011; Tatematsu et al., 1998; Tian et al., 2007; Yamanaka et al., 2003; Zenke-
Kawasaki et al., 2007) but in most cases the contribution of the respectively other two 
proteins to the observed effects was not investigated and the independence of LUBAC’s 
linear ubiquitin generating activity is therefore not fully established. LUBAC-dependent and 
-independent roles of the three proteins in these contexts will have to be unravelled and the 
identification of additional LUBAC-targets and the characterisation of their role in signal 
transduction will be necessary to fully understand the role of LUBAC and of its potential 
variants. In this context it is interesting to note that upon knockdown of any of the LUBAC-
components not only the modification pattern of RIP1, which was shown to be modified by 
M1-linked ubiquitin in the native TNF-RSC (Gerlach et al., 2011), but also that of cIAP1/2 
upon recruitment to the TNF-RSC is changed, indicating that cIAP1 and/or cIAP2 could 
potentially be targeted by LUBAC.  
6.2.3 LUBAC acts via a HECT-like mechanism 
LUBAC’s exclusive linkage specificity is not only surprising in that it does not seem to be 
shared by any other E3 investigated so far but also because linkage specificity is usually 
determined by the E2 rather than the E3, at least in reactions involving RING-class ubiquitin 
ligases (Nagy and Dikic, 2010). This is not the case for LUBAC as chains generated by this 
complex in combination of a panel of different E2s do not differ in their electrophoretic 
mobility, indicating that they are of the same linkage type. This intrinsic, E2-independent 
linkage specificity is a feature that can be observed in certain HECT-class E3s (Nagy and 
Dikic, 2010). Ubiquitin ligases of this class, in contrast to RING-E3s, form an obligatory 
thioester intermediate with ubiquitin. A recent study revealed that UBE2L3 requires an E3 
that is able to form an E3~ubiquitin adduct on a catalytic cysteine as this E2 lacks the ability 
to transfer ubiquitin to lysine residues (Wenzel et al., 2011a). The same study also showed 
that ARIH1 and Parkin, members of the RBR-family, can catalyse ubiquitination together 
with UBE2L3 and that ARIH1 indeed forms a thioester intermediate. Comparison of UBE2D3 
and UBE2L3 in in-vitro ubiquitination reactions mediated by LUBAC demonstrated that chain 
formation remains intact when LUBAC is provided as an E3 for UBE2L3 whereas ubiquitin 
6. Discussion and Outlook 
  
139 
 
conjugation on monoubiquitin and auto-ubiquitination of the E3 cannot be supported by 
combinations of cIAP1, cIAP2 or TRAF6 with this E2. This suggests that LUBAC contains a 
catalytic cysteine that can accept activated ubiquitin from the E2. Because HOIP was 
identified as the central component of LUBAC both structurally and functionally and 
because the active site identified in ARIH1 was allocated to a highly conserved cysteine 
residues within its RING2 domain (Wenzel et al., 2011a) whereas E2 binding was mediated 
via its RING1-domain (Ardley et al., 2001), it was concluded that a cysteine involved in the 
catalytic activity of LUBAC was most likely to reside in the RING2-domain of HOIP. Mutation 
of cysteine 885 that was identified as a potential candidate by alignment of HOIP’s RING2-
domain with the published consensus sequence indeed abolished HOIP’s ability to generate 
polyubiquitin when combined with SHARPIN or HOIL-1. It was reported that mutation of 
C357, the catalytic cysteine identified in ARIH1, leaves the structure of the RING2-domain 
intact as it is not a zinc-coordinating residue (Wenzel et al., 2011a). Co-precipitation studies 
showed that a cysteine-to-serine-mutation in residue 885 of HOIP does not prevent it from 
interacting with SHARPIN or HOIL-1 and that the interaction with the E2 UBE2D3 which, as 
typical for E2-E3 interactions, seems to be rather weak (Ye and Rape, 2009), was 
maintained. This strongly suggests that the overall structure of HOIP is unaffected by the 
mutation of C885 and therefore provides compelling evidence that LUBAC works via a HECT-
like mechanism.  
Thus the opportunity arises to inhibit LUBAC not only by interfering with its interaction with 
specific targets or competitively by the addition of N-terminally tagged ubiquitin, which 
might prove difficult in settings other than in-vitro assays, but also by inhibitors designed to 
prevent the obligatory formation of an E3~ubiquitin adduct. Such inhibitors targeting the 
active centre of LUBAC might not only be valuable as scientific tools to further investigate 
the role of linear ubiquitin in signalling but might also prove to have therapeutic potential in 
a context where LUBAC’s activity is causing or aggravating a pathological condition. 
Whereas no such disease-causing role of elevated activity of this E3-complex was reported 
to date, increased expression levels of individual LUBAC components have been observed in 
certain types of cancer (Jung et al., 2010; Thompson et al., 2004) and it can be envisioned 
that inhibiting LUBAC and thereby shifting the balance between pro-survival signalling and 
cell death induction towards the latter outcome could prove beneficial in this situation. 
Additional approaches to modulating LUBAC’s activity could be based on mechanisms 
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regulating this E3-complex in vivo as for example a potential regulation by post-translational 
modifications. 
6.2.4 Post-translational modifications of LUBAC-components  
The best studied post-translational modifications occurring in a signalling context are 
phosphorylations and ubiquitinations (Cohen, 2002; Pickart, 2004). Both ubiquitination, in 
the form of attachment of proteolytic or non-proteolytic ubiquitin chains to the E3 in 
reactions catalysed by auto-ubiquitination or by the action of another ubiquitin ligase, and 
phosphorylations were reported to play a role in the regulation of E3 ligases (de Bie and 
Ciechanover, 2011; Kee and Huibregtse, 2007). Although it cannot be excluded at this point 
that other types of modifications are involved in the regulation of LUBAC’s activity, only the 
potential effects of phosphorylations and ubiquitinations will be discussed here. Treatment 
of the TNF-RSC with the catalytic domain of USP2 revealed that ubiquitin-based 
modifications are present on all three components of LUBAC. However, ubiquitination 
patterns differ between the three proteins. Whereas SHARPIN and HOIL-1 are subject to 
mono-ubiquitination, several ubiquitin-molecules seem to be attached to HOIP in the form 
of multi-mono- or polyubiquitination. In addition the modified form of HOIL-1 is already 
present in unstimulated lysates while modification of HOIP occurs in a stimulation-
dependent manner. The ubiquitination of SHARPIN and HOIL-1 can be detected in in-vitro 
assays in the absence of active HOIP or another E3. This suggests that these modifications 
can be mediated by HOIL-1. However, the presence of HOIP is clearly required for HOIL-1 to 
be modified in a cellular context. Experiments based on reconstitution of HOIL-1- or HOIP-
deficient cells with RING-mutants of the respective protein are therefore required to clarify 
which RING-domain is involved in the attachment of ubiquitin to HOIL-1.  
One approach in functionally characterising the individual alterations could be to create 
non-modifiable mutants by site-directed mutagenesis and to test their effect on LUBAC’s 
activity in vitro and their ability to replace the wild-type proteins in TNF-induced signal 
transduction by reconstituting cells deficient for one of the proteins by the respective 
mutant. Identification of the modification sites would be a prerequisite for this type of 
analysis. It could be shown here that the modification of HOIL-1 occurring in vitro takes 
place in its C-terminal part. In addition, mass-spectrometry based approaches aiming to 
identify ubiquitination sites on a proteome-wide scale found several sites in SHARPIN, 
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HOIL-1 and HOIP to be modified. Based on the data obtained in these studies lysines 189 
and 318 of SHARPIN (Kim et al., 2011; Lee et al., 2011; Wagner et al., 2011), lysine 342 of 
HOIL-1 (Wagner et al., 2011) and lysines 458 and 640 in HOIP (Kim et al., 2011; Wagner et 
al., 2011) could serve as good candidates in identifying the respective modification sites. 
Additional lysines were found to be ubiquitinated on HOIL-1 and HOIP but their localisation 
within the N-terminal part of HOIL-1 or the fact that they were identified in only one of the 
studies makes them secondary candidates in comparison to the sites named above. In case 
of HOIP it also needs to be considered that its stimulation-dependent modification could 
occur at a site that is not ubiquitinated in unstimulated cells. Next to the mutagenesis-based 
investigation of modification sites suggested by previous studies a direct analysis of the 
modification status of LUBAC components in the TNF-RSC will be necessary to 
unambiguously identify the lysine residues that are or become modified in this context. The 
latter approach would also be suitable to find other, non-ubiquitin modifications on the 
three proteins. A prime candidate as an additional modification would be the 
phosphorylation of HOIL-1. It was reported that HOIL-1 is targeted by PKC and that 
phosphorylation by this kinase leads to cleavage of HOIL-1 between its NZF- and its RING1-
domain resulting in two fragments of approximately 22 kDa and 42 kDa respectively, 
thereby negatively regulating LUBAC’s activity (Nakamura et al., 2006). A different 
publication suggested S127, T151 and T191 of HOIL-1 as potential sites for phosphorylation 
by PKC (Tatematsu et al., 2008). On western blot level the anti-HOIL-1 antibody detects a 
clear double band in lysates whereas in the analysis of the TNF-RSC the upper of the two 
bands often appears blurry or as a double band in itself. The small distance between these 
bands indicates that they do not represent mono- and di-ubiquitinated forms of HOIL-1. On 
the other hand a phosphorylation event might be a possible explanation for the observed 
shift. Further analysis that could involve two-dimensional gel electrophoresis, potentially in 
combination with phosphatase treatment or mass-spectrometry is required to clarify 
whether it is indeed a phosphorylation event that is responsible for the observed banding 
pattern. If so, use of kinase inhibitors and knockdown of candidate proteins could be first 
steps in identifying the kinase catalysing this phosphorylation and in analysing the function 
of this modification. The observation that only the upper of the two bands of HOIL-1 that 
can be observed in lysates appears to be altered in the TNF-RSC suggests that only the 
ubiquitinated form of HOIL-1 can be further modified. This could have implications for 
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LUBAC’s activity and its regulation. At the moment it cannot be predicted if phosphorylation 
would promote the full activation of LUBAC or limit its E3-activity. No thorough investigation 
of the phosphorylation status of SHARPIN and HOIP upon TNF-stimulation was undertaken 
to date but both proteins were found to be phosphorylated in proteome-wide mass-
spectrometric studies. The residues in SHARPIN reported to be phosphorylated are serines 
165 and 312 (Dephoure et al., 2008; Olsen et al., 2011), whereas HOIP is modified on serine 
466 (Cantin et al., 2008; Chen et al., 2009; Dephoure et al., 2008). As in the case of HOIL-1 
additional work is required to confirm these sites, to identify the responsible kinases and to 
unravel the functions of these phosphorylations. In these investigations it also has to be 
considered that phosphorylations occurring in response to a TNF-stimulus might differ from 
those present in an unstimulated state. 
Although relatively little data is available concerning the potential regulation of LUBAC by 
post-translational modifications, data obtained in this thesis indicate that SHARPIN, HOIL-1 
and HOIP may be ubiquitinated and possibly phosphorylated. Analysis of these 
modifications and unravelling their relevance to LUBAC’s E3 activity and to TNF-induced 
signal transduction could prove to be a fascinating field of investigation in the future.
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IV Abbreviations 
A    Alanine 
aa    aminoacid 
ABIN    A20 binding inhibitor of NF-B 
AKT   V-akt murine thymoma viral oncogene homolog 
AMPK   AMP-activated protein kinase 
AP-1    Activator protein 1 
APF-1   ATP-dependent proteolysis factor 1 
APC/C    Anaphase-Promoting Complex 
ARE    AU-rich element  
ARIH   Ariadne Homolog 
ASK1    Apoptosis signal-regulating kinase 1 
ATG   Autophagy related gene 
BAFF   B-cell-activating factor 
BCA    Bicinchoninic acid 
BIR    Baculoviral IAP repeat 
C   Cysteine 
cpdm   Chronic proliferative dermatitis mutation 
cFLIP    Cellular FLICE-inhibitory protein 
cIAP    Cellular inhibitor of apoptosis protein 
CIM    cIAP1/2 interacting motif 
CLP    Cecal ligation and puncture 
CNS    Central nervous system 
CRDs   Cysteine rich domains 
CYLD    Familial Cylindromatosis Protein 
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DC    Dendritic cell 
DD   Death domain 
DDB   DNA damage binding 
DISC    Death inducing signalling complex 
DMEM   Dulbecco’s modified Eagle’s medium 
DUB    Deubiquitinases 
E   Glutamic acid 
ER    Endoplasmic reticulum 
ER   Estrogen receptor alpha 
ERAD   Endoplasmic-reticulum-associated degradation 
ERK   Extracellular signal regulated kinase 
EYA-1   Eyes absent 1 
F    Phenylalanine 
FADD   Fas-associated protein with a death domain 
Fn14   Fibroblast growth factor inducible 14    
G    Glycine 
GCKs    Germinal centre kinases 
H   Histidine 
HECT   Homologous with E6-associated protein C-terminus 
HEK   Human embryonic kidney 
HF-TNF   His-FLAG-TNF 
HHARI   Human homolog of Ariadne 
HOIL-1   Heme-oxidized IRP2 ubiquitin ligase 1 
HOIP    HOIL-1-interacting protein 
HPIV   Human parainfluenza virus 
HRP    Horseradish-peroxidase 
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HT    Hydroxy-tamoxifen 
I    Isoleucine 
IBR    In Between RING 
IBRDC   IBR domain containing protein 
ICAM   Intercellular adhesion molecule 
ICC   Intestinal cells of Cajal 
IFN    Interferon 
IB   Inhibitor of B 
IL    Interleukin 
IPTG   Isopropyl--D-thio-galactoside 
IRF   IFN regulatory factor 
IRP   Iron regulatory protein 
JNK   c-Jun N-terminal kinase 
K    Lysine 
KSHV   Kaposi’s sarcoma associated herpes virus 
L   Leucine 
LB   Lysogeny Broth 
LC3   Microtubule-associated protein1 light chain 3 
LPS   Lipopolysaccharide 
LT   Lymphotoxin 
LTR   Lymphotoxin  receptor 
LUBAC   Linear ubiquitin chain assembly complex 
M    Methionine 
MAPK   Mitogen-activated protein kinase 
MEFs    Mouse embryonic fibroblasts 
MEKK   MAPK/ERK kinase kinase 
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moTAP   Modified tandem affinity purification 
MS    Mass spectrometry 
N   Asparagine 
NEMO    NF-B essential modulator 
NES   Nuclear export sequence 
NF-B    Nuclear factorB 
NIK   NF-B inducing kinase
NLR   NOD-like receptor 
NLS   Nuclear localisation sequence 
NOD   Nucleotide-binding Oligomerisation Domain 
NZF    Npl4-type zinc finger 
P    Proline 
PAMP   Pathogen associated molecular pattern 
PAUL   Putative Ariadne-like ubiquitin ligase 
PDB    Pull-down buffer 
PI3K    Phosphoinositide 3-kinase 
PKB   Protein kinase B 
PKC    Protein kinase C 
PLAD   Pre-ligand-binding assembly domain 
PRU   Pleckstrin like receptor for ubiquitin 
Q   Glutamine 
R   Arginine 
RBCK1   RBCC protein interacting with PKC 1 
RBR    RING-IBR-RING 
RHD   Rel homology domain 
RIG-I   Retinoic acid-inducible gene I 
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RING    Really Interesting New Gene 
RIP1    Receptor interacting protein 1 
RLR   RIG-like receptor 
ROS    Reactive oxygen species 
RSC   Receptor signalling complex 
RTA   replication and transcription activator 
S   Serine 
SAPK    Stress-activated protein kinases 
SCF    Skp1/cullin/F-box 
SEM    Standard error of the mean 
SF    Superfamily 
SF1   Steroidogenic factor 1 
SHANK   SH3 and multiple ankyrin repeat domains protein 
SHARPIN  SHANK associated RH domain protein 
SLE   Systemic lupus erythematosus 
SM    Smac mimetic 
STAT   Signal transducer and activator of transcription 
SV   Simian virus 
T   Threonine 
TAB    TAK1 binding protein 
TACE   TNF-converting enzyme 
TAD   Transactivation domain 
TAK1    TGF--activated kinase 1 
TIM    TRAF-interacting motif 
TLR    Toll-like receptor 
TNF    Tumour necrosis factor 
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TNF-RSC  TNF-R1 signalling complex 
TRADD   TNF-R1-associated death domain 
TRAF    TNF-receptor associated factor 
TrCP   Transducin repeat-containing protein 
Ub   Ubiquitin 
UBA    Ubiquitin-associated 
UBAN   Ubiquitin-binding domains found in ABINs and NEMO 
Ubc   Ubiquitin conjugating 
UBD    Ubiquitin-binding domains 
UBE   Ubiquitin-conjugating enzyme 
UBL    Ubiquitin-like 
UIM    Ubiquitin-interacting motif 
UIP28   UBCM4 interacting protein 28 
UTR    Untranslated region 
V   Valine 
VEGI   Vascular endothelial growth inhibitor 
W   Tryptophan 
wt    Wild-type 
XAP3   Hepatitis virus X-associated protein 
XIAP    X-linked inhibitor of apoptosis 
Y   Tyrosine 
ZIBRA   Zinc IBR finger UBA domain containing protein 
ZIN   Zinc finger protein 
ZnF    Zinc finger 
ZAP-70  Zeta-chain associated protein of 70 kDa
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